<html xmlns="http://www.w3.org/1999/xhtml" class=" js flexbox flexboxlegacy canvas canvastext webgl no-touch geolocation postmessage no-websqldatabase indexeddb hashchange history draganddrop websockets rgba hsla multiplebgs backgroundsize borderimage borderradius boxshadow textshadow opacity cssanimations csscolumns cssgradients no-cssreflections csstransforms csstransforms3d csstransitions fontface generatedcontent video audio localstorage sessionstorage webworkers applicationcache svg inlinesvg smil svgclippaths"><!--MODERNIZED PAGE--><head id="coid_website_head" profile="http://www.w3.org/2005/10/profile"><style type="text/css">@charset "UTF-8";[ng\:cloak],[ng-cloak],[data-ng-cloak],[x-ng-cloak],.ng-cloak,.x-ng-cloak,.ng-hide{display:none !important;}ng\:form{display:block;}.ng-animate-block-transitions{transition:0s all!important;-webkit-transition:0s all!important;}</style>
	<meta http-equiv="content-type" content="text/html; charset=UTF-8">
	<meta http-equiv="X-UA-Compatible" content="IE=edge">
	<meta name="description" content="View on Westlaw or start a FREE TRIAL today, Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals International Limited, Cases">







<script>
	

	(function () {
		window['$$errors'] = [];

		//handle js errors (it will be overwritten in GlobalPageHandlers.js. And any error will be processed when this script is loaded on the page.)
		window.onerror = function() {
			window['$$errors'].push(arguments);
		}
	})();
</script>




	<title>Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals International Limited | Cases | Westlaw</title>

	
	



	
	
	



	




    
    <link href="https://ca.next.westlaw.com/StaticContent_40.1.1015/css/v2/utilities.css" type="text/css" rel="stylesheet">
<link href="https://ca.next.westlaw.com/StaticContent_40.1.1015/css/v2/core.css" type="text/css" rel="stylesheet">
<link href="https://ca.next.westlaw.com/StaticContent_40.1.1015/css/v2/components.css" type="text/css" rel="stylesheet">
<link href="https://ca.next.westlaw.com/StaticContent_40.1.1015/css/v2/features.css" type="text/css" rel="stylesheet">
<link href="https://ca.next.westlaw.com/StaticContent_40.1.1015/css/v2/document.css" type="text/css" rel="stylesheet">
<link href="https://ca.next.westlaw.com/StaticContent_40.1.1015/css/v2/print.css" type="text/css" rel="stylesheet" media="print">
<!--[if gte IE 6]>
<link href='https://ca.next.westlaw.com/StaticContent_40.1.1015/css/v2/ie.css' type='text/css' rel='stylesheet' />
<![endif]-->


	<link rel="shortcut icon" type="image/vnd.microsoft.icon" href="https://ia.next.westlaw.com/favicon.ico">
	<link rel="apple-touch-icon" href="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/v2/iphone-webclip-icon.png">
<script type="text/javascript" crossorigin="anonymous" charset="utf-8" src="//ja.next.westlaw.com/StaticContent_40.1.1015/webpack/Products/WestlawNext/js/bundle.923c80f054c89ca796f84c4fbed803b0.dll.js"></script><script type="text/javascript" crossorigin="anonymous" charset="utf-8" src="//ja.next.westlaw.com/StaticContent_40.1.1015/webpack/Products/WestlawNext/js/bundle.e94d5ee75e94c1087b529e979a552bed.dll.js"></script><script type="text/javascript" crossorigin="anonymous" charset="utf-8" src="//ja.next.westlaw.com/StaticContent_40.1.1015/webpack/Products/WestlawNext/js/bundle.83634f9482d1ddf27e96c8f1d9498ac3.dll.js"></script><script type="text/javascript" crossorigin="anonymous" charset="utf-8" src="//ja.next.westlaw.com/StaticContent_40.1.1015/webpack/Products/WestlawNext/js/bundle.82967e6fecb235c1f97c6591de01f9f7.dll.js"></script><script type="text/javascript" crossorigin="anonymous" charset="utf-8" src="//ja.next.westlaw.com/StaticContent_40.1.1015/webpack/Products/WestlawNext/js/Website/Views/Document/DocumentTabView.bootstrap.js"></script><link id="Markman_MarkmanDisplayState"><link id="Markman"></head>



<body class="co_t2Left co_docDisplay">
	<div id="co_pageContainer" class="co_bodyToolbar">
		<div id="co_mainContainer">
			











<div id="co_headerWrapper" class="wlnv2 ">
	<div id="co_newHeader"><div id="co_privacyPolicyContainer"> 
	<p id="co_privacyPolicy">
		<b>We've updated our Privacy Statement.</b> Before you continue, please read our new <a id="coid_website_privacyPolicyLinkOut" href="javascript:void(0)">Privacy Statement</a> and familiarize yourself with the terms.
		<button type="button" id="coid_website_privacyPolicyAcknowledged" title="Close message to acknowledge privacy statement" class="co_absolute">
			<span class="icon25 icon_close_x"></span>
		</button>
	</p>
</div>
		<div id="co_headerContainer">
			<div id="co_newHeader_top" class="headerContent" role="banner">
					<div class="skipButtonContainer"><a href="javascript:void(0);" data-jumpto="co_docHeaderTitle" class="co_tbButton skipButton">Skip to Document</a><a href="javascript:void(0);" data-jumpto="co_footerLinks" class="co_tbButton skipButton">Skip to Footer</a></div>
						<ul id="co_mainNav" class="co_inlineList" role="navigation">
							
														<li id="co_kmFirmNameContainer"></li>


	<li id="co_clientIdContainer" class="navigation_link co_menuListFirst"><div id="co_clientID_title_0" class="co_dropdownTabCollapsed"><span class="co_clientID_label" id="co_clientID_label_0">Client ID:</span><span></span></div><div id="co_clientID_list_0" class="co_clientID_list co_hideState" aria-hidden="true">

<div class="co_dropdownBoxExpanded">
	<div class="co_dropdownBoxHeader">
		<span></span>
	</div>
	<div class="co_dropdownBoxContent">
		<button id="co_clientID_close_0" class="co_overlayBox_closeButton" type="button">Close</button>
		<div class="co_dropdownBoxContentRight" id="co_clientID_content_0"></div>
	</div>
	<div class="co_dropdownBoxFooter">
		<span></span>
	</div>
</div></div></li>
									<li id="co_recentHistoryContainer"><div id="tabIndicator" class="co_dropdownTabCollapsed"><div class="co_dropdownTab"><a href="javascript:void(0);" class="co_dropdownBoxanchorLabel"><span class="icon"></span>History</a><button class="co_hasTooltip co_dropdownArrowCollapsed" title="Recent History Menu"><span class="th_simple_icon icon_down_arrow reversed"></span><span class="co_accessibilityLabel" aria-hidden="true" id="coid_dropdownAriaLabel_1">History Menu</span> </button></div></div><div class="co_dropdownBoxCollapsed" aria-hidden="true" aria-labelledby="coid_dropdownAriaLabel_1"><span class="co_accessibilityLabel">Beginning of history window.</span><div class="co_dropdownBoxContent"><div class="co_recentResearch iac-a11y-header-redesign" id="co_recentResearch">
	<div class="co_recentDocuments co_floatLeft">
		<div class="co_globalNavDropdownBox_header">
			<h3 class="co_recentDocumentsHeader">Recent Documents</h3>
			<a class="co_floatRight co_recentDocumentsAll" href="javascript:void(0);" id="co_recentDocumentsLink">View all</a>
		</div>
		<div class="co_scrollWrapper">
			<ul class="co_recentDocumentsList" id="co_recentDocumentsList"></ul>
		</div>
	</div>
	<div class="co_recentSearches co_floatRight">
		<div class="co_globalNavDropdownBox_header">
			<h3 class="co_recentSearchesHeader">Recent Searches</h3>
			<a class="co_floatRight co_recentSearchesAll" href="javascript:void(0);" id="co_recentSearchesLink">View all</a>
		</div>
		<div class="co_scrollWrapper">
			<ul class="co_recentSearchesList" id="co_recentSearchesList"></ul>
		</div>
	</div>
	<div class="co_clear"></div>
</div></div><button class="co_overlayBox_closeButton" type="button" title="Close history menu">Close Recent History window</button><span class="co_accessibilityLabel">End of history window.</span></div></li>
								<li id="co_signOffContainer" class="">

									<div class="co_dropdownTabCollapsed">
										<div class="co_dropdownTab">
											<button id="coid_website_signOffRegion" class="co_dropdownBoxanchorLabel co_hasTooltip iac-a11y-header-redesign" title="Settings &amp; Sign Off">
												<span class="th_simple_icon icon_user reversed"></span>
												<span class="th_simple_icon icon_down_arrow reversed"></span>
												<span class="co_accessibilityLabel" aria-hidden="true">Settings &amp; Sign Off</span>
											</button>
										</div>
									</div>
									<div class="co_dropdownBoxCollapsed co_globalNavDropdownBox" aria-hidden="true" aria-labelledby="coid_dropdownAriaLabel_0"><span class="co_accessibilityLabel">Beginning of profile settings window.</span>
										<div class="co_globalNavDropdownBox_header">
											<h3 id="coid_dropdownAriaLabel_0">Profile Settings</h3>
										</div>
										<div class="co_globalNavDropdownBox_content">
											<div class="co_signOff_profile">
												<h4></h4>
												<ul>
													<li></li>
												</ul>
											</div>

											<div class="co_signOff_links">
												<ul>


	<li>
		<a id="coid_website_mycontent" href="/MyPlan/Show\?transitionType=Default&amp;contextData=(sc.Default)">My Content</a>
	</li>


													<li>
														<a id="coid_website_userSetting" href="javascript:void(0);">My Preferences</a>
													</li>
													<li>
														<a class="co_signOff_updateProfile" href="https://onepass.westlaw.com/v2/profile/general?productid=CBT&amp;viewproductid=&amp;returnto=1.next.westlaw.com">Update OnePass Profile</a>
													</li>
												</ul>

											</div>

											<div class="co_signOff_buttons">
												<div>
													<button type="button" class="co_primaryBtn js_website_signoff">Sign Off</button>
												</div>
											</div>
										</div>
									<button class="co_overlayBox_closeButton" type="button" title="Close profile menu">Close Profile Settings window</button><span class="co_accessibilityLabel">End of profile settings window.</span></div>

								</li>
						</ul>

			</div>
			<div id="co_newHeader_bottom" class="headerContent">







<div id="headerLogo" class="" data-compartment-start-page-id="">

	<a id="coid_website_logo" href="/?transitionType=Default&amp;contextData=(sc.Default)" tabindex="1" class="co_hasTooltip">
		<img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/v2/logo.png" title="Westlaw Home">
		<span class="co_accessibilityLabel" aria-hidden="true">Westlaw Home</span>
	</a>
</div>







<div id="coid_website_searchWidget" style="display:none;"></div>
<div id="co_headerSearch" class="">
	<div id="co_searchWidgetInnerId" class="co_noAdvancedSearch">
		<form action="" onsubmit="return false;">
			<div id="co_searchFormLeft">
				<a href="javascript:void(0);" id="co_categorySearchButton">
					<span id="co_currentSelectedCategoryText">291 PATENTS</span>
					<span id="co_currentSelectedCategoryToggle" class="th_simple_icon icon_down_arrow co_hasTooltip">
						<span class="co_accessibilityLabel">Content Menu</span>
					</span>
				</a>
				<div class="co_dropdownBoxCollapsed" id="co_searchCategoryDropdown"><ul>  <li class="co_tabLeft" id="co_searchWidgetAllWestlawTab" title="Search All Content">    <div class="co_tabRight"><a href="#" onclick="return false;">All Content</a></div>  </li>  <li class="co_tabLeft co_hideState" id="co_searchWidgetCompartmentCustomTab" title="compartmentCustomTab">    <div id="compartmentCustomTabDivId" class="co_tabRight"><a title="Search " href="#" onclick="return false;">{compartmentCustomTabLinkText}</a></div>  </li>  <li class="co_tabActive co_tabLeft" id="co_searchWidgetCustomTab">    <div id="customTabDivId" class="co_tabRight"><a title="Search 291 PATENTS" href="#" onclick="return false;">291 PATENTS</a></div>  </li></ul>

				</div>
			</div>
			<div class="co_searchFormOuter">
				<div class="co_searchInputContainer" id="co_searchInputContainer">
					<div class="co_inputTop">
						<div class="co_inputTopRight"></div>
					</div>
					<div class="co_inputMidLeft">
						<div class="co_inputMidRight">
							<!-- Search text box -->
							<div class="co_textarea">
								<label id="searchInputIdLabel" for="searchInputId">Search:</label>
									<textarea style="" title="Search" name="searchInputId" aria-label="Westlaw Search. Search suggestions available after typing 3 characters. Use arrow keys to navigate suggestions." id="searchInputId" rows="1" spellcheck="false" autocorrect="off" autocapitalize="off" class="co_defaultInput"></textarea>
							</div>

							<!-- Medical litigator check box container -->
							<div id="co_medLitExpandedTerms" class="co_floatRight co_formInline"></div>



<!-- Recent search query toggle -->
<a id="co_searchLast10Link" class="th_simple_icon icon_down_arrow co_hasTooltip" href="#" onclick="return false;" title="Recent Searches Menu">
		<span class="co_accessibilityLabel">Recent Searches Menu</span>
</a>
						</div>
					</div>
					<div class="co_inputBottom">
						<div class="co_inputBottomRight"></div>
					</div>


<!-- Hold recent query drop down -->
<div id="co_recentQueryListBox" class="co_hideState">
	<ul class="co_searchSuggestionContainer" id="co_searchLast10List"></ul>
</div>
				<span role="application" id="searchBoxIndexSpan" style="display: none;"><p class="co_accessibilityLabel" id="co_resultsAvailable">Results are available, use up and down arrow keys to navigate</p><p class="co_accessibilityLabel" id="co_endOfList">End Of List</p><div id="co_typeAheadStatusAlert" aria-live="assertive" role="alert" aria-labelledby="co_resultsAvailable"></div><ul class="co_searchSuggestionContainer" aria-live="polite" aria-relevant="additions removals" id="co_searchSuggestion" style="display: none;" tabindex="-1"><li class="co_autoCompleteSection" id="coid_westlawanswers_elastic_westlawanswers_allcases" style="display:none"></li><li class="co_autoCompleteSection" id="coid_westlawanswers_elastic_westlawanswers" style="display:none"></li><li class="co_autoCompleteSection" id="coid_westlawanswers_elastic_westlawanswers" style="display:none"></li><li class="co_autoCompleteSection" id="coid_snapshotExactMatch_elastic_snapshots" style="display:none"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_categorypage"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_case"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_docket"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_statute"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_regulation"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_admindecision"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_analytical"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_pendingstatute"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_othercourtdocument"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_snapshots"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_westlawanswers"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_westlawanswers_static_questions"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_westlawanswers_static_questions_allcases"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_westlawanswers_it_depends_question"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_antitrust"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_arbitration"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_bankruptcy"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_capmarket_corpgovern"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_commtrans"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_corp_mna"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_empbenefits_excomp"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_fedcivilpract"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_finance"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_inhousecounsel"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_intelprop_tech"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_labor_emp"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_realestate"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_startup_smallbus"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_trust_estate"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointpicks_practicallaw"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointpicks_forms"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointpicks_secondarysrc"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepoint_rulebooks"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepoint_categorypage"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicallaw"></li></ul></span></div>
			</div>
			<div id="co_searchFormRight">
				<div id="co_searchFormRightWrapper">
					<!-- Jurisdiction selected -->
					<div id="co_jurisdictionWidgetContainer" class="">

<a class="co_jurisdictionSelectorDropDownArrowCollapsed" href="javascript:void(0);" id="jurisdictionId">
    <span id="jurisdictionIdInner">Federal Circuit</span>
</a>
</div>
					<!-- Search button -->
					<button title="Search" id="searchButton" class="co_hasTooltip" aria-label="Search 291 PATENTS">


						Search Westlaw
						<span class="co_accessibilityLabel">Search 291 PATENTS</span>
					</button>
					<!-- Advanced search -->
					<a href="#" onclick="return false;" class="co_hideState" id="co_search_advancedSearchLink" title="Advanced Search">Advanced</a>
					<!-- Holder jurisdiction pop up -->
					<div id="co_searchJurisdictionHoverContainer"></div>
				</div>
			</div>
			<!-- Search error container -->
			<div id="co_searchInputErrorMessageContainer" class="co_hideState"></div>
		</form>
	</div>
</div>
						<div id="coid_website_searchWidget" class="co_hideState"></div>
						<div id="co_researchAcceleratorWrapper">
							
						</div>
						<div class="co_skipToLink">
							<a id="coid_website_startContent" name="coid_website_startContent"></a>
						</div>

			</div><!--newHeader_bottom-->
		</div><!--headerContainer-->
	</div><!--newHeader-->
</div><!--co_headerWrapper-->




	
	
<!-- moved delivery toolbar to separate ascx control -->	








	<div id="co_body">
		<!-- BODY HEADER -->
		<div id="co_bodyHeader"></div>
		

	
	<!-- Reporting Name is "CTA" for document with guid "I7b55ac403f3c11e8a70fc9d8a0b2aef5". -->
	
	<!-- CENTER COLUMN -->  
	<div id="co_contentWrapper">
		<div id="co_contentColumn">
			<div class="co_innertube">










<div id="co_docHeaderContainer">
	<a class="co_skipToLink" href="#coid_website_errorsSummaryPlaceHolder">
		Skip Page Header
	</a>
	<div id="co_docHeader">
		<div id="co_docFixedHeader"><div id="co_docHeaderTitle"><h2 id="co_docHeaderTitleLine" title="Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals International Limited"><span id="title"><a class="co_drag co_draggabled co_drag_0 ui-draggable" href="https://1.next.westlaw.com/Document/I7b55ac403f3c11e8a70fc9d8a0b2aef5/View/FullText.html?listSource=Search&amp;navigationPath=Search%2fv1%2fresults%2fnavigation%2fi0ad604ab000001630667802a2028f1f7%3fNav%3dCUSTOMDIGEST%26fragmentIdentifier%3dI7b55ac403f3c11e8a70fc9d8a0b2aef5%26startIndex%3d1%26contextData%3d%2528sc.CustomDigest%2529%26transitionType%3dCustomDigestItem&amp;list=CUSTOMDIGEST&amp;rank=138&amp;listPageSource=edc4a850c828227f4c8d5f819b26133f&amp;originationContext=docHeader&amp;contextData=(sc.CustomDigest)&amp;transitionType=Document&amp;needToInjectTerms=False&amp;enableBestPortion=True&amp;docSource=094be5ec528a4ebcb516957557b7ae19">Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals International Limited</a></span></h2><ul id="co_documentStatusIcons" class="co_document_indicators"></ul><h3 id="co_docHeaderCitation" title="United States Court of Appeals, Federal Circuit. | April 13, 2018 | --- F.3d ---- | 2018 WL 1770273&nbsp;(Approx. 34 pages)"><span id="courtline">United States Court of Appeals, Federal Circuit.</span><span id="filedate">April 13, 2018</span><span id="cite0">--- F.3d ----</span><span id="cite1">2018 WL 1770273</span><em>&nbsp;(Approx. 34 pages)</em></h3><h4 id="co_docHeaderNegativeTreatment"><span id="co_document_compositeHeader_citatorFlag" class="co_citatorFlag"></span></h4></div></div>
		<div class="co_clear"></div>
		<div id="co_docPrimaryTabNavigationContainer" class="co_docTabs">
				<a id="co_iPadKeyCiteMenuToggle">
					Toggle Menu
				</a>
			<ul id="co_docPrimaryTabNavigation" class="co_tabs">










<li id="DocumentTab" class="co_tabLeft co_tabActive co_dropdownTab">
	<h2 class="co_tabRight">
		<a id="coid_DocumentTab_link" class="co_tabLink" href="javascript:void(0);">
			<span>Document</span>
		</a>
				<div class="co_clear"></div> 
	</h2>
	</li>







<li id="riFilingsTab" class="co_tabLeft" countstatus="" categoryenum="riFilings">
	<h2 class="co_tabRight">
		<a id="coid_relatedInfo_riFilings_link" class="co_tabLink" href="/RelatedInformation/I7b55ac403f3c11e8a70fc9d8a0b2aef5/riFilings.html?originationContext=documentTab&amp;transitionType=Filings&amp;contextData=(sc.CustomDigest)&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;rulebookMode=false" hiddenhref="/RelatedInformation/I7b55ac403f3c11e8a70fc9d8a0b2aef5/riFilings.html?originationContext=documentTab&amp;transitionType=Filings&amp;contextData=(sc.CustomDigest)&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;rulebookMode=false">
			
			<span>
				Filings 
			 (25)</span>
		</a>
		<div class="co_clear"></div> 
	</h2>
</li>







<li id="kcNegativeTreatmentTab" class="co_tabLeft co_tabInactive co_done" countstatus="" categoryenum="kcNegativeTreatment">
	<h2 class="co_tabRight">
		<a id="coid_relatedInfo_kcNegativeTreatment_link" class="co_tabLink" href="javascript:void(0);" hiddenhref="/RelatedInformation/I7b55ac403f3c11e8a70fc9d8a0b2aef5/kcNegativeTreatment.html?originationContext=documentTab&amp;transitionType=NegativeTreatment&amp;contextData=(sc.CustomDigest)&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;rulebookMode=false" aria-label="Negative Treatment 
			 (0) unavailable">
			
			<span>
				Negative Treatment 
			 (0)</span>
		</a>
		<div class="co_clear"></div> 
	</h2>
</li>







<li id="kcJudicialHistoryTab" class="co_tabLeft" countstatus="" categoryenum="kcJudicialHistory">
	<h2 class="co_tabRight">
		<a id="coid_relatedInfo_kcJudicialHistory_link" class="co_tabLink" href="/RelatedInformation/I7b55ac403f3c11e8a70fc9d8a0b2aef5/kcJudicialHistory.html?originationContext=documentTab&amp;transitionType=History&amp;contextData=(sc.CustomDigest)&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;rulebookMode=false" hiddenhref="/RelatedInformation/I7b55ac403f3c11e8a70fc9d8a0b2aef5/kcJudicialHistory.html?originationContext=documentTab&amp;transitionType=History&amp;contextData=(sc.CustomDigest)&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;rulebookMode=false">
			
			<span>
				History 
			 (8)</span>
		</a>
		<div class="co_clear"></div> 
	</h2>
</li>







<li id="kcCitingReferencesTab" class="co_tabLeft co_tabInactive co_done" countstatus="" categoryenum="kcCitingReferences">
	<h2 class="co_tabRight">
		<a id="coid_relatedInfo_kcCitingReferences_link" class="co_tabLink" href="javascript:void(0);" hiddenhref="/RelatedInformation/I7b55ac403f3c11e8a70fc9d8a0b2aef5/kcCitingReferences.html?originationContext=documentTab&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;rulebookMode=false" aria-label="Citing References 
			 (0) unavailable">
			
			<span>
				Citing References 
			 (0)</span>
		</a>





<span id="co_kcCitingReferencesNavAnchor" class="co_dropdownArrowCollapsed">Navigate Citing References</span>
		<div class="co_clear"></div> 
	</h2>
		<div id="co_kcCitingReferencesNavContent" class="co_dropdownBoxCollapsed" style="display:none;"></div>
</li>







<li id="kcTableOfAuthoritiesTab" class="co_tabLeft" countstatus="" categoryenum="kcTableOfAuthorities">
	<h2 class="co_tabRight">
		<a id="coid_relatedInfo_kcTableOfAuthorities_link" class="co_tabLink" href="/RelatedInformation/I7b55ac403f3c11e8a70fc9d8a0b2aef5/kcTableOfAuthorities.html?originationContext=documentTab&amp;transitionType=TableOfAuthorities&amp;contextData=(sc.CustomDigest)&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;rulebookMode=false" hiddenhref="/RelatedInformation/I7b55ac403f3c11e8a70fc9d8a0b2aef5/kcTableOfAuthorities.html?originationContext=documentTab&amp;transitionType=TableOfAuthorities&amp;contextData=(sc.CustomDigest)&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;rulebookMode=false">
			
			<span>
				Table of Authorities 
			</span>
		</a>
		<div class="co_clear"></div> 
	</h2>
</li>




<li id="co_powByKCContainer">
	<a id="co_powByKC" href="javascript:void(0)">
		Powered by KeyCite
	</a>
</li>

			</ul>
		</div>
		<div class="co_clear"></div>
		<div id="co_docToolbarContainer" class="">
			<div id="co_docToolbar"><div><ul id="co_docToolbarMenuLeft"><li id="co_docToolbarBackToResults"><div id="co_documentFooterBreadcrumb"><a class="co_tbButton" href="/Search/Results.html?jurisdiction=CTAF&amp;saveJuris=False&amp;contentType=CUSTOMDIGEST&amp;querySubmissionGuid=i0ad604ab000001630667802a2028f1f7&amp;startIndex=1&amp;tocGuid=I4aee2539c6f64c1812a4c2f3395c2607&amp;categoryPageUrl=Home%2FWestKeyNumberSystem&amp;searchId=i0ad604ab000001630667802a2028f1f7&amp;kmSearchIdRequested=False&amp;simpleSearch=False&amp;isAdvancedSearchTemplatePage=False&amp;skipSpellCheck=False&amp;isTrDiscoverSearch=False&amp;ancillaryChargesAccepted=False&amp;proviewEligible=False&amp;transitionType=ReturnToList&amp;contextData=%28sc.CustomDigest%29#I7b55ac403f3c11e8a70fc9d8a0b2aef5"><span class="icon25 icon_back_arrow btnOffset"></span>Return to list</a></div></li><li id="co_docToolbarDocumentNavigation"><div id="co_documentFooterResultsNavigation" class="co_prevNextNavigation"><button title="Previous Document" id="co_documentFooterResultsNavigationPrevious" class="co_prev co_tbButton">
	                <span class="icon25 icon_prev_arrow">Previous Document</span>
                </button>
                <span class="co_navigationText"><strong>138</strong> of <strong>1,157 results</strong></span>
                <button title="Next Document" id="co_documentFooterResultsNavigationNext" class="co_next co_tbButton">
                    <span class="icon25 icon_next_arrow">Next Document</span>
                </button></div></li></ul><ul id="co_docToolbarMenuRight"><li id="co_docToolbarMenuRightChildWidget0" class="co_hideState"></li><li id="co_docHeaderSearchGrading"></li><li id="co_docToolbarGoTo"><div class="co_dropdownTabCollapsed"><div class="co_dropdownTab"><a href="javascript:void(0);" class="co_dropdownBoxanchorLabel" role="button">Go to</a><a href="javascript:void(0);" role="button" class="co_dropdownArrowCollapsed">Open Skip to Menu</a></div></div><div id="co_docGoToWidget" class="co_dropdownBoxCollapsed"><div class="co_dropdownBoxContent" id="co_skipTo"><div class="co_dropdownBoxContentRight"><div><div><a href="#co_synopsis">Synopsis</a></div><div><a href="#co_headnoteHeader">West Headnotes</a></div><div><a href="#co_attorneysAndLawFirms">Attorneys and Law Firms</a></div><div><a href="#co_opinion">Opinion</a></div><div><a href="#co_dissent_opinion">Dissenting Opinion</a></div><div><a href="#co_allCitations">All Citations</a></div></div></div></div><div id="co_starPage" class="co_dropdownBoxContent"><div class="co_dropdownBoxContentRight"><label for="co_document_starPage_starPageNavInput">Page #</label><input id="co_document_starPage_starPageNavInput" maxlength="6" size="6" type="text"><span id="co_document_starPage_starPageNavGo" class="co_primaryBtn">Go</span><div id="co_document_starPage_starPageNavError"></div><div class="co_clear"></div></div></div></div></li><li id="co_docToolbarTocNavigation"></li><li id="co_docToolbarTocFlyout"></li><li id="co_docToolbarMenuRightChildWidget5"></li><li id="co_docToolbarMenuRightChildWidget6"></li><li id="co_docToolbarMenuRightChildWidget7" class="co_toolbarSeparator"></li><li id="co_docToolbarSearchWithinDocument"><div id="co_docSearchWithinContainer"><a role="button" href="javascript:void(0);" class="co_dropdownTitle" title="Search text in this document">Search Within this Document</a>
<div id="co_docSearchWithinDropdownContainer">
	<div id="co_docSearchWithinDropdownContainerInner">
		<div id="co_docSearchWithinDropdownContainerInnerContent" class="co_dropdownBoxCollapsed">
			<!-- toggle between co_dropDownBoxCollapsed and co_dropdownBoxExpanded to show/hide -->
			<div class="co_dropdownBoxHeader">
				<span></span>
			</div>
			<div class="co_dropdownBoxContent">
				<div class="co_dropdownBoxContentRight">
					<div id="co_docSearchWithin_input">
						
<div id="co_docSearchWithin_searchInputContainer_withRecentSearch">
	<a id="co_searchLast10Link" class="co_recentSearchesLink" href="javascript:void(0);" title="Recent Searches">
		Last 10 Searches
	</a>
	<div class="co_textarea">
		<textarea id="co_docSearchWithin_searchInput_withRecentSearch" rows="1" autocorrect="off" autocapitalize="off" role="textbox" aria-label="Enter term to search for in current document"></textarea>
	</div>
	<div id="co_documentRecentQueryListBox" class="co_hideState"><ul class="co_searchSuggestionContainer" id="co_documentSearchLast10List"></ul></div>
</div>

						<input id="co_docSearchWithin_searchButton" class="co_secondaryBtn" value="Search" role="button" aria-label="Search Within this Document" type="button">
					</div>
					<div class="co_prevNextNavigation co_hideState">
						<button title="Previous Term" class="co_prev co_tbButton">
							<span class="icon25 icon_prev_arrow">Previous Term</span>
						</button>
						<button title="Next Term" class="co_next co_tbButton">
							<span class="icon25 icon_next_arrow">Next Term</span>
						</button>
						<span class="co_navigationText co_hideState"></span>
					</div>
					<button id="co_docSearchWithin_help" class="co_helpLink">Terms &amp;amp; Connectors</button>
					<button id="co_docSearchWithinCloseButton" class="co_widget_closeIcon">Close</button>
					<div id="co_docSearchWithinMessage"></div>
					<div class="co_clear"></div>
				</div>
				<div id="searchWithinTncContainer" class="co_hideState"><div id="co_search_advancedSearch_tncLegendBox">  <h2 id="co_search_advancedSearch_tncHelpTitle">Connectors and Expanders</h2>  <a id="co_search_advancedSearch_tncHelpLink" href="#" class="co_hideState">Help</a>  <dl id="co_search_advancedSearch_tncLegendList">    <dt>&amp;</dt><dd>AND</dd>    <dt>/s</dt><dd>In same sentence</dd>    <dt>or</dt><dd>OR</dd>    <dt>+s</dt><dd>Preceding within sentence</dd>    <dt>/p</dt><dd>In same paragraph</dd>    <dt>""</dt><dd>Phrase</dd>    <dt>+p</dt><dd>Preceding within paragraph</dd>    <dt>%</dt><dd>But not</dd>    <dt>/n</dt><dd>Within n terms of</dd>    <dt>!</dt><dd>Root expander</dd>    <dt>+n</dt><dd>Preceding within n terms of</dd>    <dt>*</dt><dd>Universal character</dd>    <dt>#</dt><dd>Prefix to turn off plurals and equivalents</dd>  </dl></div></div>
			</div>
			<div class="co_dropdownBoxFooter">
				<span></span>
			</div>
		</div>
	</div>
</div></div></li><li id="co_docToolbarDisplayOptions"><a role="button" id="co_displayOptionsLink" class="co_tbButton" href="javascript:void(0);" title="Display Options"><span class="icon25 icon_text_resize">Display Options</span></a></li><li id="co_docToolbarDeliveryWidget"><div id="deliveryWidget1" class="co_dropDownMenu collapsed"><div class="co_dropDownButton"><a role="button" id="deliveryLink1" title="Email" class="co_tbButton" href="javascript:void(0);"><span class="icon25 icon_email">Email</span></a><a href="javascript:void(0);" class="co_tbButton co_dropDownAnchor" role="button" id="deliveryDropButton1" aria-label="Delivery menu" title="Delivery menu" aria-describedby="navigation1"><span class="icon25 icon_down_blue_arrow"></span></a><span id="navigation1" class="co_accessibilityLabel">Enter to open, tab to navigate, enter to select</span></div><div id="deliveryWidgetMenu1" class="co_dropDownMenuContent" role="document"><ul class="co_dropDownMenuList checkmarks icons" role="listbox" aria-multiselectable="true" aria-hidden="false" aria-expanded="true"><li id="deliveryRow1Email" name="Email" role="presentation" class="checked"><a title="Email" id="deliveryLinkRow1Email" role="option" aria-posinset="1" aria-setsize="3" class="co_deliveryLinkOptions" tabindex="0" aria-selected="true"><span class="icon25 icon_email"></span>Email</a></li><li id="deliveryRow1Print" name="Print" role="presentation"><a title="Print" id="deliveryLinkRow1Print" role="option" aria-posinset="2" aria-setsize="3" class="co_deliveryLinkOptions" tabindex="0" aria-selected="false"><span class="icon25 icon_print"></span>Print</a></li><li id="deliveryRow1Download" name="Download" role="presentation"><a title="Download" id="deliveryLinkRow1Download" role="option" aria-posinset="3" aria-setsize="3" class="co_deliveryLinkOptions" tabindex="0" aria-selected="false"><span class="icon25 icon_download"></span>Download</a></li></ul><div class="co_deliveryWidgetMenuFooter"></div></div><div id="co_deliveryWidget_Message1"></div></div></li><li id="co_docToolbarReadingModeWidget"><a role="button" id="co_fullscreenModeLink" class="co_tbButton" href="javascript:void(0);" title="Fullscreen Mode"><span class="icon25 icon_fullscreen">Fullscreen Mode</span></a></li></ul></div></div> 
			<div class="co_clear"></div>
		</div>
	</div>
</div>

				<div id="coid_website_errorsSummaryPlaceHolder"><div class="co_infoBox failure" style="display: none;"><div class="co_infoBox_container"><div class="co_infoBox_outer"><div class="co_infoBox_inner"><a id="co_website_errorSumarryCloseLink" class="co_infoBox_closeButton">Close</a><div class="co_infoBox_message" tabindex="-1">Sorry, there was an error on this page.<a href="javascript:void(0);" id="co_website_errorSummaryToggleLink">More info</a><a href="javascript:void(0);" id="co_website_errorSummaryToggleLinkLessInfo" style="display: none; margin-left: 6px;">Less info</a><ul class="co_website_errorsSummaryList" style="display: none;"></ul></div></div></div></div></div></div>
				<div id="coid_website_messagePlaceholder"></div>







				<div id="test_hplink"></div>
				<div class="co_scrollWrapper">





							<div id="coid_website_documentWidgetDiv" class=" co_khSpeedReadExpandAll">
<div id="co_briefItDiv" class="co_excludeAnnotations"><button id="co_briefItButton" class="co_primaryBtn co_floatRight">Brief It</button><div class="undefined"></div></div><div id="co_document" class="co_addFocusCorrection"><div id="co_document_0" class="co_document co_caselawNRS"><input id="co_keyCiteFlagPlaceHolder" type="hidden"><input id="co_document_starPageMetadata" value="{ &quot;citations&quot;: { &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;:&quot;2018 WL 1770273 (C.A.Fed. (Del.))&quot; }, &quot;westlawCiteOnly&quot;:true, &quot;pubs&quot;: { &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;:&quot;999&quot; } }" alt="metadata" type="hidden"><div class="co_cites">2018 WL 1770273</div><input id="co_document_paraNumbersSourceCiteMetadata" value="{ &quot;paraNumbersSourceCite&quot;: &quot;2018 WL 1770273&quot;, &quot;publicationNumber&quot;: &quot;999&quot; }" alt="metadata" type="hidden"><div class="co_contentBlock co_briefItState co_editorialNoteBlock"><div>Only the Westlaw citation is currently available.</div></div><div class="co_contentBlock co_briefItState co_courtBlock"><div>United States Court of Appeals, Federal Circuit.</div></div><div class="co_title"><div class="co_suit"><div class="co_partyLine">VANDA PHARMACEUTICALS INC., Plaintiff-Appellee</div><div class="co_partyLine"><a id="co_link_I3784b3903f4f11e8b6a4b140d77433d6" class="co_link" href="https://1.next.westlaw.com/Search/Results.html?query=advanced%3a+OAID(5000067560)&amp;saveJuris=False&amp;contentType=BUSINESS-INVESTIGATOR&amp;startIndex=1&amp;contextData=(sc.Default)&amp;categoryPageUrl=Home%2fCompanyInvestigator&amp;originationContext=document&amp;transitionType=DocumentItem">Aventisub LLC</a>, Plaintiff</div><div>v.</div><div class="co_partyLine">WEST-WARD PHARMACEUTICALS INTERNATIONAL LIMITED, <a id="co_link_I378c7bc13f4f11e8b6a4b140d77433d6" class="co_link" href="https://1.next.westlaw.com/Search/Results.html?query=advanced%3a+OAID(5059305620)&amp;saveJuris=False&amp;contentType=BUSINESS-INVESTIGATOR&amp;startIndex=1&amp;contextData=(sc.Default)&amp;categoryPageUrl=Home%2fCompanyInvestigator&amp;originationContext=document&amp;transitionType=DocumentItem">West-Ward Pharmaceuticals Corp.</a>, Defendants-Appellants</div></div></div><div class="co_docketDate"><div class="co_contentBlock co_briefItState co_docketBlock"><span>2016-2707, 2016-2708</span></div><div class="co_date"><span>Decided: April 13, 2018</span></div></div><div class="co_contentBlock co_briefItState co_synopsis"><h2 id="co_synopsis" class="co_printHeading">Synopsis</h2><div><div class="co_paragraph"><div class="co_paragraphText"><strong>Background:</strong> Owner of patent related to a method of treating schizophrenia patients with iloperidone wherein the dosage range was based on the patient's genotype brought infringement action against manufacturer of generic drug. Following bench trial, the United States District Court for the District of Delaware, Nos. 1:13-cv-01973-GMS, 1:14-cv-00757-GMS, <a id="co_link_I34bb9efd41b411e8a9a7ae522723c830" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0132747001&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Gregory M. Sleet</a>, J., <a id="co_link_I34bb9ef841b411e8a9a7ae522723c830" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039653953&amp;pubNum=0007903&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">203 F.Supp.3d 412</a>, determined that patent claims were infringed and not invalid. Manufacturer appealed.</div></div></div><div class="co_contentBlock co_briefItState co_synopsisHolding"><div class="co_paragraph"><div class="co_paragraphText"><strong>Holdings:</strong> The Court of Appeals, <a id="co_link_I34bdc1d041b411e8a9a7ae522723c830" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0225327201&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Lourie</a>, Circuit Judge, held that:</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F32044320422" class="co_internalLink co_excludeAnnotations co_disableHighlightFeatures">1</a> district court had subject matter jurisdiction over patent infringement suit;</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F112044320422" class="co_internalLink co_excludeAnnotations co_disableHighlightFeatures">2</a> patent owner established that if proposed product were marketed, it would infringe patent;</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F182044320422" class="co_internalLink co_excludeAnnotations co_disableHighlightFeatures">3</a> claims were directed to patent eligible subject matter; and</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F212044320422" class="co_internalLink co_excludeAnnotations co_disableHighlightFeatures">4</a> claims were not invalid for lack of adequate written description.</div></div></div><div class="co_paragraph"><div class="co_paragraphText">Affirmed.</div></div><div class="co_paragraph"><div class="co_paragraphText"><a id="co_link_I34c42a7041b411e8a9a7ae522723c830" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0324402101&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Prost</a>, Chief Judge, filed a dissenting opinion.</div></div></div><div id="co_headnotes" class="co_headnotes co_fancyHeadnotes"><h2 id="co_headnoteHeader" class="co_headnoteHeader co_printHeading"><span class="co_headnoteHeaderSpan">West Headnotes (28)</span><a id="co_headnoteExpandCollapseLink" class="co_accLink co_excludeAnnotations co_disableHighlightFeatures" href="javascript:void(0);" role="button">Collapse West Headnotes</a></h2><div class="co_headnotesContentContainer"><div id="co_expandedHeadnotes"><div id="co_headnoteTools"><a id="co_headnotesShowOrHideFancy" href="javascript:void(0);" class="co_fancyHeadnotesShowHide co_excludeAnnotations co_disableHighlightFeatures">Change View</a></div><div class="co_headnoteRow" id="co_anchor_2044320422001"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F12044320422"><span class="co_headnoteNumber" id="co_anchor_headNote_1"><a href="#co_anchor_B12044320422" class="co_internalLink">1</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EFEAC" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170B/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Federal Courts</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EXFAC" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk3566/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Questions of Law in General</a></span></div><div class="co_secondaryHeadnoteNodes"> <span class="co_hiddenKeyText"><strong><a id="co_link_ID0EUGAC" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170B/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Federal Courts</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0ECJAC" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk3603(2)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">"Clearly erroneous" standard of review in general</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">On appeal from a bench trial, the Court of Appeals reviews a district court's conclusions of law de novo and its findings of fact for clear error.</div></div><div id="co_headnoteId_204432042200120180423222802" class="co_headnoteCitedCaseRef"><a id="co_link_ID0ERJAC" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;headnoteId=204432042200120180423222802&amp;originationContext=document&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 1">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e5e6ea0476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170B/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170B</a></span><span class="co_headnoteTopicKey">Federal Courts</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e5e6ea1476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170BXVII/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170BXVII</a></span><span class="co_headnoteTopicKey">Courts of Appeals</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e5e6ea2476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170BXVII(K)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170BXVII(K)</a></span><span class="co_headnoteTopicKey">Scope and Extent of Review</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e5f0ae0476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170BXVII(K)2/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170BXVII(K)2</a></span><span class="co_headnoteTopicKey">Standard of Review</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e5ff540476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk3566/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170Bk3566</a></span><span class="co_headnoteTopicKey">Questions of Law in General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e5ff541476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk3567/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170Bk3567</a></span><span class="co_headnoteTopicKey">In general</span></div></div></div></div></div><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e601c50476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170B/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170B</a></span><span class="co_headnoteTopicKey">Federal Courts</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e601c51476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170BXVII/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170BXVII</a></span><span class="co_headnoteTopicKey">Courts of Appeals</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e601c52476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170BXVII(K)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170BXVII(K)</a></span><span class="co_headnoteTopicKey">Scope and Extent of Review</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e601c53476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170BXVII(K)2/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170BXVII(K)2</a></span><span class="co_headnoteTopicKey">Standard of Review</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e601c54476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk3576/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170Bk3576</a></span><span class="co_headnoteTopicKey">Procedural Matters</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e604360476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk3603/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170Bk3603</a></span><span class="co_headnoteTopicKey">Findings</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e604361476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk3603(2)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170Bk3603(2)</a></span><span class="co_headnoteTopicKey">"Clearly erroneous" standard of review in general</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2044320422002"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F22044320422"><span class="co_headnoteNumber" id="co_anchor_headNote_2"><a href="#co_anchor_B22044320422" class="co_internalLink">2</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EDKAC" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170B/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Federal Courts</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0ERMAC" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk3603(7)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Definite and firm conviction of mistake</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">A factual finding is only clearly erroneous if, despite some supporting evidence, the court is left with the definite and firm conviction that a mistake has been made.</div></div><div id="co_headnoteId_204432042200220180423222802" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EANAC" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;headnoteId=204432042200220180423222802&amp;originationContext=document&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 2">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e606a70476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170B/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170B</a></span><span class="co_headnoteTopicKey">Federal Courts</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e606a71476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170BXVII/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170BXVII</a></span><span class="co_headnoteTopicKey">Courts of Appeals</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e606a72476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170BXVII(K)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170BXVII(K)</a></span><span class="co_headnoteTopicKey">Scope and Extent of Review</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e606a73476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170BXVII(K)2/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170BXVII(K)2</a></span><span class="co_headnoteTopicKey">Standard of Review</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e606a74476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk3576/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170Bk3576</a></span><span class="co_headnoteTopicKey">Procedural Matters</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e606a75476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk3603/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170Bk3603</a></span><span class="co_headnoteTopicKey">Findings</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e606a76476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk3603(7)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170Bk3603(7)</a></span><span class="co_headnoteTopicKey">Definite and firm conviction of mistake</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2044320422003"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F32044320422"><span class="co_headnoteNumber" id="co_anchor_headNote_3"><a href="#co_anchor_B32044320422" class="co_internalLink">3</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0ESNAC" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EIPAC" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1590/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Filing of applications for drug approval</a></span></div><div class="co_secondaryHeadnoteNodes"> <span class="co_hiddenKeyText"><strong><a id="co_link_ID0EXPAC" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EKBAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1712/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Jurisdiction</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">District court had subject matter jurisdiction over patent infringement suit against manufacturer of generic drug, although drug patent issued after Abbreviated New Drug Application (ANDA) was filed and complaint was filed before ANDA applicant submitted a Paragraph IV certification for the asserted patent; complaint alleged infringement by filing ANDA, and actual controversy existed between the parties from the time when the suit was commenced. <a id="co_link_I34f91d2041b411e8a9a7ae522723c830" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=28USCAS1331&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">28 U.S.C.A. §§ 1331</a>, <a id="co_link_I34f91d2141b411e8a9a7ae522723c830" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=28USCAS1338&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_8b3b0000958a4">1338(a)</a>; <a id="co_link_I34f96b4041b411e8a9a7ae522723c830" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">35 U.S.C.A. § 271(e)(2)</a>.</div></div><div id="co_headnoteId_204432042200320180423222802" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EHCAE" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;headnoteId=204432042200320180423222802&amp;originationContext=document&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 3">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e60dfa1476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e6106b0476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII</a></span><span class="co_headnoteTopicKey">Patent Infringement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e6106b1476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(A)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(A)</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e6106b2476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1587/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1587</a></span><span class="co_headnoteTopicKey">Patents for Compositions of Matter</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e6106b3476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1590/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1590</a></span><span class="co_headnoteTopicKey">Filing of applications for drug approval</span></div></div></div></div></div><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e60b890476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e60b891476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII</a></span><span class="co_headnoteTopicKey">Patent Infringement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e60b892476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(C)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(C)</a></span><span class="co_headnoteTopicKey">Actions</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e60b893476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(C)1/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(C)1</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e60b894476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1712/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1712</a></span><span class="co_headnoteTopicKey">Jurisdiction</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e60dfa0476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1713/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1713</a></span><span class="co_headnoteTopicKey">In general</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2044320422004"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F42044320422"><span class="co_headnoteNumber" id="co_anchor_headNote_4"><a href="#co_anchor_B42044320422" class="co_internalLink">4</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EUDAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170B/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Federal Courts</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0E3EAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk2106/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Inception and duration of dispute;  recurrence;  "capable of repetition yet evading review"</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">To qualify as a case fit for federal-court adjudication, an actual controversy must be extant at all stages of review, including at the time the complaint is filed.</div></div><div id="co_headnoteId_204432042200420180423222802" class="co_headnoteCitedCaseRef"><a id="co_link_ID0ELFAE" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;headnoteId=204432042200420180423222802&amp;originationContext=document&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 4">Cases that cite this headnote<input id="co_docMarker_0" type="hidden"></a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e6154d0476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170B/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170B</a></span><span class="co_headnoteTopicKey">Federal Courts</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e6154d1476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170BIII/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170BIII</a></span><span class="co_headnoteTopicKey">Case or Controversy Requirement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e6154d2476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170BIII(A)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170BIII(A)</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e6154d3476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk2106/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170Bk2106</a></span><span class="co_headnoteTopicKey">Inception and duration of dispute;  recurrence;  "capable of repetition yet evading review"</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2044320422005"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F52044320422"><span class="co_headnoteNumber" id="co_anchor_headNote_5"><a href="#co_anchor_B52044320422" class="co_internalLink">5</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0E4FAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EPHAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1848/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Questions of law or fact</a></span></div><div class="co_secondaryHeadnoteNodes"> <span class="co_hiddenKeyText"><strong><a id="co_link_ID0E5HAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EMKAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1970(15)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Infringement or noninfringement</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">In a bench trial, infringement is a question of fact that the Court of Appeals reviews for clear error.</div></div><div id="co_headnoteId_204432042200520180423222802" class="co_headnoteCitedCaseRef"><a id="co_link_ID0E2KAE" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;headnoteId=204432042200520180423222802&amp;originationContext=document&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 5">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e617be0476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e617be1476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII</a></span><span class="co_headnoteTopicKey">Patent Infringement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e617be2476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(C)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(C)</a></span><span class="co_headnoteTopicKey">Actions</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e617be3476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(C)4/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(C)4</a></span><span class="co_headnoteTopicKey">Trial, Hearing, and Determination</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e617be4476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1848/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1848</a></span><span class="co_headnoteTopicKey">Questions of law or fact</span></div></div></div></div></div><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e61a2f0476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e61a2f1476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII</a></span><span class="co_headnoteTopicKey">Patent Infringement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e61a2f2476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(C)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(C)</a></span><span class="co_headnoteTopicKey">Actions</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e61a2f3476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(C)7/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(C)7</a></span><span class="co_headnoteTopicKey">Appellate Review</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e61a2f4476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1965/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1965</a></span><span class="co_headnoteTopicKey">Scope, Standard, and Extent of Review</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e61a2f5476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1970/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1970</a></span><span class="co_headnoteTopicKey">Particular Matters</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e61ca00476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1970(15)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1970(15)</a></span><span class="co_headnoteTopicKey">Infringement or noninfringement</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2044320422006"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F62044320422"><span class="co_headnoteNumber" id="co_anchor_headNote_6"><a href="#co_anchor_B62044320422" class="co_internalLink">6</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0ENLAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EDNAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1590/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Filing of applications for drug approval</a></span></div><div class="co_secondaryHeadnoteNodes"> <span class="co_hiddenKeyText"><strong><a id="co_link_ID0ESNAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EIPAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1668/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Drugs and medicines</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">A patent infringement inquiry under statute stating that submitting application for drug claimed in patent is infringement if purpose of submission is to obtain approval to engage in commercial manufacture, use, or sale of drug before expiration of patent, is focused on a comparison of the asserted patent claims against the product that is likely to be sold following Abbreviated New Drug Application (ANDA) approval. <a id="co_link_I351557b041b411e8a9a7ae522723c830" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_9e660000185f2">35 U.S.C.A. § 271(e)(2)(A)</a>.</div></div><div id="co_headnoteId_204432042200620180423222802" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EXPAE" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;headnoteId=204432042200620180423222802&amp;originationContext=document&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 6">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e61ca01476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e61f110476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII</a></span><span class="co_headnoteTopicKey">Patent Infringement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e61f111476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(A)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(A)</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e61f112476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1587/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1587</a></span><span class="co_headnoteTopicKey">Patents for Compositions of Matter</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e61f113476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1590/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1590</a></span><span class="co_headnoteTopicKey">Filing of applications for drug approval</span></div></div></div></div></div><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e621820476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e621821476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII</a></span><span class="co_headnoteTopicKey">Patent Infringement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e621822476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(B)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(B)</a></span><span class="co_headnoteTopicKey">Particular Fields of Invention</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e621823476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1666/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1666</a></span><span class="co_headnoteTopicKey">Health Care and Medical Products</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e621824476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1668/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1668</a></span><span class="co_headnoteTopicKey">Drugs and medicines</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2044320422007"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F72044320422"><span class="co_headnoteNumber" id="co_anchor_headNote_7"><a href="#co_anchor_B72044320422" class="co_internalLink">7</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0ETQAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EFSAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1824/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Degree of proof</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">The patentee bears the burden of proving infringement under statute stating that submitting application for drug claimed in patent is infringement if purpose of submission is to obtain approval to engage in commercial manufacture, use, or sale of drug before expiration of patent by a preponderance of the evidence. <a id="co_link_I35229e2041b411e8a9a7ae522723c830" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_9e660000185f2">35 U.S.C.A. § 271(e)(2)(A)</a>.</div></div><div id="co_headnoteId_204432042200720180423222802" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EUSAE" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;headnoteId=204432042200720180423222802&amp;originationContext=document&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 7">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e623f30476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e626640476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII</a></span><span class="co_headnoteTopicKey">Patent Infringement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e626641476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(C)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(C)</a></span><span class="co_headnoteTopicKey">Actions</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e626642476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(C)3/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(C)3</a></span><span class="co_headnoteTopicKey">Evidence</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e626643476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1824/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1824</a></span><span class="co_headnoteTopicKey">Degree of proof</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2044320422008"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F82044320422"><span class="co_headnoteNumber" id="co_anchor_headNote_8"><a href="#co_anchor_B82044320422" class="co_internalLink">8</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EQTAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170B/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Federal Courts</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0ECVAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk3574/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Statutes, regulations, and ordinances, questions concerning in general</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">The Court of Appeals reviews the district court's statutory interpretation without deference.</div></div><div id="co_headnoteId_204432042200820180423222802" class="co_headnoteCitedCaseRef"><a id="co_link_ID0ERVAE" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;headnoteId=204432042200820180423222802&amp;originationContext=document&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 8">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e628d50476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170B/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170B</a></span><span class="co_headnoteTopicKey">Federal Courts</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e628d51476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170BXVII/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170BXVII</a></span><span class="co_headnoteTopicKey">Courts of Appeals</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e628d52476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170BXVII(K)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170BXVII(K)</a></span><span class="co_headnoteTopicKey">Scope and Extent of Review</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e62b460476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170BXVII(K)2/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170BXVII(K)2</a></span><span class="co_headnoteTopicKey">Standard of Review</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e62b461476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk3574/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170Bk3574</a></span><span class="co_headnoteTopicKey">Statutes, regulations, and ordinances, questions concerning in general</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2044320422011"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F92044320422"><span class="co_headnoteNumber" id="co_anchor_headNote_9"><a href="#co_anchor_B92044320422" class="co_internalLink">9</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EDWAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EZXAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1590/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Filing of applications for drug approval</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Amendments to an Abbreviated New Drug Application (ANDA), including a Paragraph IV certification for a later-issued patent, can constitute an act of patent infringement under statute stating that submitting application for drug claimed in patent is infringement if purpose of submission is to obtain approval to engage in commercial manufacture, use, or sale of drug before expiration of patent. <a id="co_link_I3551eb8041b411e8a9a7ae522723c830" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">35 U.S.C.A. § 271(e)(2)</a>.</div></div><div id="co_headnoteId_204432042201120180423222802" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EIYAE" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;headnoteId=204432042201120180423222802&amp;originationContext=document&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 9">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e62db70476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e62db71476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII</a></span><span class="co_headnoteTopicKey">Patent Infringement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e62db72476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(A)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(A)</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e62db73476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1587/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1587</a></span><span class="co_headnoteTopicKey">Patents for Compositions of Matter</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e62db74476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1590/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1590</a></span><span class="co_headnoteTopicKey">Filing of applications for drug approval</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2044320422009"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F102044320422"><span class="co_headnoteNumber" id="co_anchor_headNote_10"><a href="#co_anchor_B102044320422" class="co_internalLink">10</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EEZAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0E11AE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1590/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Filing of applications for drug approval</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">A filer of an Abbreviated New Drug Application (ANDA) is subject to an infringement claim on a patent that issues after the filing of the ANDA, but before FDA approval. <a id="co_link_I353080d041b411e8a9a7ae522723c830" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_9e660000185f2">35 U.S.C.A. § 271(e)(2)(A)</a>.</div></div><div id="co_headnoteId_204432042200920180423222802" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EJ2AE" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;headnoteId=204432042200920180423222802&amp;originationContext=document&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 10">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e630280476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e632990476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII</a></span><span class="co_headnoteTopicKey">Patent Infringement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e632991476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(A)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(A)</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e632992476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1587/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1587</a></span><span class="co_headnoteTopicKey">Patents for Compositions of Matter</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e632993476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1590/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1590</a></span><span class="co_headnoteTopicKey">Filing of applications for drug approval</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2044320422010"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F112044320422"><span class="co_headnoteNumber" id="co_anchor_headNote_11"><a href="#co_anchor_B112044320422" class="co_internalLink">11</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EF3AE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0E24AE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1668/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Drugs and medicines</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Owner of patent related to a method of treating schizophrenia patients with iloperidone wherein the dosage range was based on the patient's genotype established that if proposed Abbreviated New Drug Application (ANDA) product were marketed, it would infringe patent under statute stating that submitting application for drug claimed in patent was infringement if purpose of submission was to obtain approval to engage in commercial manufacture, use, or sale of drug before expiration of patent, as required for finding of inducement; proposed label recommended that physicians perform genotyping tests on iloperidone patients as claimed in patent. <input id="co_docMarker_1" type="hidden"><a id="co_link_I35458f7041b411e8a9a7ae522723c830" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">35 U.S.C.A. §§ 271(b)</a>, <a id="co_link_I35458f7141b411e8a9a7ae522723c830" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">271(e)(2)</a>.</div></div><div id="co_headnoteId_204432042201020180423222802" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EK5AE" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;headnoteId=204432042201020180423222802&amp;originationContext=document&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 11">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e6350a0476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e6350a1476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII</a></span><span class="co_headnoteTopicKey">Patent Infringement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e6350a2476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(B)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(B)</a></span><span class="co_headnoteTopicKey">Particular Fields of Invention</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e6350a3476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1666/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1666</a></span><span class="co_headnoteTopicKey">Health Care and Medical Products</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e6377b0476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1668/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1668</a></span><span class="co_headnoteTopicKey">Drugs and medicines</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2044320422012"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F122044320422"><span class="co_headnoteNumber" id="co_anchor_headNote_12"><a href="#co_anchor_B122044320422" class="co_internalLink">12</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EP6AE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EGBAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1600/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Inducement to infringe</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Direct infringement is a necessary predicate for a finding of induced infringement in the usual patent infringement case. <a id="co_link_I3558f06041b411e8a9a7ae522723c830" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">35 U.S.C.A. § 271(b)</a>.</div></div><div id="co_headnoteId_204432042201220180423222802" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EVBAG" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;headnoteId=204432042201220180423222802&amp;originationContext=document&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 12">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e639ec0476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e639ec1476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII</a></span><span class="co_headnoteTopicKey">Patent Infringement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e639ec2476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(A)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(A)</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e639ec3476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1597/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1597</a></span><span class="co_headnoteTopicKey">Indirect Infringement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e639ec4476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1600/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1600</a></span><span class="co_headnoteTopicKey">Inducement to infringe</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2044320422013"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F132044320422"><span class="co_headnoteNumber" id="co_anchor_headNote_13"><a href="#co_anchor_B132044320422" class="co_internalLink">13</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0ERCAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EHEAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1600/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Inducement to infringe</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">For a finding of induced infringement, it must be established that the defendant possessed specific intent to encourage another's infringement and not merely that the defendant had knowledge of the acts alleged to constitute inducement. <a id="co_link_I356aa3a041b411e8a9a7ae522723c830" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">35 U.S.C.A. § 271(b)</a>.</div></div><div id="co_headnoteId_204432042201320180423222802" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EWEAG" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;headnoteId=204432042201320180423222802&amp;originationContext=document&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 13">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e63c5d0476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e63ece0476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII</a></span><span class="co_headnoteTopicKey">Patent Infringement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e63ece1476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(A)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(A)</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e63ece2476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1597/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1597</a></span><span class="co_headnoteTopicKey">Indirect Infringement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e63ece3476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1600/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1600</a></span><span class="co_headnoteTopicKey">Inducement to infringe</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2044320422014"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F142044320422"><span class="co_headnoteNumber" id="co_anchor_headNote_14"><a href="#co_anchor_B142044320422" class="co_internalLink">14</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0ESFAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0ESHAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1832/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Participation, intent, and contributory infringement</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Circumstantial evidence can support a finding of specific intent to induce infringement. <a id="co_link_I35710c4041b411e8a9a7ae522723c830" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">35 U.S.C.A. § 271(b)</a>.</div></div><div id="co_headnoteId_204432042201420180423222802" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EBIAG" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;headnoteId=204432042201420180423222802&amp;originationContext=document&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 14">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e6413f0476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e6413f1476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII</a></span><span class="co_headnoteTopicKey">Patent Infringement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e6413f2476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(C)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(C)</a></span><span class="co_headnoteTopicKey">Actions</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e6413f3476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(C)3/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(C)3</a></span><span class="co_headnoteTopicKey">Evidence</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e643b00476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1825/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1825</a></span><span class="co_headnoteTopicKey">Weight and Sufficiency</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e643b01476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1832/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1832</a></span><span class="co_headnoteTopicKey">Participation, intent, and contributory infringement</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2044320422015"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F152044320422"><span class="co_headnoteNumber" id="co_anchor_headNote_15"><a href="#co_anchor_B152044320422" class="co_internalLink">15</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0E4IAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0E4KAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1832/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Participation, intent, and contributory infringement</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">A proposed label that instructs users to perform the patented method may provide evidence of the Abbreviated New Drug Application (ANDA) applicant's affirmative intent to induce infringement. <a id="co_link_I357ad04041b411e8a9a7ae522723c830" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">35 U.S.C.A. § 271(b)</a>.</div></div><div id="co_headnoteId_204432042201520180423222802" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EMLAG" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;headnoteId=204432042201520180423222802&amp;originationContext=document&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 15">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e646210476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e646211476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII</a></span><span class="co_headnoteTopicKey">Patent Infringement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e646212476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(C)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(C)</a></span><span class="co_headnoteTopicKey">Actions</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e646213476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(C)3/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(C)3</a></span><span class="co_headnoteTopicKey">Evidence</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e646214476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1825/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1825</a></span><span class="co_headnoteTopicKey">Weight and Sufficiency</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e648920476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1832/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1832</a></span><span class="co_headnoteTopicKey">Participation, intent, and contributory infringement</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2044320422016"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F162044320422"><span class="co_headnoteNumber" id="co_anchor_headNote_16"><a href="#co_anchor_B162044320422" class="co_internalLink">16</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EIMAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0E5NAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1668/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Drugs and medicines</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">When proof of specific intent depends on the label accompanying the marketing of a drug inducing infringement by physicians, the label must encourage, recommend, or promote infringement. <a id="co_link_I358334b041b411e8a9a7ae522723c830" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">35 U.S.C.A. § 271(b)</a>.</div></div><div id="co_headnoteId_204432042201620180423222802" class="co_headnoteCitedCaseRef"><a id="co_link_ID0ENOAG" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;headnoteId=204432042201620180423222802&amp;originationContext=document&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 16">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e64b030476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e64b031476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII</a></span><span class="co_headnoteTopicKey">Patent Infringement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e64b032476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(B)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(B)</a></span><span class="co_headnoteTopicKey">Particular Fields of Invention</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e64b033476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1666/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1666</a></span><span class="co_headnoteTopicKey">Health Care and Medical Products</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e64b034476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1668/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1668</a></span><span class="co_headnoteTopicKey">Drugs and medicines</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2044320422018"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F172044320422"><span class="co_headnoteNumber" id="co_anchor_headNote_17"><a href="#co_anchor_B172044320422" class="co_internalLink">17</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EJPAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0E6QAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1600/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Inducement to infringe</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">A person can be liable for inducing an infringing use of a product even if the product has substantial noninfringing uses. <a id="co_link_I358be74041b411e8a9a7ae522723c830" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">35 U.S.C.A. § 271(b)</a>.</div></div><div id="co_headnoteId_204432042201820180423222802" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EORAG" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;headnoteId=204432042201820180423222802&amp;originationContext=document&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 17">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e64fe50476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e64fe51476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII</a></span><span class="co_headnoteTopicKey">Patent Infringement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e64fe52476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(A)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(A)</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e64fe53476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1597/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1597</a></span><span class="co_headnoteTopicKey">Indirect Infringement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e64fe54476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1600/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1600</a></span><span class="co_headnoteTopicKey">Inducement to infringe</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2044320422021"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F182044320422"><span class="co_headnoteNumber" id="co_anchor_headNote_18"><a href="#co_anchor_B182044320422" class="co_internalLink">18</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EKSAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EAUAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k465/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Drugs and medicines</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Claims in patent related to a method of treating schizophrenia patients with iloperidone wherein the dosage range was based on the patient's genotype were directed to patent eligible subject matter; claims were a new way of using an existing drug that was safer for patients because it reduced the risk of QTc prolongation, and claims recited steps of carrying out a dosage regimen based on results of genetic testing and did not broadly tie up doctor's subsequent treatment decision. <a id="co_link_I35acdcc041b411e8a9a7ae522723c830" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C.A. § 101</a>.</div></div><div id="co_headnoteId_204432042202120180423222802" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EPUAG" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;headnoteId=204432042202120180423222802&amp;originationContext=document&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 18">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e652560476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e652561476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II</a></span><span class="co_headnoteTopicKey">Patentability and Validity</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e652562476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(B)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II(B)</a></span><span class="co_headnoteTopicKey">Eligible Subject Matter</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e654c70476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k463/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k463</a></span><span class="co_headnoteTopicKey">Health Care and Medical Products</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e654c71476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k465/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k465</a></span><span class="co_headnoteTopicKey">Drugs and medicines</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2044320422019"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F192044320422"><span class="co_headnoteNumber" id="co_anchor_headNote_19"><a href="#co_anchor_B192044320422" class="co_internalLink">19</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EKVAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0ESWAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k450/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Exceptions to Eligibility;  Ineligible Subject Matter</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">At step one of the patent eligibility analysis, it is not enough to merely identify a patent-ineligible concept underlying the claim; the court must determine whether that patent-ineligible concept is what the claim is directed to. <a id="co_link_I35986a6041b411e8a9a7ae522723c830" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C.A. § 101<input id="co_docMarker_2" type="hidden"></a>.</div></div><div id="co_headnoteId_204432042201920180423222802" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EPXAG" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;headnoteId=204432042201920180423222802&amp;originationContext=document&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 19">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e657380476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e657381476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II</a></span><span class="co_headnoteTopicKey">Patentability and Validity</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e657382476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(B)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II(B)</a></span><span class="co_headnoteTopicKey">Eligible Subject Matter</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e657383476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k450/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k450</a></span><span class="co_headnoteTopicKey">Exceptions to Eligibility;  Ineligible Subject Matter</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e657384476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k451/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k451</a></span><span class="co_headnoteTopicKey">In general</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2044320422020"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F202044320422" tabindex="0"><span class="co_headnoteNumber" id="co_anchor_headNote_20"><a href="#co_anchor_B202044320422" class="co_internalLink">20</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EKYAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EIZAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(B)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Eligible Subject Matter</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">If the claims are not directed to a patent ineligible concept at step one of the patent eligibility analysis, the court need not address step two of the inquiry. <a id="co_link_I35a059a041b411e8a9a7ae522723c830" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C.A. § 101</a>.</div></div><div id="co_headnoteId_204432042202020180423222802" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EB1AG" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;headnoteId=204432042202020180423222802&amp;originationContext=document&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 20">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e65c1a0476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e65c1a1476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II</a></span><span class="co_headnoteTopicKey">Patentability and Validity</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e65c1a2476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(B)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II(B)</a></span><span class="co_headnoteTopicKey">Eligible Subject Matter</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e65c1a3476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k441/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k441</a></span><span class="co_headnoteTopicKey">In general</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2044320422022"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F212044320422"><span class="co_headnoteNumber" id="co_anchor_headNote_21"><a href="#co_anchor_B212044320422" class="co_internalLink">21</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0E31AG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EA4AG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k907(6)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Particular products or processes</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Claims in patent related to a method of treating schizophrenia patients with iloperidone wherein the dosage range was based on the patient's genotype were not invalid for lack of adequate written description; patent reported results of tests comparing the concentrations iloperidone's two main metabolites, and changes in QTc interval upon administration of doses of iloperidone, both with and without the addition of a cytochrome P450 2D6 gene (CYP2D6) inhibitor, to individuals with wildtype or a poor metabolizer genotype associated with two common CYP2D6 polymorphisms, and explained that reported results showed that patients could be more safely treated with iloperidone if the dose of iloperidone was adjusted based on the CYP2D6 genotype of each patient, and provided examples of such doses.</div></div><div id="co_headnoteId_204432042202220180423222802" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EP4AG" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;headnoteId=204432042202220180423222802&amp;originationContext=document&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 21">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e65e8b0476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e65e8b1476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291IV/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291IV</a></span><span class="co_headnoteTopicKey">Patent Applications and Proceedings</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e65e8b2476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291IV(A)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291IV(A)</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e65e8b3476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k904/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k904</a></span><span class="co_headnoteTopicKey">Specification</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e65e8b4476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k907/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k907</a></span><span class="co_headnoteTopicKey">Written Description Requirement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e660fc0476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k907(6)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k907(6)</a></span><span class="co_headnoteTopicKey">Particular products or processes</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2044320422024"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F222044320422"><span class="co_headnoteNumber" id="co_anchor_headNote_22"><a href="#co_anchor_B222044320422" class="co_internalLink">22</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EB5AG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EFABG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k907(2)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Disclosure as directed to one skilled in the art</a></span></div><div class="co_secondaryHeadnoteNodes"> <span class="co_hiddenKeyText"><strong><a id="co_link_ID0EUABG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EYCBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k907(3)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Possession of claimed invention</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">To satisfy the written description requirement the patent disclosure must reasonably convey to those skilled in the art that the inventor had possession of the claimed subject matter as of the filing date.</div></div><div id="co_headnoteId_204432042202420180423222802" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EHDBG" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;headnoteId=204432042202420180423222802&amp;originationContext=document&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 22">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e6636d0476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e6636d1476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291IV/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291IV</a></span><span class="co_headnoteTopicKey">Patent Applications and Proceedings</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e6636d2476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291IV(A)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291IV(A)</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e6636d3476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k904/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k904</a></span><span class="co_headnoteTopicKey">Specification</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e6636d4476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k907/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k907</a></span><span class="co_headnoteTopicKey">Written Description Requirement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e6636d5476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k907(2)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k907(2)</a></span><span class="co_headnoteTopicKey">Disclosure as directed to one skilled in the art</span></div></div></div></div></div><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e665de0476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e665de1476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291IV/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291IV</a></span><span class="co_headnoteTopicKey">Patent Applications and Proceedings</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e665de2476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291IV(A)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291IV(A)</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e665de3476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k904/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k904</a></span><span class="co_headnoteTopicKey">Specification</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e665de4476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k907/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k907</a></span><span class="co_headnoteTopicKey">Written Description Requirement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e665de5476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k907(3)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k907(3)</a></span><span class="co_headnoteTopicKey">Possession of claimed invention</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2044320422023"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F232044320422"><span class="co_headnoteNumber" id="co_anchor_headNote_23"><a href="#co_anchor_B232044320422" class="co_internalLink">23</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EZDBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0ELFBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1956/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Presentation and Reservation in Lower Court of Grounds of Review</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Competitor in patent infringement action waived its written description challenge to patent related to a method of treating schizophrenia patients with iloperidone wherein the dosage range was based on the patient's genotype with respect to non-poor metabolizers by failing to properly present it to the trial court.</div></div><div id="co_headnoteId_204432042202320180423222802" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EIGBG" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;headnoteId=204432042202320180423222802&amp;originationContext=document&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 23">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e6684f0476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e66ac00476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII</a></span><span class="co_headnoteTopicKey">Patent Infringement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e66ac01476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(C)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(C)</a></span><span class="co_headnoteTopicKey">Actions</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e66ac02476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(C)7/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(C)7</a></span><span class="co_headnoteTopicKey">Appellate Review</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e66ac03476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1956/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1956</a></span><span class="co_headnoteTopicKey">Presentation and Reservation in Lower Court of Grounds of Review</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e66ac04476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1957/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1957</a></span><span class="co_headnoteTopicKey">In general</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2044320422027"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F242044320422"><span class="co_headnoteNumber" id="co_anchor_headNote_24"><a href="#co_anchor_B242044320422" class="co_internalLink">24</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0E1GBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EMIBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1862/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Injunctions</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Injunction prohibiting manufacturer of proposed Abbreviated New Drug Application (ANDA) product from engaging in the commercial manufacture, use, offer to sell, sale in or importation into the United States of product prior the expiration of patent related to a method of treating schizophrenia patients with iloperidone wherein the dosage range was based on the patient's genotype was warranted, upon finding of patent infringement under statute stating that submitting application for drug claimed in patent was infringement if purpose of submission was to obtain approval to engage in commercial manufacture, use, or sale of drug before expiration of patent. <a id="co_link_I35ec7dd041b411e8a9a7ae522723c830" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_22700000861f0">35 U.S.C.A. § 271(e)(4)<input id="co_docMarker_3" type="hidden"></a>.</div></div><div id="co_headnoteId_204432042202720180423222802" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EJJBG" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;headnoteId=204432042202720180423222802&amp;originationContext=document&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 24">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e66d310476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e66d311476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII</a></span><span class="co_headnoteTopicKey">Patent Infringement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e66d312476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(C)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(C)</a></span><span class="co_headnoteTopicKey">Actions</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e66d313476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(C)5/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(C)5</a></span><span class="co_headnoteTopicKey">Relief</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e66fa20476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1862/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1862</a></span><span class="co_headnoteTopicKey">Injunctions</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e66fa21476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1863/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1863</a></span><span class="co_headnoteTopicKey">In general</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2044320422025"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F252044320422"><span class="co_headnoteNumber" id="co_anchor_headNote_25"><a href="#co_anchor_B252044320422" class="co_internalLink">25</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EFKBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170B/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Federal Courts</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0E2LBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk3258/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Appellees;  necessity of filing cross-appeal</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Without filing a cross-appeal, an appellee may urge in support of a decree any matter appearing in the record, although his argument may involve an attack upon the reasoning of the lower court, but may not attack the decree with a view either to enlarging his own rights thereunder or of lessening the rights of his adversary.</div></div><div id="co_headnoteId_204432042202520180423222802" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EKMBG" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;headnoteId=204432042202520180423222802&amp;originationContext=document&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 25">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e672130476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170B/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170B</a></span><span class="co_headnoteTopicKey">Federal Courts</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e672131476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170BXVII/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170BXVII</a></span><span class="co_headnoteTopicKey">Courts of Appeals</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e672132476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170BXVII(B)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170BXVII(B)</a></span><span class="co_headnoteTopicKey">Appellate Jurisdiction and Procedure in General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e672133476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk3253/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170Bk3253</a></span><span class="co_headnoteTopicKey">Persons Entitled to Seek Review or Assert Arguments;  Parties;  Standing</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e674840476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk3258/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170Bk3258</a></span><span class="co_headnoteTopicKey">Appellees;  necessity of filing cross-appeal</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2044320422026"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F262044320422"><span class="co_headnoteNumber" id="co_anchor_headNote_26"><a href="#co_anchor_B262044320422" class="co_internalLink">26</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0E3MBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170B/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Federal Courts</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0ESOBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk3258/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Appellees;  necessity of filing cross-appeal</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">A party that is not adversely affected by a judgment lacks standing to cross-appeal.</div></div><div id="co_headnoteId_204432042202620180423222802" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EBPBG" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;headnoteId=204432042202620180423222802&amp;originationContext=document&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 26">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e674841476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170B/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170B</a></span><span class="co_headnoteTopicKey">Federal Courts</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e676f50476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170BXVII/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170BXVII</a></span><span class="co_headnoteTopicKey">Courts of Appeals</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e676f51476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170BXVII(B)/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170BXVII(B)</a></span><span class="co_headnoteTopicKey">Appellate Jurisdiction and Procedure in General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e676f52476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk3253/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170Bk3253</a></span><span class="co_headnoteTopicKey">Persons Entitled to Seek Review or Assert Arguments;  Parties;  Standing</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e676f53476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Bk3258/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170Bk3258</a></span><span class="co_headnoteTopicKey">Appellees;  necessity of filing cross-appeal</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2044320422001_0"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_2044320422"><span class="co_headnoteNumber" id="co_anchor_headNote_27">27</span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0ERPBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EPQBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k2091/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">In general;  utility</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">US Patent <a id="co_link_Idab23790425b11e89d06d8678cb98810" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">8,586,610</a>. Valid and Infringed.</div></div><div id="co_headnoteId_204432042200120180423222802_0" class="co_headnoteCitedCaseRef"><a id="co_link_ID0E5QBG" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;headnoteId=204432042200120180423222802&amp;originationContext=document&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 27">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e679660476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e679661476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291X/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291X</a></span><span class="co_headnoteTopicKey">Patents Enumerated</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e679662476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k2091/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k2091</a></span><span class="co_headnoteTopicKey">In general;  utility</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2044320422002_0"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_2044320422_0"><span class="co_headnoteNumber" id="co_anchor_headNote_28">28</span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EYRBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EWSBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k2094/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Reissue</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">US Patent <a id="co_link_Idabcbee0425b11e89d06d8678cb98810" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2009579817&amp;pubNum=0004073&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">RE39,198</a>. Cited.</div></div><div id="co_headnoteId_204432042200220180423222802_0" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EFTBG" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;headnoteId=204432042200220180423222802&amp;originationContext=document&amp;docSource=094be5ec528a4ebcb516957557b7ae19&amp;rank=138&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 28">Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e67bd70476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e67bd71476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291X/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291X</a></span><span class="co_headnoteTopicKey">Patents Enumerated</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_I7e67bd72476f11e8a94cdbee4df18b01" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k2094/View.html?docGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k2094</a></span><span class="co_headnoteTopicKey">Reissue</span></div></div></div></div></div></div><div class="co_clear"></div></div></div></div><div> </div></div><a id="co_headnotesEnd"></a><div class="co_contentBlock co_briefItState co_actionBlock"><div>Appeals from the United States District Court for the District of Delaware in Nos. 1:13-cv-01973-GMS, 1:14-cv-00757-GMS, Judge <a id="co_link_I37a226a03f4f11e8b6a4b140d77433d6" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0132747001&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Gregory M. Sleet</a>.</div></div><h2 class="co_attorneyBlockLabel co_printHeading co_briefItState" id="co_attorneysAndLawFirms">Attorneys and Law Firms</h2><div class="co_contentBlock co_briefItState co_attorneyBlock"><div><a id="co_link_I38a984803f4f11e8b6a4b140d77433d6" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0142351601&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Nicholas P. Groombridge</a>, Paul, Weiss, Rifkind, Wharton &amp; Garrison LLP, New York, NY, argued for plaintiff-appellee. Also represented by <a id="co_link_I38a984813f4f11e8b6a4b140d77433d6" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0384392301&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Kira A. Davis</a>, <a id="co_link_I38a984823f4f11e8b6a4b140d77433d6" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0498677299&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Daniel Klein</a>, <a id="co_link_I38a984833f4f11e8b6a4b140d77433d6" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0330769501&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Eric Alan Stone</a>, <a id="co_link_I38a984843f4f11e8b6a4b140d77433d6" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0426581101&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Josephine Young</a>.</div><div><a id="co_link_I3977f8103f4f11e8b6a4b140d77433d6" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0108551301&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Kenneth G. Schuler</a>, Latham &amp; Watkins LLP, Chicago, IL, argued for defendants-appellants. Also represented by <a id="co_link_I3977f8113f4f11e8b6a4b140d77433d6" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0189595701&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Daniel Brown</a>, New York, NY; <a id="co_link_I3977f8123f4f11e8b6a4b140d77433d6" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0426877301&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Robert J. Gajarsa</a>, Washington, DC.</div></div><div class="co_contentBlock co_briefItState co_panelBlock"><div>Before <a id="co_link_I398bf5403f4f11e8b6a4b140d77433d6" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0324402101&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Prost</a>, Chief Judge, <a id="co_link_I398bf5413f4f11e8b6a4b140d77433d6" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0225327201&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Lourie</a> and <a id="co_link_I398bf5423f4f11e8b6a4b140d77433d6" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0211865201&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Hughes</a>, Circuit Judges.</div></div><div class="co_contentBlock co_briefItState co_opinionBlock"><h2 id="co_opinion" class="co_printHeading">Opinion</h2><div class="co_docDelivery_dottedLine"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/co_docDelivery_dottedLine.png" alt=""></div><div class="co_contentBlock x_opinionBlockBody"><div class="co_contentBlock x_opinionLead"><div class="co_contentBlock x_voteBlock"><div class="co_contentBlock x_voteLine">Dissenting opinion filed by <em>Chief Judge</em> <span class="co_smallCaps"><a id="co_link_I399062103f4f11e8b6a4b140d77433d6" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0324402101&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Prost</a></span>.</div></div><div class="co_contentBlock x_leadAuthorLineBlock"><div class="co_contentBlock x_leadAuthorLine"><a id="co_link_I39951d003f4f11e8b6a4b140d77433d6" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0225327201&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Lourie</a>, Circuit Judge.</div></div><div class="co_contentBlock x_opinionBody"><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I7f198140476f11e8a94cdbee4df18b01"><div class="co_paragraph"><div class="co_paragraphText"> <span class="co_starPage" id="co_pp_sp_999_1"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;1&quot; }" alt="metadata" type="hidden">*1</span> West-Ward Pharmaceuticals International Limited and West-Ward Pharmaceuticals Corp. (collectively, “West-Ward”) appeal from the decision of the United States District Court for the District of Delaware holding, after a bench trial, claims 1–9, 11–13, and 16 (“the asserted claims”) of <a id="co_link_I99c4a8733f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">U.S. Patent 8,586,610 (“the '610 patent”)</a> infringed and not invalid. <em>See </em><a id="co_link_I99c4a8753f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039653953&amp;pubNum=0007903&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Vanda Pharm. Inc. v. Roxane Labs., Inc.</em>, 203 F.Supp.3d 412 (D. Del. 2016)</a> (“<a id="co_link_I1835d7503f5211e8b6a5b2f679615c92" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039653953&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Opinion</em></a>”). For the following reasons, we affirm.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I7f1a6ba0476f11e8a94cdbee4df18b01"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">Background</span></div><div class="co_headtext co_hAlign2">I.</div><div class="co_paragraph"><div class="co_paragraphText">Aventisub LLC (“Aventisub”) owns and Vanda Pharmaceuticals Inc. (“Vanda” and collectively, with Aventisub, “Plaintiffs”) holds an exclusive worldwide license to <a id="co_link_I99cd33f33f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2009579817&amp;pubNum=0004073&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">U.S. Reissue Patent 39,198 (“the '198 patent”)</a>. The <a id="co_link_I99cd33f43f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2009579817&amp;pubNum=0004073&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'198 patent</a> expired on November 15, 2016.<sup id="co_footnoteReference_B00012044320422_ID0E22BG"><a href="#co_footnote_B00012044320422" class="co_footnoteReference">1</a></sup> Vanda also owns the <a id="co_link_I99cd33f53f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a>, which will expire on November 2, 2027.</div></div><div class="co_paragraph"><div class="co_paragraphText">The <a id="co_link_I99f6dc003f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> relates to a method of treating <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Ic8ad584c475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ic8ad584c475411db9765f9243f53508a">schizophrenia</a> patients with iloperidone wherein the dosage range is based on the patient's genotype. The cytochrome P450 2D6 gene (“CYP2D6”) encodes an enzyme known to metabolize a large number of drugs, including iloperidone. <a id="co_link_I99f6dc013f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> col. 1 ll. 29–36. The <a id="co_link_I99f6dc023f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> teaches “that treatment of a patient, who has lower CYP2D6 activity than a normal person, with a drug[, such as iloperidone,] that is pre-disposed to cause QT<sup id="co_footnoteReference_B00022044320422_ID0EE6BG"><a href="#co_footnote_B00022044320422" class="co_footnoteReference">2</a></sup> prolongation and is metabolized by the CYP2D6 enzyme, can be accomplish[ed] more safely by administering a lower dose of the drug than would be administered to a person who has normal CYP2D6 enzyme activity.”<input id="co_docMarker_4" type="hidden"> <em>Id</em><em>.</em> col. 2 ll. 15–21. QT prolongation can lead to serious cardiac problems. The <a id="co_link_I99f6dc043f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> refers to patients who have lower than normal CYP2D6 activity as CYP2D6 poor metabolizers. It provides examples of dose reductions for poor metabolizers compared to the dose given to someone with a wildtype genotype. <em>Id</em><em>.</em> col. 9 ll. 34–47, col. 11 ll. 22–28.</div></div><div class="co_paragraph"><div class="co_paragraphText">Claim 1 of the <a id="co_link_I99f9e9403f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> is representative and reads as follows:</div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText">A method for treating a patient with iloperidone, wherein the patient is suffering from <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Ic8ad584c475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ic8ad584c475411db9765f9243f53508a_0">schizophrenia</a>, the method comprising the steps of:</div></div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText">determining whether the patient is a CYP2D6 poor metabolizer by:</div></div><div class="co_paragraph co_indentLeft2"><div class="co_paragraphText">obtaining or having obtained a biological sample from the patient;</div></div><div class="co_paragraph co_indentLeft2"><div class="co_paragraphText">and</div></div><div class="co_paragraph co_indentLeft2"><div class="co_paragraphText">performing or having performed a <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=mproc&amp;entityId=Ib3510dc6475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ib3510dc6475411db9765f9243f53508a">genotyping</a> assay on the biological sample to determine if the patient has a CYP2D6 poor metabolizer genotype; and</div></div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText">if the patient has a CYP2D6 poor metabolizer genotype, then internally administering iloperidone to the patient in an amount of 12 mg/day or less, and</div></div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText">if the patient does not have a CYP2D6 poor metabolizer genotype, then internally administering iloperidone to the patient in an amount that is greater than 12 mg/day, up to 24 mg/day,</div></div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText"> <span class="co_starPage" id="co_pp_sp_999_2"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;2&quot; }" alt="metadata" type="hidden">*2</span> wherein a risk of QTc prolongation for a patient having a CYP2D6 poor metabolizer genotype is lower following the internal administration of 12 mg/day or less than it would be if the iloperidone were administered in an amount of greater than 12 mg/day, up to 24 mg/day.</div></div><div class="co_paragraphText co_flush"><em>Id.</em> col. 17 ll. 2–25.</div></div><div class="co_paragraph"><div class="co_paragraphText">Vanda owns New Drug Application (“NDA”) 22-192 for Fanapt® (iloperidone), an atypical antipsychotic approved by the U.S. Food and Drug Administration (“FDA”) in 2009 under <a id="co_link_I9a36cb303f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=21USCAS355&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">21 U.S.C. § 355(b)</a> for the treatment of patients with <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Ic8ad584c475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ic8ad584c475411db9765f9243f53508a_1">schizophrenia</a>. Vanda was able to obtain FDA approval for iloperidone based, at least in part, on the invention disclosed in the <a id="co_link_I9a36cb313f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a>, which reduces the side effects associated with QTc prolongation, enabling safer treatment of patients with <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Ic8ad584c475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ic8ad584c475411db9765f9243f53508a_2">schizophrenia</a>. The <a id="co_link_I9a36cb323f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2009579817&amp;pubNum=0004073&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'198 patent</a> and the <a id="co_link_I9a36cb333f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> are listed in connection with Fanapt® in the FDA's <em>Approved Drug Products with Therapeutic Equivalence Evaluations</em>, commonly known as the “Orange Book.”</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I7f3546a0476f11e8a94cdbee4df18b01"><div class="co_headtext co_hAlign2">II.</div><div class="co_paragraph"><div class="co_paragraphText">In 2013, West-Ward<sup id="co_footnoteReference_B00032044320422_ID0EMHAI"><a href="#co_footnote_B00032044320422" class="co_footnoteReference">3</a></sup> filed Abbreviated New Drug Application (“ANDA”) 20-5480 seeking approval to commercially manufacture, use, offer to sell, and sell a generic version of Fanapt® in 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg strengths for the treatment of <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Ic8ad584c475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ic8ad584c475411db9765f9243f53508a_3">schizophrenia</a> pursuant to <a id="co_link_I9a5db4203f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=21USCAS355&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_267600008f864">21 U.S.C. § 355(j)</a>. At that time, the <a id="co_link_I9a5db4213f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> had not yet issued and only the <a id="co_link_I9a5db4223f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2009579817&amp;pubNum=0004073&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'198 patent</a> was listed in the Orange Book. The ANDA contained a certification per <a id="co_link_I9a5db4233f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=21USCAS355&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_0123000089ab5">21 U.S.C. § 355(j)(2)(A)(vii)(IV)</a> (“Paragraph IV certification”) that the <a id="co_link_I9a5db4243f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2009579817&amp;pubNum=0004073&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'198 patent</a> was invalid and/or would not be infringed by West-Ward. West-Ward then sent the notice required by <a id="co_link_I9a5db4253f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=21USCAS355&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_979c0000b55d2">21 U.S.C. § 355(j)(2)(B)</a> (“Paragraph IV notice”) of its Paragraph IV certification. On November 25, 2013, Plaintiffs filed Civil Action No. 13-1973 (“2013 suit”) in the U.S. District Court for the District of Delaware (“district court”) alleging infringement of the <a id="co_link_I9a5db42a3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2009579817&amp;pubNum=0004073&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'198 patent</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">The proposed ANDA label is substantially identical in all material respects to the Fanapt® label. The proposed label states that: iloperidone is “indicated for the treatment of adults with <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Ic8ad584c475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ic8ad584c475411db9765f9243f53508a_4">schizophrenia</a>,” J.A. 15104 § 1; “[t]he recommended target dosage of iloperidone tablets is 12 to 24 mg/day,” J.A. 15103; “[t]he recommended starting dose for iloperidone tablets is 1 mg twice daily,” J.A. 15105 § 2.1; and “[i]loperidone must be titrated slowly from a low starting dose,”<input id="co_docMarker_5" type="hidden"> J.A. 15105 § 2.1. The proposed label provides that the “[i]loperidone dose should be reduced by one-half for poor metabolizers of CYP2D6 [<em>see Pharmacokinetics (12.3)</em> ].” J.A. 15105 § 2.2. Section 5.2, entitled “QT Prolongation,” explains: “iloperidone was associated with QTc prolongation of 9 msec at an iloperidone dose of 12 mg twice daily” and that “[c]aution is warranted when prescribing iloperidone ... in patients with reduced activity of CYP2D6 [<em>see</em> <em>Clinical Pharmacology (12.3)</em> ].” J.A. 5106–07 § 5.2.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I7f3805c0476f11e8a94cdbee4df18b01"><div class="co_headtext co_hAlign2">III.</div><div class="co_paragraph"><div class="co_paragraphText">Meanwhile, the <a id="co_link_I9a9231a03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> issued on November 19, 2013, and on June 16, 2014, Vanda filed Civil Action No. 14-757 (“2014 suit”) in the district court alleging infringement of the <a id="co_link_I9a9231a53f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a>. On January 15, 2015, Vanda listed the <a id="co_link_I9a9231a63f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> in the Orange Book for Fanapt®. On May 6, 2015, West-Ward sent Vanda a Paragraph IV notice with respect to the <a id="co_link_I9a9231a73f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> notifying Vanda that it amended ANDA 20-5480 to contain a Paragraph IV certification that the <a id="co_link_I9a9231a83f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> is invalid and/or not infringed. J.A. 19696; <em>see</em> <a id="co_link_I9a9231a93f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=21USCAS355&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_0123000089ab5">21 U.S.C. § 355(j)(2)(B)(ii)(II)</a>. The district court consolidated the 2013 and 2014 suits.</div></div><div class="co_paragraph"><div class="co_paragraphText"> <span class="co_starPage" id="co_pp_sp_999_3"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;3&quot; }" alt="metadata" type="hidden">*3</span> Following a bench trial, the district court found that West-Ward's proposed products induce infringement of the asserted claims of the <a id="co_link_I9aa98a303f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a>, but do not contributorily infringe them. <a id="co_link_I9aa98a323f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039653953&amp;pubNum=0007903&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_7903_435&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_7903_435"><em>Opinion</em>, 203 F.Supp.3d at 435</a>. The court held that West-Ward's “submission of a paragraph IV certification for the <a id="co_link_I9aa98a333f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610</a> [p]atent is an act of infringement” and that Vanda's expert Dr. Alva “practiced the steps of the <a id="co_link_I9aa98a343f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610</a> [p]atent claims” with Fanapt®. <a id="co_link_I9aa98a353f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039653953&amp;pubNum=0007903&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_7903_433&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_7903_433"><em>Id.</em> at 433</a>. The court found that the proposed ANDA label “recommends”: (1) “practitioners use iloperidone to treat patients suffering from <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Ic8ad584c475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ic8ad584c475411db9765f9243f53508a_5">schizophrenia</a>”; (2) “oral administration of iloperidone tablets at 12 to 24 mg/day to non-genotypic CYP2D6 poor metabolizers and 12 mg/day or less to genotypic CYP2D6 poor metabolizers”; and (3) “practitioners perform or have performed a <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=mproc&amp;entityId=Ib3510dc6475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ib3510dc6475411db9765f9243f53508a_0">genotyping</a> assay to determine whether patients are CYP2D6 poor metabolizers.” <a id="co_link_I9aa98a363f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039653953&amp;pubNum=0007903&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_7903_432&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_7903_432"><em>Id.</em> at 432</a> (first citing J.A. 15104–05 §§ 1, 2.1, 2.2; then citing J.A. 15120–21 § 12.3).</div></div><div class="co_paragraph"><div class="co_paragraphText">The district court also held that the asserted claims were not invalid under § 101, § 103, or § 112 for lack of written description. The court did conclude that “the asserted claims depend upon laws of nature,” specifically, “the relationship between iloperidone, CYP2D6 metabolism, and QTc prolongation.” <a id="co_link_I9ab793f03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039653953&amp;pubNum=0007903&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_7903_428&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_7903_428"><em>Id.</em> at 428–29</a>. But the court explained that the <a id="co_link_I9ab793f13f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> “addresses natural relationships to which the claims add conducting CYP2D6 <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=mproc&amp;entityId=Ib3510dc6475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ib3510dc6475411db9765f9243f53508a_1">genotyping</a> tests to determine the appropriate dose of iloperidone to reduce QTc-related risks.” <a id="co_link_I9ab793f23f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039653953&amp;pubNum=0007903&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_7903_429&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_7903_429"><em>Id.</em> at 429</a>. “The court f[ound] that while it may have been conventional to investigate for side-effects, [West-Ward] has not proven by clear and convincing evidence that the precise test and the discovered results were routine or conventional.” <a id="co_link_I9ab793f33f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039653953&amp;pubNum=0007903&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em></a> The court found that the data disclosed in the patent were “sufficient to support possession of the claimed dosage range, even if not statistically significant.” <a id="co_link_I9ab793f43f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039653953&amp;pubNum=0007903&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_7903_431&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_7903_431"><em>Id.</em> at 431</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">The court determined that <a id="co_link_I9ac576a03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_f4aa000038542">35 U.S.C. § 271(e)(4)(A)</a> relief was unavailable for the <a id="co_link_I9ac576a13f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> because it did not issue until after the ANDA was filed.<sup id="co_footnoteReference_B00042044320422_ID0ETZAI"><a href="#co_footnote_B00042044320422" class="co_footnoteReference">4</a></sup> <a id="co_link_I9ac576a23f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039653953&amp;pubNum=0007903&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_7903_435&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_7903_435"><em>Id.</em> at 435</a>. The court determined that injunctive relief was appropriate, however, pursuant to its “general equitable power.” <a id="co_link_I9ac576a33f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039653953&amp;pubNum=0007903&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em></a> The court enjoined West-Ward from engaging in the commercial manufacture, use, offer to sell, sale in or importation into the United States of West-Ward's ANDA product prior the expiration of the <input id="co_docMarker_6" type="hidden"><a id="co_link_I9ac576a43f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a>. The court further ordered that “[t]he effective date of any [FDA] approval of [West-Ward's] ANDA No. 20-5480 shall be a date not earlier than the latest of the expiration of the <a id="co_link_I9ac576a93f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610</a> [p]atent or any applicable exclusivities and extensions.” J.A. 33</div></div><div class="co_paragraph"><div class="co_paragraphText">West-Ward timely appealed from the district court's final judgment. We have jurisdiction under <a id="co_link_I9ad6b4b03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=28USCAS1295&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_7b9b000044381">28 U.S.C. § 1295(a)(1)</a>.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I7f3f0aa0476f11e8a94cdbee4df18b01"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">Discussion</span></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F12044320422" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF1">1</a><a id="co_anchor_B12044320422"></a><a href="#co_anchor_F22044320422" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF2">2</a><a id="co_anchor_B22044320422"></a>On appeal from a bench trial, we review a district court's conclusions of law <em>de novo</em> and its findings of fact for clear error. <a id="co_link_I9ae645113f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2004340643&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1058&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1058"><em>Golden Blount, Inc. v. Robert H. Peterson Co.</em>, 365 F.3d 1054, 1058 (Fed. Cir. 2004)</a>. A factual finding is only clearly erroneous if, despite some supporting evidence, we are left with the definite and firm conviction that a mistake has been made. <a id="co_link_I136fcc2441b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1948119024&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>United States v. U.S. Gypsum Co.</em>, 333 U.S. 364, 395, 68 S.Ct. 525, 92 L.Ed. 746 (1948)</a>; <em>see also </em><a id="co_link_I9ae645153f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1986121975&amp;pubNum=0000350&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_350_1559&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_1559"><em>Polaroid Corp. v. Eastman Kodak Co.</em>, 789 F.2d 1556, 1559 (Fed. Cir. 1986)</a> (“The burden of overcoming the district court's factual findings is, as it should be, a heavy one.”).</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I7f404320476f11e8a94cdbee4df18b01"><div class="co_headtext co_hAlign2">I. Jurisdiction</div><div class="co_paragraph"><div class="co_paragraphText"> <span class="co_starPage" id="co_pp_sp_999_4"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;4&quot; }" alt="metadata" type="hidden">*4</span> <a href="#co_anchor_F32044320422" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF3">3</a><a id="co_anchor_B32044320422"></a>We must first address whether the district court properly exercised jurisdiction over the 2014 suit. On November 16, 2017, we directed supplemental briefing on jurisdiction. Both parties responded with supplemental briefing, which, <em>inter alia</em>, addressed whether there is district court jurisdiction under the Drug Price Competition and Patent Term Restoration Act of 1984 (“the Hatch-Waxman Act”), <a id="co_link_I9aeab1e13f3c11e8bd0794319e761151" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=l&amp;pubNum=1077005&amp;cite=UUID(IE18BBC5D63-B24B84B86B5-560A5141A87)&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SL&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Pub. L. No. 98-417, 98 Stat. 1585 (1984)</a> over an action in which the asserted patent issued after the ANDA was filed and the complaint was filed before the ANDA applicant submitted a Paragraph IV certification for the asserted patent.</div></div><div class="co_paragraph"><div class="co_paragraphText">Vanda argues that its allegations of infringement under <a id="co_link_I9af2ef403f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">35 U.S.C. § 271(e)(2)</a> created subject matter jurisdiction in the district court under <a id="co_link_I9af2ef413f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=28USCAS1331&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">28 U.S.C. § 1331</a> and <a id="co_link_I9af2ef423f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=28USCAS1338&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_8b3b0000958a4">§ 1338(a)</a>, and presented a justiciable controversy. Vanda further argues that the Declaratory Judgment Act, <a id="co_link_I9af2ef433f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=28USCAS2201&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">28 U.S.C. § 2201</a>, provides an alternative basis for jurisdiction because it alleged that West-Ward would infringe the <a id="co_link_I9af2ef443f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> under <a id="co_link_I9af2ef453f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_8b3b0000958a4">35 U.S.C. § 271(a)</a>, <a id="co_link_I9af2ef463f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">(b)</a>, or <a id="co_link_I9af2ef473f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_4b24000003ba5">(c)</a> by selling iloperidone.</div></div><div class="co_paragraph"><div class="co_paragraphText">West-Ward argues that <a id="co_link_I9b027fa03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">35 U.S.C. § 271(e)(2)</a> does not create a basis for subject matter jurisdiction over Vanda's infringement claims. West-Ward contends that a claim for <a id="co_link_I9b027fa13f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">§ 271(e)(2)</a> infringement can only be based on patents that have issued before an ANDA is filed. Moreover, West-Ward argues, even if the amended Paragraph IV certification could qualify as an act of infringement under <a id="co_link_I9b027fa23f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">§ 271(e)(2)</a>, jurisdiction would still be lacking because the certification was not made before the 2014 suit was filed. West-Ward further argues that there is declaratory judgment jurisdiction over its claims for relief, but not over Vanda's claims for infringement.</div></div><div class="co_paragraph"><div class="co_paragraphText">We agree with Vanda that the district court had jurisdiction over this case. We have previously explained that:</div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText">By enacting <a id="co_link_I9b0b32313f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">§ 271(e)(2)</a>, Congress thus established a specialized new cause of action for patent infringement. When patentees pursue this route, their claims necessarily arise under an Act of Congress relating to patents. In short, “[o]nce Congress creates an act of infringement, jurisdiction in the district courts is proper under <a id="co_link_I9b0b32303f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=28USCAS1338&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_8b3b0000958a4">28 U.S.C. § 1338(a)</a>.”</div></div><div class="co_paragraphText co_flush"><a id="co_link_I9b22fff13f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027068440&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1377&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1377"><em>AstraZeneca Pharm. LP v. Apotex Corp.</em> (<em>AstraZeneca II</em> ), 669 F.3d 1370, 1377 (Fed. Cir. 2012)</a> (alteration in original) (quoting <a id="co_link_I9b22fff33f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003243620&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1330&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1330"><em>Allergan, Inc. v. Alcon Labs., Inc.,</em> 324 F.3d 1322, 1330 (Fed. Cir. 2003)</a> ). The Supreme Court has similarly explained that <input id="co_docMarker_7" type="hidden">“the federal courts have jurisdiction over [a suit alleging infringement under <a id="co_link_I9b22fff73f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">§ 271(e)(2)</a> ] for a single, simple reason: It ‘ar[ose] under a[n] Act of Congress relating to patents.’ ” <a id="co_link_I13bbc94641b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027504856&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Caraco Pharm. Labs., Ltd. v. Novo Nordisk A/S</em> (<em>Caraco II</em> ), 566 U.S. 399, 412 n.5, 132 S.Ct. 1670, 182 L.Ed.2d 678 (2012)</a> (second and third alterations in original) (quoting <a id="co_link_I9b22fff63f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=28USCAS1338&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_8b3b0000958a4">28 U.S.C. § 1338(a)</a> ).</div></div><div class="co_paragraph"><div class="co_paragraphText">Here, Vanda's complaint alleged that West-Ward infringed the <a id="co_link_I9b3109b03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> under <a id="co_link_I9b3109b13f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_9e660000185f2">35 U.S.C. § 271(e)(2)(A)</a> by filing the ANDA. J.A. 10002. Nothing more was required to establish the district court's subject matter jurisdiction pursuant to <a id="co_link_I9b3109b23f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=28USCAS1338&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_8b3b0000958a4">28 U.S.C. § 1338(a)</a>. <em>See </em><a id="co_link_I9b3109b43f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027068440&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1377&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1377"><em>AstraZeneca II</em>, 669 F.3d at 1377</a> (explaining that “the requirements for jurisdiction in the district courts are met once a patent owner alleges that another's filing of an ANDA infringes its patent under <a id="co_link_I9b3109b53f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">§ 271(e)(2)</a>, and this threshold jurisdictional determination does not depend on the ultimate merits of the claims”).</div></div><div class="co_paragraph"><div class="co_paragraphText">West-Ward's arguments relating to whether there was a qualifying act of infringement raise potential merits problems, not jurisdictional issues. We have previously rejected the argument that a court's jurisdiction “hinged on whether [plaintiff] asserted a ‘valid’ claim under <a id="co_link_I9b41d2933f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">§ 271(e)(2)</a>.” <a id="co_link_I9b41d2903f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027068440&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em></a> The Supreme Court has similarly explained that “[t]he want of an infringing act [under <a id="co_link_I9b41d2943f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">§ 271(e)(2)</a> ] is a merits problem, not a jurisdictional one.” <a id="co_link_I9b41d2923f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027504856&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_708_412&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_708_412"><em>Caraco II</em>, 566 U.S. at 412 n.5, 132 S.Ct. 1670</a>. Thus, whether Vanda alleged, and subsequently proved, an infringing act is a merits question, not a jurisdictional one.</div></div><div class="co_paragraph"><div class="co_paragraphText"> <span class="co_starPage" id="co_pp_sp_999_5"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;5&quot; }" alt="metadata" type="hidden">*5</span> <a href="#co_anchor_F42044320422" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF4">4</a><a id="co_anchor_B42044320422"></a>Moreover, an actual controversy has existed between the parties from the time when the suit was commenced. <em>See </em><a id="co_link_I9b664a813f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2011826376&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1339&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1339"><em>Teva Pharm. USA, Inc. v. Novartis Pharm. Corp.</em>, 482 F.3d 1330, 1339–45 (Fed. Cir. 2007)</a> (reversing district court's conclusion that it lacked jurisdiction because there was no justiciable controversy between the ANDA applicant and NDA holder where there was a prior suit between the parties involving a different patent to which the ANDA applicant had submitted a Paragraph IV certification). “To qualify as a case fit for federal-court adjudication, ‘an actual controversy must be extant at all stages of review,’ ” including “ ‘at the time the complaint is filed.’ ” <a id="co_link_I141de67441b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1997060684&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Arizonans for Official English v. Arizona</em>, 520 U.S. 43, 67, 117 S.Ct. 1055, 137 L.Ed.2d 170 (1997)</a> (quoting <a id="co_link_I141de67841b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1975129828&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Preiser v. Newkirk</em>, 422 U.S. 395, 401, 95 S.Ct. 2330, 45 L.Ed.2d 272 (1975)</a> ). Here, West-Ward had filed an ANDA and Vanda had sued it. The mere fact that West-Ward had not submitted a Paragraph IV certification for the <a id="co_link_I9b664a863f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> until after Vanda filed suit does not establish that there was not a justiciable controversy over which the court could exercise jurisdiction. <em>See </em><a id="co_link_I9b664a883f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1997083946&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1569&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1569"><em>Glaxo, Inc. v. Novopharm, Ltd.</em>, 110 F.3d 1562, 1569 (Fed. Cir. 1997)</a> (“[<a id="co_link_I9b664a893f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">Section] 271(e)(2)</a> provide[s] patentees with a defined act of infringement sufficient to create case or controversy jurisdiction to enable a court to promptly resolve any dispute concerning infringement and validity.”); <a id="co_link_I9b664a8b3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1995163589&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1401&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1401"><em>DuPont Merck Pharm. Co. v. Bristol-Myers Squibb Co.</em>, 62 F.3d 1397, 1401 (Fed. Cir. 1995)</a> (reversing a district court's determination in declaratory judgment action “that an actual controversy would only occur upon [ANDA applicants'] filing of paragraph IV certifications”).<sup id="co_footnoteReference_B00052044320422_ID0EKVBI"><a href="#co_footnote_B00052044320422" class="co_footnoteReference">5</a></sup></div></div><div class="co_paragraph"><div class="co_paragraphText">Thus, the district court properly had jurisdiction over the <a id="co_link_I3b5088a03f4f11e8b6a4b140d77433d6" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> under the Hatch-Waxman Act.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I7f4c02f0476f11e8a94cdbee4df18b01"><div class="co_headtext co_hAlign2">II. Infringement</div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F52044320422" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF5">5</a><a id="co_anchor_B52044320422"></a><a href="#co_anchor_F62044320422" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF6">6</a><a id="co_anchor_B62044320422"></a><a href="#co_anchor_F72044320422" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF7">7</a><a id="co_anchor_B72044320422"></a>In a bench trial, infringement is a question of fact that we review for clear error. <input id="co_docMarker_8" type="hidden"><a id="co_link_I9b7cdfc13f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2010230679&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1289&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1289"><em>Alza Corp. v. Mylan Labs., Inc.</em>, 464 F.3d 1286, 1289 (Fed. Cir. 2006)</a>. An infringement inquiry pursuant to <a id="co_link_I9b7cdfc23f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_9e660000185f2">35 U.S.C. § 271(e)(2)(A)</a> “is focused on a comparison of the asserted patent [claims] against 'the product that is likely to be sold following ANDA approval.'” <a id="co_link_I9b7cdfc43f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032909107&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1186&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1186"><em>Alcon Research Ltd. v. Barr Labs., Inc.</em>, 745 F.3d 1180, 1186 (Fed. Cir. 2014)</a> (quoting <a id="co_link_I9b7cdfc63f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2002504341&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1373&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1373"><em>Abbott Labs. v. TorPharm, Inc.</em>, 300 F.3d 1367, 1373 (Fed. Cir. 2002)</a> ). The patentee bears the burden of proving infringement by a preponderance of the evidence. <a id="co_link_I9b7cdfc83f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003082816&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1366&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1366"><em>Warner–Lambert Co. v. Apotex Corp.</em>, 316 F.3d 1348, 1366 (Fed. Cir. 2003)</a>.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I7f4d6280476f11e8a94cdbee4df18b01"><div class="co_headtext co_hAlign2">A. The Applicability of <a id="co_link_I9b7f02a03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_9e660000185f2">35 U.S.C. § 271(e)(2)(A)</a></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F82044320422" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF8">8</a><a id="co_anchor_B82044320422"></a>We first address whether, beyond the jurisdictional question, a claim for infringement of the <a id="co_link_I9b8a26303f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> under <a id="co_link_I9b8a26313f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_9e660000185f2">35 U.S.C. § 271(e)(2)(A)</a> can lie where the <a id="co_link_I9b8a26323f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> issued after the original ANDA was submitted and Vanda sued West-Ward for infringement of the asserted claims prior to West-Ward submitting a Paragraph IV certification. The district court held that West-Ward's submission of the Paragraph IV certification for the <a id="co_link_I9b8a26333f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> was an act of infringement. <em>See </em><a id="co_link_I9b8a26353f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039653953&amp;pubNum=0007903&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_7903_433&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_7903_433"><em>Opinion</em>, 203 F.Supp.3d at 433</a>. We review the district court's statutory interpretation without deference. <a id="co_link_I9b8a26373f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003082816&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1355&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1355"><em>Warner–Lambert</em>, 316 F.3d at 1355</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F92044320422" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF9">9</a><a id="co_anchor_B92044320422"></a>Vanda argues that it proved an act of infringement under <a id="co_link_I9b94d4903f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">35 U.S.C. § 271(e)(2)</a>. According to Vanda, “[w]here a patent issues after an ANDA is filed but before FDA approval, and where—as here—the applicant submits a Paragraph IV certification directed at the new patent, that amendment of the ANDA is an act of infringement under <a id="co_link_I9b94d4913f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">Section 271(e)(2)</a>.” Appellee Br. 60.</div></div><div class="co_paragraph"><div class="co_paragraphText">West-Ward responds that there can be no infringement under <a id="co_link_I9ba0bb723f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">§ 271(e)(2)</a> because the ANDA was filed before the <a id="co_link_I9ba0bb703f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> issued. West-Ward contends that the statutorily defined act of infringement excludes amendments to an ANDA and “only reaches ANDAs submitted ‘for a drug claim<em>ed</em> in a <em>patent</em> or the use of which is claim<em>ed</em> in a <em>patent</em>’—not a drug that might or might not later be claimed in a patent or one that has been claimed in a provisional patent application or a patent-pending.” Reply Br. 33 (emphases in original) (quoting <a id="co_link_I9ba0bb713f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_9e660000185f2">35 U.S.C. § 271(e)(2)(A)</a> ) (other internal quotation marks omitted).</div></div><div class="co_paragraph"><div class="co_paragraphText">The Hatch-Waxman Act amended the Federal Food, Drug, and Cosmetic Act and the patent laws to enable generic drugs to be more easily approved and to respond to loss of effective patent life resulting from the requirement that drug products require premarket testing and then must undergo FDA review, actions that consume significant portions of a patent term. <em>See </em><a id="co_link_I1558895241b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1990094366&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Eli Lilly &amp; Co. v. Medtronic, Inc.</em>, 496 U.S. 661, 669–70, 110 S.Ct. 2683, 110 L.Ed.2d 605 (1990)</a>. The Hatch-Waxman Act “str[ikes] a balance between two competing policy interests: (1) inducing pioneering research and development of new drugs and (2) enabling competitors to bring low-cost, generic copies of those drugs to market.” <a id="co_link_I9baddad33f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2002075387&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1371&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1371"><em>Andrx Pharm., Inc. v. Biovail Corp.</em>, 276 F.3d 1368, 1371 (Fed. Cir. 2002)</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText"> <span class="co_starPage" id="co_pp_sp_999_6"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;6&quot; }" alt="metadata" type="hidden">*6</span> Section 202 of the Act, codified at <a id="co_link_I9bb506c03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_9e660000185f2">35 U.S.C. § 271(e)(2)(A)</a>, created an “artificial” act of infringement. <a id="co_link_I1564703341b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1990094366&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Eli Lilly</em>, 496 U.S. at 678, 110 S.Ct. 2683</a>. That provision provides in relevant part:</div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText"><blockquote><div>It shall be <em>an act of infringement</em> to submit ... <em>an application</em> under section 505(j) of the Federal Food, Drug, and Cosmetic Act[, codified at <a id="co_link_I9bba0fd03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=21USCAS355&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_267600008f864">21 U.S.C. § 355(j)</a>,] ... <em>for a drug</em> claimed in a patent or <em>the use of which is claimed in a patent</em>, ... if the purpose of such submission is to obtain approval under such Act to engage in the commercial manufacture, use, or sale of a drug <input id="co_docMarker_9" type="hidden">... claimed in a patent or the use of which is claimed in a patent before the expiration of such patent.</div></blockquote></div></div><div class="co_paragraphText co_flush"><a id="co_link_I9bc3acc03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">35 U.S.C. § 271(e)(2)</a> (emphases added). It “facilitates the early resolution of patent disputes between generic and pioneering drug companies by providing that the mere act of filing a Paragraph IV ANDA constitutes an act of patent infringement.” <a id="co_link_I9bc3acc23f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2015647167&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1283&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1283"><em>Caraco Pharm. Labs., Ltd. v. Forest Labs., Inc.</em> (<em>Caraco I</em> ), 527 F.3d 1278, 1283 (Fed. Cir. 2008)</a>. Litigation does not have to be delayed until actual sale of an accused product.</div></div><div class="co_paragraph"><div class="co_paragraphText">Although we agree with West-Ward that only an issued patent can give rise to a valid infringement claim under <a id="co_link_I9be872d03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_9e660000185f2">§ 271(e)(2)(A)</a>, we disagree that that conclusion precludes Vanda's infringement claim in this case. The <a id="co_link_I9be872d13f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> is a patent “for a drug ... the use of which is claimed in a patent,” <a id="co_link_I9be872d23f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_9e660000185f2">35 U.S.C. § 271(e)(2)(A)</a>, as contemplated in the Act even though it issued after West-Ward filed its ANDA. West-Ward subsequently amended its ANDA to include a Paragraph IV certification for the <a id="co_link_I9be872d33f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> after it issued. The infringement analysis under <a id="co_link_I9be872d43f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_9e660000185f2">§ 271(e)(2)(A)</a> “require[s] consideration of the amended ANDA.” <a id="co_link_I9be872d63f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2034181282&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1390&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1390"><em>Ferring B.V. v. Watson Labs., Inc.-Fla.</em>, 764 F.3d 1382, 1390 (Fed. Cir. 2014)</a>. “There is no support for the proposition that the question of infringement must be addressed solely based on the initial ANDA filing, given that the statute contemplates that the ANDA will be amended as a matter of course.” <a id="co_link_I9be872d73f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2034181282&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em></a> Thus, amendments to an ANDA, including a Paragraph IV certification for a later-issued patent, can constitute an act of infringement under <a id="co_link_I9be872d83f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_9e660000185f2">§ 271(e)(2)(A)</a>. <em>See </em><a id="co_link_I9be872da3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1995220011&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1135&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1135"><em>Bristol-Myers Squibb Co. v. Royce Labs., Inc.</em>, 69 F.3d 1130, 1135 (Fed. Cir. 1995)</a> (holding that by amending an ANDA to include a Paragraph IV certification, the applicant “committed an act of infringement under the Hatch-Waxman Act because it sought ‘to obtain approval ... to engage in the commercial manufacture, use, or sale of a drug ... claimed in a patent ... before the expiration of such patent’ ” (alternations in original) (quoting <a id="co_link_I9be872db3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_9e660000185f2">35 U.S.C. § 271(e)(2)(A)</a> ) ).</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F102044320422" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF10">10</a><a id="co_anchor_B102044320422"></a>Here, it is undisputed that West-Ward amended the ANDA by submitting a Paragraph IV certification regarding the <a id="co_link_I9c0570b03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> after that patent issued. J.A. 19696; J.A. 6414–15; Appellant Br. 10; Appellee Br. 59. Such an act is a qualifying act of infringement under <a id="co_link_I9c0570b13f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_9e660000185f2">§ 271(e)(2)(A)</a>.<sup id="co_footnoteReference_B00062044320422_ID0E3MCI"><a href="#co_footnote_B00062044320422" class="co_footnoteReference">6</a></sup> A filer of an ANDA is therefore subject to a <a id="co_link_I9c0570b23f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_9e660000185f2">§ 271(e)(2)(A)</a> infringement claim on a patent that issues after the filing of the ANDA, but before FDA approval. The resolution of infringement claims under <a id="co_link_I9c0570b33f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_9e660000185f2">§ 271(e)(2)(A)</a> for patents that issue after an ANDA is submitted, but before it is approved, “facilitates the early resolution of patent disputes between generic and pioneering drug companies” in accordance with the purpose of <a id="co_link_I9c0570b43f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_9e660000185f2">§ 271(e)(2)(A)</a>. <a id="co_link_I9c0570b63f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2015647167&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1283&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1283"><em>Caraco I</em>, 527 F.3d at 1283</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText"> <span class="co_starPage" id="co_pp_sp_999_7"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;7&quot; }" alt="metadata" type="hidden">*7</span> The FDA regulatory framework and the legislative history further demonstrate that West-Ward is incorrect in asserting that “application” in <a id="co_link_I9c226e903f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_9e660000185f2">§ 271(e)(2)(A)</a> excludes amendments to the ANDA. Sections 101 and 102 of the Hatch-Waxman Act amended the Federal Food, Drug, and Cosmetics Act to create an abbreviated regulatory pathway for approval of generic drugs, codified at <a id="co_link_I9c226e913f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=21USCAS355&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_267600008f864">21 U.S.C. § 355(j)</a>, and to require NDA applicants to file certain patent information with the FDA, codified at <a id="co_link_I9c226e923f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=21USCAS355&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_3fed000053a85">21 U.S.C. § 355(b)(1)</a>, <a id="co_link_I9c226e933f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=21USCAS355&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_fcf30000ea9c4">(c)(2)</a>. NDA holders have a continuing obligation to amend the NDA to include the same patent information for patents that issue after the NDA is approved. <em>See</em> <a id="co_link_I9c226e943f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=21USCAS355&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_fcf30000ea9c4">21 U.S.C. § 355(c)(2)<input id="co_docMarker_10" type="hidden"></a>. The FDA lists this patent information in the Orange Book.</div></div><div class="co_paragraph"><div class="co_paragraphText">ANDA applications must contain one of four certifications for patents “for which information is required to be filed under [<a id="co_link_I9c3dbec03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=21USCAS355&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">21 U.S.C. § 355(b)</a> or <a id="co_link_I9c3dbec13f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=21USCAS355&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_4b24000003ba5">(c)</a> ]”: (1) “that such patent information has not been filed;” (2) “that such patent has expired;” (3) “the date on which such patent will expire;” and (4) “that such patent is invalid or will not be infringed by the manufacture, use, or sale of the new drug for which the application is submitted.” <a id="co_link_I9c3dbec23f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=21USCAS355&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_77230000858d4">21 U.S.C. § 355(j)(2)(A)(vii)</a>. If the ANDA applicant makes a Paragraph IV certification, it must provide notice to the NDA holder of the certification. <a id="co_link_I6d3b60b3476f11e89f4896f3856dc5c1" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=21USCAS355&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_979c0000b55d2"><em>Id.</em> § 355(j)(2)(B)</a>. Prior to FDA approval, ANDA applicants generally must amend or supplement ANDAs to submit an appropriate patent certification for patents that issue after submission of the ANDA. <em>See </em><a id="co_link_I6d3b87c0476f11e89f4896f3856dc5c1" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=21USCAS355&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_0123000089ab5"><em>id.</em> § 355(j)(2)(B)(ii)(II)</a>; <a id="co_link_I9c3dbec53f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000547&amp;cite=21CFRS314.94&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">21 C.F.R. § 314.94(a)(12)(viii)(C)(ii)</a>. Thus, the regulatory framework expressly contemplates certifications for patents that issue after the ANDA is filed.</div></div><div class="co_paragraph"><div class="co_paragraphText">The type of certification under <a id="co_link_I9c4b7a603f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=21USCAS355&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_77230000858d4">21 U.S.C. § 355(j)(2)(A)(vii)</a> impacts when FDA approval may be made effective. <a id="co_link_I9c4b7a613f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=21USCAS355&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_9fbc0000bd582">21 U.S.C. § 355(j)(5)</a>. If an ANDA applicant submits a Paragraph IV certification, the statute provides for a thirty-month stay of effective FDA approval that may be shortened or lengthened in certain circumstances. <a id="co_link_I6d4db032476f11e89f4896f3856dc5c1" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=21USCAS355&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_83fb0000a4d76"><em>Id.</em> § 355(j)(5)(B)(iii)</a>. Congressional amendment of the thirty-month stay provision since the enactment of the Hatch-Waxman Act further supports the conclusion that “application” in <a id="co_link_I9c4b7a633f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">35 U.S.C. § 271(e)(2)</a> includes amendments to the ANDA.</div></div><div class="co_paragraph"><div class="co_paragraphText">As originally enacted, the Hatch-Waxman Act provided for a thirty-month stay as long as the suit was brought within 45 days of receipt of the Paragraph IV notice. <em>See</em> Hatch-Waxman Act, <a id="co_link_I9c558c813f3c11e8bd0794319e761151" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=l&amp;pubNum=1077005&amp;cite=UUID(IE18BBC5D63-B24B84B86B5-560A5141A87)&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SL&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Pub. L. 98–417</a>, § 101, 98 Stat. at 1589. Multiple thirty-month stays could therefore be triggered for the same ANDA as a consequence of the ANDA applicant submitting Paragraph IV certifications and notices for patents listed in the Orange Book that issued both before and after the submission of the original ANDA application. <em>See </em><a id="co_link_I9c558c813f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2002075387&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1378&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1378"><em>Andrx</em>, 276 F.3d at 1378</a> (noting that FDA “treated the listing in the Orange Book of [a patent that issued after the ANDA was submitted] as requiring a new thirty-month stay of its approval of Andrx's ANDA”).</div></div><div class="co_paragraph"><div class="co_paragraphText">In 2003, Congress amended <a id="co_link_I9c9ad2e03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=21USCAS355&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_267600008f864">21 U.S.C. § 355(j)</a> to eliminate the possibility of multiple thirty-month stays for the same ANDA. <em>See</em> Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (“the MMA”), <a id="co_link_I6d8c8df2476f11e8ba14fd08c73d85bc" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=l&amp;pubNum=1077005&amp;cite=UUID(IAD8DA5DB03-D4438C99E4B-5B321B98D02)&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SL&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Pub. L. 108-173, § 1101, 117 Stat. 2066</a>, 2449 (2003); <a id="co_link_I9c9ad2e43f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=0364206349&amp;pubNum=0100015&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=TV&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">H.R. Conf. Rep. No. 108-391, at 835–36</a> (2003), <em>reprinted in</em> 2003 U.S.C.C.A.N. 1808, 2187. The MMA changed the requirements to obtain a thirty-month stay to add that the patent information for the patent to which the Paragraph IV certification is directed must have been submitted to the FDA “before the date on which the [ANDA] <em>application (excluding an amendment or supplement to the application)</em> ... was submitted.” MMA, <a id="co_link_I6d8cb502476f11e8ba14fd08c73d85bc" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=l&amp;pubNum=1077005&amp;cite=UUID(IAD8DA5DB03-D4438C99E4B-5B321B98D02)&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SL&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Pub. L. 108-173</a>, § 1101(a)(2), 117 Stat. at 2449 (emphasis added) (codified at <a id="co_link_I9c9ad2e93f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=21USCAS355&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_83fb0000a4d76">21 U.S.C. § 355(j)(5)(B)(iii)</a> ). The MMA did not contain a corresponding amendment to <a id="co_link_I9c9ad2ea3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">35 U.S.C. § 271(e)(2)</a> to exclude amendments and supplements to the ANDA as cognizable acts of infringement even though it amended <a id="co_link_I9c9ad2eb3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_7fdd00001ca15">§ 271(e)</a> in other ways. <em>Id.</em> § 1101(d), 117 Stat. at 2457. This history thus further supports the conclusion that “application” in <a id="co_link_I9c9ad2ec3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">§ 271(e)(2)</a> includes amendments to the ANDA. <em>See </em><a id="co_link_I166edb5f41b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2019144488&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Gross v. FBL Fin. Servs., Inc.<input id="co_docMarker_11" type="hidden"></em>, 557 U.S. 167, 174, 129 S.Ct. 2343, 174 L.Ed.2d 119 (2009)</a> (“When Congress amends one statutory provision but not another, it is presumed to have acted intentionally.”). Thus, the district court properly conducted its infringement analysis for the <a id="co_link_I9c9ad2ef3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> pursuant to <a id="co_link_I9c9ad2f03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_9e660000185f2">35 U.S.C. § 271(e)(2)(A)</a>.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I7f630d60476f11e8a94cdbee4df18b01"><div class="co_headtext co_hAlign2">B. Inducement<sup id="co_footnoteReference_B00072044320422_ID0ES5CI"><a href="#co_footnote_B00072044320422" class="co_footnoteReference">7</a></sup></div><div class="co_paragraph"><div class="co_paragraphText"> <span class="co_starPage" id="co_pp_sp_999_8"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;8&quot; }" alt="metadata" type="hidden">*8</span> <a href="#co_anchor_F112044320422" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF11">11</a><a id="co_anchor_B112044320422"></a>We now turn to the merits of the infringement finding. West-Ward argues that the district court clearly erred in finding that it would induce infringement because Vanda failed to prove the requisite direct infringement and specific intent to induce infringement. Vanda responds that the district court correctly found that West-Ward will induce infringement of the asserted claims.</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F122044320422" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF12">12</a><a id="co_anchor_B122044320422"></a><a href="#co_anchor_F132044320422" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF13">13</a><a id="co_anchor_B132044320422"></a><a href="#co_anchor_F142044320422" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF14">14</a><a id="co_anchor_B142044320422"></a>The statute provides that “[w]hoever actively induces infringement of a patent shall be liable as an infringer.” <a id="co_link_I9cba41c03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">35 U.S.C. § 271(b)</a>. However, direct infringement is a necessary predicate for a finding of induced infringement in the usual patent infringement case. <a id="co_link_I9cba41c23f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2033496706&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_708_2117&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_708_2117"><em>Limelight Networks, Inc. v. Akamai Techs., Inc.</em>, ––– U.S. ––––, 134 S.Ct. 2111, 2117, 189 L.Ed.2d 52 (2014)</a>. It also “must be established that the defendant possessed specific intent to encourage another's infringement and not merely that the defendant had knowledge of the acts alleged to constitute inducement.” <a id="co_link_I9cba41c43f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2010878868&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1306&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1306"><em>DSU Med. Corp. v. JMS Co.</em>, 471 F.3d 1293, 1306 (Fed. Cir. 2006)</a> (en banc in relevant part) (internal quotation omitted). Circumstantial evidence can support a finding of specific intent to induce infringement. <a id="co_link_I9cba41c63f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2023571452&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1060&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1060"><em>AstraZeneca LP v. Apotex, Inc.</em> (<em>AstraZeneca I</em> ), 633 F.3d 1042, 1060 (Fed. Cir. 2010)</a> (citing <a id="co_link_I9cba41c83f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1988078737&amp;pubNum=0000350&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_350_668&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_668"><em>Water Techs. Corp. v. Calco, Ltd.</em>, 850 F.2d 660, 668 (Fed. Cir. 1988)</a> ).</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F152044320422" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF15">15</a><a id="co_anchor_B152044320422"></a><a href="#co_anchor_F162044320422" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF16">16</a><a id="co_anchor_B162044320422"></a>We have held that “[i]nducement can be found where there is ‘[e]vidence of active steps taken to encourage direct infringement,’ which can in turn be found in ‘advertising an infringing use or instructing how to engage in an infringing use.’ ” <a id="co_link_I9cd4a7913f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2036222044&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_630&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_630"><em>Takeda Pharm. U.S.A., Inc. v. W.-Ward Pharm. Corp.</em>, 785 F.3d 625, 630–31 (Fed. Cir. 2015)</a> (second alteration in original) (quoting <a id="co_link_I16fdd4e641b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2006858550&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Metro–Goldwyn–Mayer Studios Inc. v. Grokster, Ltd.</em>, 545 U.S. 913, 936, 125 S.Ct. 2764, 162 L.Ed.2d 781 (2005)</a> ). Where “the proposed label instructs users to perform the patented method ... the proposed label may provide evidence of [the ANDA applicant's] affirmative intent to induce infringement.” <a id="co_link_I9cd4a7973f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2023571452&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1060&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1060"><em>AstraZeneca I</em>, 633 F.3d at 1060</a>. When proof of specific intent depends on the label accompanying the marketing of a drug inducing infringement by physicians, “[t]he label must encourage, recommend, or promote infringement.” <a id="co_link_I9cd4a7993f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2036222044&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_631&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_631"><em>Takeda</em>, 785 F.3d at 631</a>. The contents of the label itself may permit the inference of specific intent to encourage, recommend, or promote infringement. <em>See </em><a id="co_link_I9cd4a79b3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2043134164&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_646&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_646"><em>Sanofi v. Watson Labs. Inc.</em>, 875 F.3d 636, 646 (Fed. Cir. 2017)</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">West-Ward argues that the district court clearly erred in finding that its proposed label “satisfies” the asserted claims because the language of the label itself cannot constitute direct infringement of the asserted method claims. <em>See </em><a id="co_link_I9cdbac713f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039653953&amp;pubNum=0007903&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_7903_432&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_7903_432"><em>Opinion</em>, 203 F.Supp.3d at 432</a>. West-Ward also contends that the court clearly erred in finding that Dr. Alva practiced the asserted claims because he never administered an allegedly infringing dose to a poor metabolizer.</div></div><div class="co_paragraph"><div class="co_paragraphText">Vanda responds that it did not need to prove instances of direct infringement by physicians because this is a Hatch-Waxman case where infringement is statutorily-defined to be the filing of an ANDA or an amendment thereto, not by selling a product. Even though not required, Vanda contends, it identified a doctor, Dr. Alva, who practiced the steps of the asserted claims with Fanapt®. <input id="co_docMarker_12" type="hidden">Vanda argues that the asserted claims do not require that a single physician administer iloperidone to both poor and non-poor CYP2D6 metabolizers, and that West-Ward's argument to the contrary is waived because it was raised for the first time on appeal.</div></div><div class="co_paragraph"><div class="co_paragraphText"> <span class="co_starPage" id="co_pp_sp_999_9"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;9&quot; }" alt="metadata" type="hidden">*9</span> We agree with Vanda that a patentee does not need to prove an actual past instance of direct infringement by a physician to establish infringement under <a id="co_link_I9cfa7f103f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_9e660000185f2">35 U.S.C. § 271(e)(2)(A)</a>. As we have explained, “<a id="co_link_I9cfa7f173f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_9e660000185f2">section 271(e)(2)(A)</a> makes it possible for a patent owner to have the court determine whether, if a particular drug <em>were</em> put on the market, it <em>would</em> infringe the relevant patent.” <a id="co_link_I9cfa7f123f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1995220011&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1135&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1135"><em>Bristol-Myers Squibb</em>, 69 F.3d at 1135</a> (emphases in original). A <a id="co_link_I9cfa7f183f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_9e660000185f2">§ 271(e)(2)(A)</a> infringement suit differs from typical infringement suits in that the infringement inquiries “are <em>hypothetical</em> because the allegedly infringing product has not yet been marketed.” <a id="co_link_I9cfa7f143f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003082816&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1365&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1365"><em>Warner-Lambert</em>, 316 F.3d at 1365</a> (emphasis added); <em>see also </em><a id="co_link_I9cfa7f163f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1997083946&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1570&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1570"><em>Glaxo</em>, 110 F.3d at 1570</a> (“The relevant inquiry is whether patentee has proven by a preponderance of the evidence that the alleged infringer will likely market an infringing product.”).</div></div><div class="co_paragraph"><div class="co_paragraphText">Similarly, patentees in Hatch-Waxman litigations asserting method patents do not have to prove that prior use of the NDA-approved drug satisfies the limitations of the asserted claims. <em>See, e.g.</em>, <a id="co_link_I9d0c0b413f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2043134164&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_643&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_643"><em>Sanofi</em>, 875 F.3d at 643</a> (affirming inducement finding where the district court found “the inducing act will be the marketing by [ANDA applicants] of their generic dronedarone drugs with the label described” and “the induced act will be the administration of dronedarone by medical providers to patients meeting the criteria set forth in the [claims at issue]”); <a id="co_link_I9d0c0b433f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2040743290&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1368&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1368"><em>Eli Lilly &amp; Co. v. Teva Parenteral Meds., Inc.</em>, 845 F.3d 1357, 1368 (Fed. Cir. 2017)</a> (explaining “we have not required evidence regarding the general prevalence of the induced activity”); <a id="co_link_I9d0c0b453f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2023571452&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1057&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1057"><em>AstraZeneca I</em>, 633 F.3d at 1057</a> (affirming district court's grant of a preliminary injunction based on claims of induced infringement where the district court found that “the proposed label would cause some users to infringe the asserted method claims”); <em>see also </em><a id="co_link_I9d0c0b473f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003082816&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1364&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1364"><em>Warner-Lambert</em>, 316 F.3d at 1364</a> (“The infringement case is therefore limited to an analysis of whether what the generic drug maker is requesting authorization for in the ANDA would be an act of infringement if performed.”).</div></div><div class="co_paragraph"><div class="co_paragraphText">Accordingly, Vanda can satisfy its burden to prove the predicate direct infringement by showing that if the proposed ANDA product were marketed, it would infringe the <a id="co_link_I9d1ad8503f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a>. The district court made factual findings that the proposed label “recommends” that physicians perform the claimed steps, <em>see </em><a id="co_link_I9d1ad8523f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039653953&amp;pubNum=0007903&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_7903_432&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_7903_432"><em>Opinion</em>, 203 F.Supp.3d at 432–33</a>, and its analysis of the proposed label to assess potential direct infringement by physicians was proper under our precedent. <em>See, e.g.</em>, <a id="co_link_I9d1ad8543f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2034181324&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1408&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1408"><em>Ferring B.V. v. Watson Labs., Inc.-Fla.</em>, 764 F.3d 1401, 1408 (Fed. Cir. 2014)</a> (“The infringement determination is thus based on consideration of all the relevant evidence, and because drug manufacturers are bound by strict statutory provisions to sell only those products that comport with the ANDA's description of the drug, the ANDA itself dominates the analysis.” (internal quotation marks and alterations omitted) ); <a id="co_link_I9d1ad8563f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2023571452&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1060&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1060"><em>AstraZeneca I</em>, 633 F.3d at 1060</a> (explaining that the district court “correctly determined” that language in the ANDA label “would inevitably lead some consumers to practice the claimed method”).</div></div><div class="co_paragraph"><div class="co_paragraphText">Turning to specific intent, West-Ward argues that Vanda failed to prove that its proposed label would <input id="co_docMarker_13" type="hidden">“ ‘encourage’ or ‘recommend’ a direct infringer (a psychiatrist or other physician) to perform each step of the claimed methods.” Appellant Br. 36 (quoting <a id="co_link_I9d2427213f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2036222044&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_631&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_631"><em>Takeda</em>, 785 F.3d at 631</a>). West-Ward contends that the substantial number of noninfringing uses precludes a finding of specific intent as a matter of law. <em>See </em><a id="co_link_I9d2427233f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003082816&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1365&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1365"><em>Warner-Lambert</em>, 316 F.3d at 1365</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">Vanda responds that the district court did not clearly err in finding that the proposed label recommends performance of all the claimed steps. Vanda argues that potential noninfringing uses do not preclude a finding of specific intent to induce infringement in this case.</div></div><div class="co_paragraph"><div class="co_paragraphText"> <span class="co_starPage" id="co_pp_sp_999_10"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;10&quot; }" alt="metadata" type="hidden">*10</span> We agree with Vanda that the district court did not clearly err in finding induced infringement of independent claims 1, 9, and 13.<sup id="co_footnoteReference_B00082044320422_ID0EMUDI"><a href="#co_footnote_B00082044320422" class="co_footnoteReference">8</a></sup> Section 2 of the proposed label is entitled “Dosage and Administration.” J.A. 15105 § 2. Section 2.1 entitled, “Usual Dose,” states:</div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText"><blockquote><div>Iloperidone must be titrated slowly from a low starting dose.... The recommended starting dose for iloperidone tablets is 1 mg twice daily. Dose increases to reach the <em>target range</em> of 6 to 12 mg twice daily (<em>12 to 24 mg/day</em> ) may be made with daily dosage adjustments not to exceed 2 mg twice daily (4 mg/day). The <em>maximum recommended dose</em> is 12 mg twice daily (<em>24 mg/day</em> ).... Prescribers should be mindful of the fact that patients need to be titrated to an effective dose of iloperidone.</div></blockquote></div></div><div class="co_paragraphText co_flush"><em>Id.</em> § 2.1 (emphases added). Section 2.2, entitled “Dosage in Special Populations,” states: “<em>Dosage adjustment for</em> <em>patients taking iloperidone who are poor metabolizers of CYP2D6:</em> Iloperidone dose should be <em>reduced by one-half</em> for poor metabolizers of CYP2D6 [<em>see</em> <em>Pharmacokinetics (12.3)</em> ].” <em>Id.</em> § 2.2 (second emphasis added).</div></div><div class="co_paragraph"><div class="co_paragraphText">Section 12.3 of the proposed label, entitled “Pharmacokinetics,” states:</div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText">Approximately 7 to 10% of Caucasians and 3 to 8% of Black/African Americans lack the capacity to metabolize CYP2D6 substrates and are classified as poor metabolizers (PM), whereas the rest are intermediate, extensive or ultrarapid metabolizers. Co-administration of iloperidone with known strong inhibitors of CYP2D6 like <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3ab2a1c5475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3ab2a1c5475111db9765f9243f53508a">fluoxetine</a> results in a 2.3 fold increase in iloperidone plasma exposure, and therefore one-half of the iloperidone dose should be administered.</div></div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText">Similarly, PMs of CYP2D6 have higher exposure to iloperidone compared with [extensive metabolizers] and <em>PMs should have their dose reduced by one-half. Laboratory tests are available to identify CYP2D6 PMs</em>.</div></div><div class="co_paragraphText co_flush">J.A. 15121 § 12.3 (emphasis added).</div></div><div class="co_paragraph"><div class="co_paragraphText">Thus, the district court did not clearly err in finding that § 12.3 “recommends that practitioners perform or have performed a <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=mproc&amp;entityId=Ib3510dc6475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ib3510dc6475411db9765f9243f53508a_2">genotyping</a> assay to determine whether patients are CYP2D6 poor metabolizers.” <a id="co_link_I9d49fea13f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039653953&amp;pubNum=0007903&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_7903_432&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_7903_432"><em>Opinion</em>, 203 F.Supp.3d at 432</a>. Experts for both parties testified that the referred-to “laboratory tests” are “<a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=mproc&amp;entityId=Ib3510dc6475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ib3510dc6475411db9765f9243f53508a_3">genotyping</a> tests.” J.A. 6939 (234:8–235:13) (Vanda's expert); J.A. 7103–04 (566:10–568:2) (West-Ward's expert). The district court thus found that “when the label states that ‘laboratory tests’ are available to identify poor metabolizers, the label is referring to ‘genotyping tests.’ ” <a id="co_link_I9d49fea33f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039653953&amp;pubNum=0007903&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_7903_433&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_7903_433"><em>Opinion</em>, 203 F.Supp.3d at 433</a> (citing testimony of both parties' experts). We discern no clear error in this finding.</div></div><div class="co_paragraph"><div class="co_paragraphText"> <span class="co_starPage" id="co_pp_sp_999_11"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;11&quot; }" alt="metadata" type="hidden">*11</span> The label instructs practitioners that “PMs should have their dose reduced by one-half. [Genotyping tests] are available to identify CYP2D6 PMs.” J.A. 15121 § 12.3. The court did not clearly err in finding that this constitutes a recommendation to perform genotyping tests on iloperidone patients. That West-Ward introduced other evidence that could have supported a contrary finding does not compel the conclusion that the district court clearly erred. <input id="co_docMarker_14" type="hidden"><em>See </em><a id="co_link_I18efb9d241b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1985114055&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Anderson v. City of Bessemer City</em>, 470 U.S. 564, 574, 105 S.Ct. 1504, 84 L.Ed.2d 518 (1985)</a> (“Where there are two permissible views of the evidence, the factfinder's choice between them cannot be clearly erroneous.”). Moreover, the court's decision to credit the plausible testimony of certain witnesses and reject the testimony of West-Ward's witness as not credible, <a id="co_link_I9d5ac7833f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039653953&amp;pubNum=0007903&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_7903_433&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_7903_433"><em>Opinion</em>, 203 F.Supp.3d at 433</a>, “can virtually never be clear error,” <a id="co_link_I18efb9d841b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1985114055&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Anderson</em>, 470 U.S. at 575, 105 S.Ct. 1504</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">We reject West-Ward's contention that the lack of an express finding by the district court that the label recommends obtaining a biological sample requires a remand. The district court found induced infringement of the independent claims, which necessarily required a finding of inducement of the limitation requiring “obtaining or having obtained a biological sample from the patient.” <a id="co_link_I9d6723903f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> col. 17 ll. 7–8 (claim 1), col. 18 ll. 9–10 (claim 9), col. 18 ll. 34–35 (claim 13). West-Ward has pointed to no evidence in the record to dispute the testimony of Vanda's witnesses at trial that the genotyping assays the court found were recommended by the label require obtaining a biological sample. J.A. 6928 (190:14–191:1); J.A. 6939 (235:18–23). Given this undisputed evidence and the court's finding that the label recommends genotyping assays, we see no clear error in the court's implicit finding that the proposed label recommends obtaining a biological sample. <em>See, e.g.</em>, <a id="co_link_I9d6723923f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1995252576&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1090&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1090"><em>Para-Ordnance Mfg., Inc. v. SGS Importers Int'l, Inc.</em>, 73 F.3d 1085, 1090 (Fed. Cir. 1995)</a> (explaining that “[f]rom the decision of the district court, we can, and do, accept the implicit fact-finding”).</div></div><div class="co_paragraph"><div class="co_paragraphText">The district court also did not clearly err in finding that “[t]he label recommends oral administration of iloperidone tablets at 12 to 24 mg/day to non-genotypic CYP2D6 poor metabolizers and 12 mg/day or less to genotypic CYP2D6 poor metabolizers.” <a id="co_link_I9d6faf113f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039653953&amp;pubNum=0007903&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_7903_432&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_7903_432"><em>Opinion</em>, 203 F.Supp.3d at 432</a> (citing J.A. 15105 §§ 2.1, 2.2). The label recommends a “[u]sual” target dose range (12 to 24 mg/day) and maximum dose (24 mg/day) and then instructs medical providers to “reduce[ ]” the dose for genetic CYP2D6 poor metabolizers (a “[s]pecial population”) “by one-half.” J.A. 15015 §§ 2.1, 2.2; <em>see also</em> J.A. 15103; J.A. 15121 § 12.3. A one-half reduction of the usual dose amounts yields a target dose range of 6 to 12 mg/day and a maximum dose of 12 mg/day for poor metabolizers. That the label also directs a medical provider to titrate the dosage does not negate its clear recommendations on ultimate dosage range and maximum amount.</div></div><div class="co_paragraph"><div class="co_paragraphText">Similarly, the fact that the target dose range for genotypic non-poor metabolizers (12 to 24 mg/day) includes 12 mg/day does not compel a finding of noninfringement. The independent claims require administering “greater than 12 mg/day, up to 24 mg/day” of iloperidone to non-poor metabolizers. <a id="co_link_I9d7ca7603f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> col. 17 ll. 17–20 (claim 1), col. 18 ll. 16–18 (claim 9), col. 18 ll. 44–47 (claim 13). Even if not every practitioner will prescribe an infringing dose, that the target dose range “instructs users to perform the patented method” is sufficient to “provide evidence of [West-Ward's] affirmative intent to induce infringement.” <a id="co_link_I9d7ca7623f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2023571452&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1060&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1060"><em>AstraZeneca I</em>, 633 F.3d at 1060</a>; <em>see also</em> <a id="co_link_I9d7ca7643f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2040743290&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1369&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1369"><em>Eli Lilly</em>, 845 F.3d at 1369</a> (explaining that “evidence that the product labeling that Defendants seek would inevitably lead some physicians to infringe establishes the requisite intent for inducement”).</div></div><div class="co_paragraph"><div class="co_paragraphText"> <span class="co_starPage" id="co_pp_sp_999_12"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;12&quot; }" alt="metadata" type="hidden">*12</span> Finally, West-Ward's reliance on <a id="co_link_I9d84e4c43f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003082816&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Warner-Lambert<input id="co_docMarker_15" type="hidden"></em></a>, an off-label use case, is misplaced. In <a id="co_link_I9d84e4c93f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003082816&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Warner-Lambert</em></a>, we explained that “it defies common sense to expect that [ANDA applicant] will actively promote the sale of its approved [ANDA product], in contravention of FDA regulations, for a use that (a) might infringe [NDA holder's] patent and (b) constitutes such a small fraction of total sales.” <a id="co_link_I9d84e4cb3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003082816&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1365&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1365"><em>Warner-Lambert</em>, 316 F.3d at 1365</a>. In the context of that off-label use case where there were “substantial noninfringing uses,” we declined to “infer” intent to induce infringement. <a id="co_link_I9d84e4cc3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2003082816&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em></a> Here, the district court found that the proposed label itself recommends infringing acts.</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F172044320422" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF17">17</a><a id="co_anchor_B172044320422"></a>Accordingly, even if the proposed ANDA product has “substantial noninfringing uses,” West-Ward may still be held liable for induced infringement. “<a id="co_link_I9da676853f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_a83b000018c76">Section 271(b)</a>, on inducement, does not contain the ‘substantial noninfringing use’ restriction of <a id="co_link_I9da676863f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_4b24000003ba5">section 271(c)</a>, on contributory infringement.” <a id="co_link_I9da676813f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2043134164&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_646&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_646"><em>Sanofi</em>, 875 F.3d at 646</a>. Thus, “a person can be liable for inducing an infringing use of a product even if the product has substantial noninfringing uses....” <a id="co_link_I9da676823f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2043134164&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em></a> (citing <a id="co_link_I1959ed5541b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2006858550&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Grokster</em>, 545 U.S. at 934–37, 125 S.Ct. 2764</a>).</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I7f85b090476f11e8a94cdbee4df18b01"><div class="co_headtext co_hAlign2">III. Patent Subject Matter Eligibility</div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F182044320422" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF18">18</a><a id="co_anchor_B182044320422"></a>We next address whether the asserted claims are directed to patent-eligible subject matter. West-Ward argues that the asserted claims are ineligible under § 101 because they are directed to a natural relationship between iloperidone, CYP2D6 metabolism, and QT prolongation, and add nothing inventive to those natural laws and phenomena. West-Ward contends that the asserted claims are indistinguishable from those held invalid in <a id="co_link_I1979f87241b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2030717666&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Association for Molecular Pathology v. Myriad Genetics, Inc.</em>, 569 U.S. 576, 133 S.Ct. 2107, 186 L.Ed.2d 124 (2013)</a> and <a id="co_link_I1979f87641b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo Collaborative Services v. Prometheus Laboratories, Inc.</em>, 566 U.S. 66, 132 S.Ct. 1289, 182 L.Ed.2d 321 (2012)</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">Vanda responds that the asserted claims are patent-eligible under § 101 at both steps of <a id="co_link_Ib9a8c1d0440511e8bbbcdb5bee63666e" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a>/<a id="co_link_Ie8a569c0440511e888eeba1db7ac8e31" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2033619398&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Alice</em></a>. Vanda contends that the district court erred in holding that the asserted claims are directed to a law of nature. According to Vanda, the court's “conclusions that the asserted claims ‘depend upon,’ ‘touch[ ] upon,’ and ‘address’ laws of nature and natural phenomena do not, as a matter of law, establish that the asserted claims are <em>directed to</em> a patent-ineligible concept under Step 1 of the <a id="co_link_I094c5490440611e880acb32dec375f7b" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2033619398&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Alice</em></a>/<a id="co_link_I104797a0440611e88f2fc3aa44d2bedf" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a> analysis.” Appellee Br. 45 (alteration and emphasis in original).</div></div><div class="co_paragraph"><div class="co_paragraphText">Section 101 of the Patent Act states that “[w]hoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.” <a id="co_link_I9de3cda03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C. § 101</a>. However, <a id="co_link_I9de3f4b33f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a> “contains an important implicit exception”: “ ‘laws of nature, natural phenomena, and abstract ideas’ are not patentable.” <a id="co_link_I199dad1341b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em>, 566 U.S. at 70, 132 S.Ct. 1289</a> (alteration omitted) (quoting <a id="co_link_I199dad1641b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1981109598&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Diamond v. Diehr</em>, 450 U.S. 175, 185, 101 S.Ct. 1048, 67 L.Ed.2d 155 (1981)</a> ).</div></div><div class="co_paragraph"><div class="co_paragraphText">The Supreme Court has established a two-step framework to determine patent subject matter eligibility under <a id="co_link_I9de5f0803f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C. § 101</a>:</div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText">First, we determine whether the claims at issue are directed to one of those patent-ineligible concepts. If so, we then ask, “[w]hat else is there in the claims before us?” To answer that question, we consider the elements of each claim both individually and “as an ordered combination” to determine whether the additional elements “transform the nature of the claim” into a patent-eligible application. <input id="co_docMarker_16" type="hidden">We have described step two of this analysis as a search for an “ ‘inventive concept’ ”—<em>i.e.,</em> an element or combination of elements that is “sufficient to ensure that the patent in practice amounts to significantly more than a patent upon the [ineligible concept] itself.”</div></div><div class="co_paragraphText co_flush"> <span class="co_starPage" id="co_pp_sp_999_13"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;13&quot; }" alt="metadata" type="hidden">*13</span> <a id="co_link_I9dff93013f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2033619398&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_708_2355&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_708_2355"><em>Alice Corp. Pty. v. CLS Bank Int'l</em>, ––– U.S. ––––, 134 S.Ct. 2347, 2355, 189 L.Ed.2d 296 (2014)</a> (citations omitted) (alteration in original) (quoting <a id="co_link_I19b9c09641b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em>, 566 U.S. at 72–73, 75–79, 132 S.Ct. 1289</a>).</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F192044320422" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF19">19</a><a id="co_anchor_B192044320422"></a><a href="#co_anchor_F202044320422" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF20">20</a><a id="co_anchor_B202044320422"></a>Step one requires determining “whether the claims at issue are <em>directed to</em> one of those patent-ineligible concepts.” <a id="co_link_I9e20d6a03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2033619398&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em></a> (emphasis added); <em>see also </em><a id="co_link_I9e20d6a23f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2038839002&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1335&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1335"><em>Enfish, LLC v. Microsoft Corp.</em>, 822 F.3d 1327, 1335 (Fed. Cir. 2016)</a>. The Supreme Court has cautioned that “too broad an interpretation of” ineligible subject matter “could eviscerate patent law” because “all inventions at some level embody, use, reflect, rest upon, or apply laws of nature, natural phenomena, or abstract ideas.” <a id="co_link_I19e193e541b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em>, 566 U.S. at 71, 132 S.Ct. 1289</a>. Accordingly, at step one, “it is not enough to merely identify a patent-ineligible concept underlying the claim; we must determine whether that patent-ineligible concept is what the claim is ‘directed to.’ ” <a id="co_link_I9e20d6a63f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039315377&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1050&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1050"><em>Rapid Litig. Mgmt. Ltd. v. CellzDirect, Inc.</em>, 827 F.3d 1042, 1050 (Fed. Cir. 2016)</a>. If the claims are not directed to a patent ineligible concept at step one, we need not address step two of the inquiry. See <a id="co_link_I9e20d6a83f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2038839002&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1339&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1339">Enfish, 822 F.3d at 1339</a>. That is the case here.</div></div><div class="co_paragraph"><div class="co_paragraphText">Consistent with Supreme Court precedent, we agree with Vanda that the asserted claims are not directed to patent-ineligible subject matter.<sup id="co_footnoteReference_B00092044320422_ID0ECWAK"><a href="#co_footnote_B00092044320422" class="co_footnoteReference">9</a></sup> Claim 1 recites “[a] method for treating a patient with iloperidone, wherein the patient is suffering from <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Ic8ad584c475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ic8ad584c475411db9765f9243f53508a_6">schizophrenia</a>.” <a id="co_link_I9e26a3003f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> col. 17 ll. 2–3. Claim 1 requires specific steps: (1) determining the patient's CYP2D6 metabolizer genotype by (a) obtaining a biological sample and (b) performing a <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=mproc&amp;entityId=Ib3510dc6475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ib3510dc6475411db9765f9243f53508a_4">genotyping</a> assay; and (2) administering specific dose ranges of iloperidone depending on the patient's CYP2D6 genotype. Id. col. 17 ll. 2–25.</div></div><div class="co_paragraph"><div class="co_paragraphText">West-Ward contends that the Supreme Court held that similar claims were patent ineligible in <a id="co_link_I9e32ff113f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a> and <a id="co_link_I9e32ff1c3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2030717666&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Myriad</em></a>. The patent in <a id="co_link_I9e32ff1f3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a> claimed a method for “optimizing” the dosage of thiopurine drugs by administering thiopurine drugs to a patient and measuring the level of certain metabolites in the blood, wherein the level of metabolites indicates whether to adjust the dosage. <a id="co_link_I1a098e5441b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em>, 566 U.S. at 74–75, 132 S.Ct. 1289</a>. The Supreme Court held that the claims recited a natural law, and did not include any “additional features that provide practical assurance that the process is more than a drafting effort designed to monopolize the law of nature itself.” <a id="co_link_I1a098e5641b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 77, 132 S.Ct. 1289</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">This case, however, is not <a id="co_link_I9e398ec13f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a>. First, the claims in <a id="co_link_I9e398ecc3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a> were not directed to a novel method of treating a disease. Instead, the claims were directed to a diagnostic method based on the “relationships between concentrations of certain metabolites in the blood and the likelihood that a dosage of a thiopurine drug will prove ineffective or cause harm.” <a id="co_link_I9e398ed63f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em></a> This “relation is a consequence of the ways in which thiopurine compounds are metabolized by the body—entirely natural processes. And so a patent that simply describes that relation sets forth a natural law.” <a id="co_link_I9e398ed73f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em></a></div></div><div class="co_paragraph"><div class="co_paragraphText">Although the representative claim in <a id="co_link_I9e491f213f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a> recited administering a thiopurine drug to a patient, the claim as a whole was not directed to the application of a drug to treat a particular disease. <em>See </em><a id="co_link_I9e491f2b3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_708_74&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_708_74"><em>id.</em> at 74, 87, 132 S.Ct. 1289<input id="co_docMarker_17" type="hidden"></a>. Importantly, the Supreme Court explained that the administering step was akin to a limitation that tells engineers to apply a known natural relationship or to apply an abstract idea with computers. <em>See </em><a id="co_link_I9e491f2c3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_708_78&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_708_78"><em>id.</em> at 78, 132 S.Ct. 1289</a> (comparing the claim in <a id="co_link_I9e491f2e3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a> to “Einstein telling linear accelerator operators about his basic law and then trusting them to use it where relevant”). To further underscore the distinction between method of treatment claims and those in <a id="co_link_I9e491f393f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a>, the Supreme Court noted that “[u]nlike, say, a typical patent on a new drug or a new way of using an existing drug, the patent claims do not confine their reach to particular applications of those laws.” <a id="co_link_I9e491f433f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_708_87&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_708_87"><em>Id.</em> at 87, 132 S.Ct. 1289</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText"> <span class="co_starPage" id="co_pp_sp_999_14"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;14&quot; }" alt="metadata" type="hidden">*14</span> In this case, the <a id="co_link_I9e57ec303f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> claims are directed to a method of using iloperidone to treat <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Ic8ad584c475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ic8ad584c475411db9765f9243f53508a_7">schizophrenia</a>. The inventors recognized the relationships between iloperidone, CYP2D6 metabolism, and QTc prolongation, but that is not what they claimed. They claimed an application of that relationship. Unlike the claim at issue in <a id="co_link_I9e57ec323f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a>, the claims here require a treating doctor to administer iloperidone in the amount of either (1) 12 mg/day or less or (2) between 12 mg/day to 24 mg/day, depending on the result of a <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=mproc&amp;entityId=Ib3510dc6475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ib3510dc6475411db9765f9243f53508a_5">genotyping</a> assay. The specification further highlights the significance of the specific dosages by explaining how certain ranges of administered iloperidone correlate with the risk of QTc prolongation. <em>See, e.g.</em>, <a id="co_link_I9e57ec3c3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> at col. 4 ll. 1–15. Thus, the <a id="co_link_I9e57ec3d3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> claims are “a new way of using an existing drug” that is safer for patients because it reduces the risk of QTc prolongation. <a id="co_link_I1a4fe62241b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em>, 566 U.S. at 87, 132 S.Ct. 1289</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">Moreover, unlike the claim in <a id="co_link_I9e70cb613f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a>, to the extent that preemption is a concern, the <a id="co_link_I9e70cb6b3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> claims do not “tie up the doctor's subsequent treatment decision.” <a id="co_link_I1a91f82f41b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 86, 132 S.Ct. 1289</a>. The claim in <a id="co_link_I9e70cb6e3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a> did not go beyond recognizing (<em>i.e.</em>, “indicates”) a need to increase or decrease a dose. <a id="co_link_I1a921f3241b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 75, 132 S.Ct. 1289</a>. In <a id="co_link_I9e70cb7a3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a>, “a doctor ... could violate the patent even if he did not actually alter his treatment decision in the light of the test.” <a id="co_link_I9e70cb843f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em></a> The claim was not a treatment claim. It was “not limited to instances in which the doctor actually decreases (or increases) the dosage level where the test results suggest that such an adjustment is advisable.” <a id="co_link_I1a921f4241b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 76, 132 S.Ct. 1289</a>. Thus, the claim in <a id="co_link_I9e70cb873f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a> did not involve doctors <em>using</em> the natural relationship between the metabolite level and lessening “the likelihood that a dosage of a thiopurine drug will prove ineffective or cause harm.” <a id="co_link_I1a921f5141b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 77, 132 S.Ct. 1289</a>. The claims in <a id="co_link_I9e70cb933f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a> therefore “tie up the doctor's subsequent treatment decision whether that treatment does, or does not, change in light of the inference he has drawn using the correlations. And they threaten to inhibit the development of more refined treatment recommendations....” <a id="co_link_I1a921f6041b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 86–87, 132 S.Ct. 1289</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">Here, the <a id="co_link_I9e7e38e03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> claims recite the steps of carrying out a dosage regimen based on the results of genetic testing. The claims require doctors to “internally administer[ ] iloperidone to the patient in an amount of 12 mg/day or less” if the patient has a CYP2D6 poor metabolizer genotype; and “internally administer[ ] iloperidone to the patient in an amount that is greater than 12 mg/day, up to 24 mg/day” if the patient does not have a CYP2D6 poor metabolizer genotype. <a id="co_link_I9e7e38e13f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> col. 17 ll. 13–20. These are treatment steps. In contrast, as shown above, the claim in <a id="co_link_I9e7e38e33f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a> stated that the metabolite level in blood simply “indicates” a need to increase or decrease dosage, without prescribing a specific dosage regimen or other added steps to take as a result of that indication. <input id="co_docMarker_18" type="hidden"><a id="co_link_I1ab055a141b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em>, 566 U.S. at 75, 132 S.Ct. 1289</a>. Here, the claims do not broadly “tie up the doctor's subsequent treatment decision.” <a id="co_link_I1ab055a341b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 86, 132 S.Ct. 1289</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">Our decision in <a id="co_link_I9e9458f23f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039315377&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>CellzDirect</em></a> supports concluding that these claims are patent eligible. In that case, we held that “a method of producing a desired preparation of multi-cryopreserved hepatocytes cells” was patent eligible. <a id="co_link_I9e9458f43f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039315377&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1047&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1047"><em>CellzDirect</em>, 827 F.3d at 1047</a>. We explained that “[t]he end result of the ... claims is not simply an observation or detection of the ability of hepatocytes to survive multiple freeze-thaw cycles. Rather, the claims [were] directed to a new and useful method of preserving hepatocyte cells.” <a id="co_link_I9e9458f53f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039315377&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1048&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1048"><em>Id.</em> at 1048</a>. We further emphasized that “the natural ability of the subject matter to <em>undergo</em> the process does not make the claim ‘directed to’ that natural ability.” <a id="co_link_I9e9458f63f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039315377&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1049&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1049"><em>Id.</em> at 1049</a> (emphasis in original). Otherwise, claims directed to actually “treating <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a">cancer</a> with chemotherapy” or “treating headaches with <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3af17fb7475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3af17fb7475111db9765f9243f53508a">aspirin</a>” would be patent ineligible. <a id="co_link_I9e9458f73f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039315377&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em></a></div></div><div class="co_paragraph"><div class="co_paragraphText"> <span class="co_starPage" id="co_pp_sp_999_15"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;15&quot; }" alt="metadata" type="hidden">*15</span> Nor does <a id="co_link_I9e9fcaa13f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2030717666&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Myriad</em></a> compel a different outcome. The Supreme Court in <a id="co_link_I9e9fcaa43f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2030717666&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Myriad</em></a> held “that a naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated, but that cDNA is patent eligible because it is not naturally occurring.” <a id="co_link_I1af3a02c41b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2030717666&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Myriad</em>, 569 U.S. at 580, 133 S.Ct. 2107</a>. The Court was careful to note that “method claims” and “patents on new applications of knowledge about [particular] genes” were “<em>not</em> implicated by [its] decision.” <a id="co_link_I9e9fcaa83f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2030717666&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> 595–96, 133 S.Ct. 2107</a> (emphasis in original). The <a id="co_link_I9e9fcaa93f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> does not claim naturally occurring DNA segments. Rather, the asserted claims fall squarely within categories of claims that the Court stated were not implicated by its decision.</div></div><div class="co_paragraph"><div class="co_paragraphText">At bottom, the claims here are directed to a specific method of treatment for specific patients using a specific compound at specific doses to achieve a specific outcome. They are different from <a id="co_link_I9ea374213f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a>. They recite more than the natural relationship between CYP2D6 metabolizer genotype and the risk of QTc prolongation. Instead, they recite a method of treating patients based on this relationship that makes iloperidone safer by lowering the risk of QTc prolongation. Accordingly, the claims are patent eligible.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I7fa06480476f11e8a94cdbee4df18b01"><div class="co_headtext co_hAlign2">IV. Written Description</div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F212044320422" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF21">21</a><a id="co_anchor_B212044320422"></a><a href="#co_anchor_F222044320422" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF22">22</a><a id="co_anchor_B222044320422"></a>We next consider West-Ward's argument that the district court erred in finding that the claims are not invalid for lack of adequate written description. To satisfy the written description requirement the patent disclosure must “reasonably convey[ ] to those skilled in the art that the inventor had possession of the claimed subject matter as of the filing date.” <a id="co_link_I9eae49913f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2021584873&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1351&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1351"><em>Ariad Pharm., Inc. v. Eli Lilly &amp; Co.</em>, 598 F.3d 1336, 1351 (Fed. Cir. 2010)</a> (en banc). Whether a claim satisfies the written description requirement is a question of fact that we review for clear error following a bench trial. <a id="co_link_I9eae49933f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032909107&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1190&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1190"><em>Alcon Research</em>, 745 F.3d at 1190</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">West-Ward argues that the asserted claims are invalid for lack of written description because nothing in the <a id="co_link_I9eb12fc03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> demonstrates possession of the claimed dosage ranges for poor and non-poor CYP2D6 metabolizer genotypes. West-Ward contends that the description does not contain experiments with doses of 12 mg/day or less given to poor metabolizers, and reports data that does not support the claimed poor-metabolizer dose range.</div></div><div class="co_paragraph"><div class="co_paragraphText">Vanda responds that the district court did not clearly err in finding that the <a id="co_link_I9eb3c7d03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> adequately describes the claimed dosages for poor metabolizers. Vanda contends that West-Ward waived any written description challenge to the dosages for non-poor metabolizers, and that West-Ward's argument is, in any event, meritless.<input id="co_docMarker_19" type="hidden"></div></div><div class="co_paragraph"><div class="co_paragraphText">We agree with Vanda that the district court did not clearly err in finding that the <a id="co_link_I9ebaa5a03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> contains adequate written description for the claimed “12 mg/day or less” dosage range for poor metabolizers. The patent reports the results of tests comparing the concentrations of P88 and P95, iloperidone's two main metabolites, and changes in QTc interval upon administration of doses of iloperidone, both with and without the addition of a CYP2D6 inhibitor, to individuals with wildtype or a poor metabolizer genotype associated with two common CYP2D6 polymorphisms. <a id="co_link_I9ebaa5a13f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> col. 4 l. 62–col. 10 l. 56. The patent reports that “QTc prolongation is correlated to the ratios of P88/P95 and (iloperidone+P88)/P95.” <em>Id.</em> col. 9 ll. 57–58.</div></div><div class="co_paragraph"><div class="co_paragraphText">The <a id="co_link_I9ed818b03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> further explains that the reported results “show that patients can be more safely treated with iloperidone if the dose of iloperidone is adjusted based on the CYP2D6 genotype of each patient,” <em>id</em><em>.</em> col. 9 ll. 31–34; <em>accord </em><em>id.</em> col. 2 ll. 15–24, and provides examples of such doses, <em>id.</em> col. 9 ll. 34–47, col. 11 ll. 22–28. For a poor metabolizer, those examples include reducing the dose of iloperidone administered by “75% or less, 50% or less, or 25% or less of the dose typically administered to a patient having a CYP2D6 genotype that results in a CYP2D6 protein” with wildtype activity. <em>Id.</em> col. 9 ll. 34–43. The patent then provides a specific example of a dose for non-poor metabolizers, “24 mg per day,” and the appropriate reduction for a poor metabolizer “reduced dosage of 18, 12, or 6 mg per day.” <em>Id</em><em>.</em> col. 9 ll. 43–47. The disclosure of a dose outside of the claimed range does not compel a finding that the asserted claims lack adequate written description. <em>See </em><a id="co_link_I9ed818b73f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2033982646&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1359&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1359"><em>Scriptpro, LLC v. Innovation Assocs., Inc.</em>, 762 F.3d 1355, 1359 (Fed. Cir. 2014)</a> (“It is common, and often permissible, for particular claims to pick out a subset of the full range of described features, omitting others.”).</div></div><div class="co_paragraph"><div class="co_paragraphText"> <span class="co_starPage" id="co_pp_sp_999_16"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;16&quot; }" alt="metadata" type="hidden">*16</span> The district court heard testimony that the data reported in the <a id="co_link_I9ee38a603f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> show a trend for higher QTc prolongation among genotypic CYP2D6 poor metabolizers given a 24 mg/day dose, and support a reduction in dose for CYP2D6 poor metabolizers by a factor of 1.5 to 3.5. West-Ward introduced some testimony challenging the sufficiency of the data and the lack of statistical analysis, but that does not render the court's reliance on testimony supporting validity impermissible. <em>See </em><a id="co_link_I1b5c9b2341b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1985114055&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Anderson</em>, 470 U.S. at 574–75, 105 S.Ct. 1504</a>. On this record, we cannot say that the district court clearly erred in finding that the <a id="co_link_I9ee38a633f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> sufficiently discloses the claimed range for poor metabolizers.</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F232044320422" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF23">23</a><a id="co_anchor_B232044320422"></a>Moreover, West-Ward waived its written description challenge with respect to non-poor metabolizers by failing to properly present it to the trial court. The Supreme Court has observed that as a “general rule ... a federal appellate court does not consider an issue not passed upon below.” <a id="co_link_I1b7f8c7241b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1976142445&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Singleton v. Wulff</em>, 428 U.S. 106, 120, 96 S.Ct. 2868, 49 L.Ed.2d 826 (1976)</a>. Although appellate courts have discretion to decide when to deviate from this general waiver rule, <em>see </em><a id="co_link_I1b7f8c7541b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1976142445&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>id.</em> at 121, 96 S.Ct. 2868</a>, West-Ward has not articulated a basis for us to reach this issue for the first time on appeal and we discern none, <em>see </em><a id="co_link_I9efdc9243f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2026945608&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1282&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1282"><em>HTC Corp. v. IPCom GmbH &amp; Co., KG</em>, 667 F.3d 1270, 1282–83 (Fed. Cir. 2012)</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">West-Ward points only to a single page in each of its opening and reply post-trial briefs to support its claim that this issue is not waived. Those pages make passing reference to the dosage range for non-poor metabolizers in the context of the written description arguments West-Ward advanced for poor metabolizers. <input id="co_docMarker_20" type="hidden">West-Ward does not point us to any argument or evidence that it advanced before the district court specifically with respect to non-poor metabolizers. Indeed, West-Ward did not identify lack of written description with respect to non-poor metabolizer dose range in its pretrial submissions identifying the issues to be tried. West-Ward has thus waived any further argument that the non-poor metabolizer dosage range was not adequately supported by the written description.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I7fa74250476f11e8a94cdbee4df18b01"><div class="co_headtext co_hAlign2">V. Injunctive Relief</div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F242044320422" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF24">24</a><a id="co_anchor_B242044320422"></a>We finally address the propriety of the injunctive relief awarded by the district court. West-Ward argues that the injunctions were not supported by the courts “general equitable power,” and the lack of jurisdiction or an infringing act under <a id="co_link_I9f0f2e403f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">35 U.S.C. § 271(e)(2)</a> precludes upholding the injunctions under <a id="co_link_I9f0f2e413f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_22700000861f0">35 U.S.C. § 271(e)(4)</a>. West-Ward contends that “the FDA has independently determined that litigation over the <a id="co_link_I9f0f2e423f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> should not delay approval of iloperidone ANDAs filed before the patent issued and was submitted to the agency.” Appellant Br. 62 (citing https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/207231Orig1s000ltr.pdf). West-Ward further argues that because Vanda did not cross-appeal the denial of an injunction under <a id="co_link_I9f0f2e433f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_22700000861f0">35 U.S.C. § 271(e)(4)</a> that provision cannot be an alternative ground to uphold the FDA injunction.</div></div><div class="co_paragraph"><div class="co_paragraphText">Vanda responds that the district court's injunctions can be affirmed under <a id="co_link_I9f1325e03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_22700000861f0">35 U.S.C. § 271(e)(4)</a> and that the court erred in not granting relief pursuant to that provision. In any event, Vanda contends that the district court did not err in granting injunctive relief pursuant to its equitable powers against West-Ward.</div></div><div class="co_paragraph"><div class="co_paragraphText">We agree with Vanda that <a id="co_link_I9f2638b03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_22700000861f0">35 U.S.C. § 271(e)(4)</a> supports the injunctive relief granted by the district court. As discussed above, the district court properly held that Vanda had established infringement of the <a id="co_link_I9f2638b13f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> under <a id="co_link_I9f2638b23f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">§ 271(e)(2)</a>. <a id="co_link_I9f2638b33f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_22700000861f0">Section 271(e)(4)</a> provides in relevant part:</div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText">For an act of infringement described in paragraph (2)—</div></div><div class="co_paragraph co_indentLeft2"><div class="co_paragraphText"> <span class="co_starPage" id="co_pp_sp_999_17"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;17&quot; }" alt="metadata" type="hidden">*17</span> (A) the court shall order the effective date of any approval of the drug or veterinary biological product involved in the infringement to be a date which is not earlier than the date of the expiration of the patent which has been infringed,</div></div><div class="co_paragraph co_indentLeft2"><div class="co_paragraphText">(B) injunctive relief may be granted against an infringer to prevent the commercial manufacture, use, offer to sell, or sale within the United States or importation into the United States of an approved drug, veterinary biological product, or biological product,</div></div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText">...</div></div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText">The remedies prescribed by subparagraphs (A), (B), (C), and (D) are the only remedies which may be granted by a court for an act of infringement described in paragraph (2), except that a court may award attorney fees under section 285.</div></div><div class="co_paragraphText co_flush"><a id="co_link_I9f502ee03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_22700000861f0">35 U.S.C. § 271(e)(4)</a>. <a id="co_link_I9f502ee13f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_22700000861f0">Section 271(e)(4)</a> contains no carve-out for patents that issue after the date of submission of the original ANDA. Moreover, the statute explicitly states that “the only remedies” a court may grant following an infringement finding under <a id="co_link_I9f502ee23f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">§ 271(e)(2)</a> are pursuant to <a id="co_link_I9f502ee33f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_f4aa000038542">§ 271(e)(4)(A)–(D)</a> and attorney fees pursuant to § 285. Accordingly, upon a finding of patent infringement under <a id="co_link_I9f502ee43f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">§ 271(e)(2)</a>, the district court must order remedies in accordance with <a id="co_link_I9f502ee53f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_22700000861f0">§ 271(e)(4)</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">West-Ward's reliance on the FDA's letter approving a different company's ANDA 20-7231 for iloperidone tablets is misplaced. The letter indicates that because the <a id="co_link_I9f8aedf03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> was “submitted to the [FDA] after submission of [that] ANDA,” litigation with respect to the <a id="co_link_I9f8aedf13f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent<input id="co_docMarker_21" type="hidden"></a> “would not create a statutory stay of approval.” https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/207231Orig1s000ltr.pdf. The FDA letter merely recognizes that the issuance of the <a id="co_link_I9f8aedf23f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> after submission of that ANDA renders the thirty-month statutory stay inapplicable. <em>See</em> <a id="co_link_I9f8aedf33f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=21USCAS355&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_83fb0000a4d76">21 U.S.C. § 355(j)(5)(B)(iii)</a> (providing that triggering of thirty-month stay requires, <em>inter alia</em>, that the NDA holder submit necessary “patent information <em>before the date on which the application (excluding an amendment or supplement to the application</em> ) ... was submitted” (emphasis added) ). It says nothing about whether the FDA would or would not change the effective approval date of the ANDA pursuant to a <a id="co_link_I9f8aedf43f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_f4aa000038542">35 U.S.C. § 271(e)(4)(A)</a> court order if the <a id="co_link_I9f8aedf53f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> were found valid and infringed. West-Ward's argument thus improperly conflates the requirements to obtain a thirty-month stay under <a id="co_link_I9f8aedf63f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=21USCAS355&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_83fb0000a4d76">§ 355(j)(5)(B)(iii)</a> with the relief available pursuant to <a id="co_link_I9f8aedf73f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_22700000861f0">§ 271(e)(4)</a> following a finding of patent infringement under <a id="co_link_I9f8aedf83f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">§ 271(e)(2)</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">In fact, where “the FDA has already approved the ANDA, the district court's [<a id="co_link_I9fb9ed3a3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_f4aa000038542">§ 271(e)(4)(A)</a> ] order would [only] alter the effective date of the application, thereby converting a final approval into a tentative approval.” <a id="co_link_I9fb9ed313f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2016791128&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1367&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1367"><em>In re Omeprazole Patent Litig.</em>, 536 F.3d 1361, 1367–68 (Fed. Cir. 2008)</a>; <em>see also </em><a id="co_link_I9fb9ed333f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2005558672&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1281&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1281"><em>Mylan Labs., Inc. v. Thompson</em>, 389 F.3d 1272, 1281–84 (D.C. Cir. 2004)</a> (affirming revocation of final FDA approval of an ANDA and resetting of the effective approval date following a judgment of patent infringement pursuant to the district court's <a id="co_link_I9fb9ed3b3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_f4aa000038542">§ 271(e)(4)(A)</a> order where the infringement suit was filed too late to trigger the 30-month stay). And the FDA is entitled not to set an approval date prior to the expiration of a patent that has been found to be infringed under <a id="co_link_I9fb9ed3c3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_f4aa000038542">§ 271(e)(4)(A)</a> and not invalid in a Hatch-Waxman case. The district court's authority to grant the remedies provided in <a id="co_link_I9fb9ed343f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_22700000861f0">35 U.S.C. § 271(e)(4)</a> following a judgment of patent infringement under <a id="co_link_I9fb9ed3d3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">§ 271(e)(2)</a> is not limited to those circumstances expressly listed in <a id="co_link_I9fb9ed353f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=21USCAS355&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_83fb0000a4d76">21 U.S.C. § 355(j)(5)(B)(iii)</a>. <em>See </em><a id="co_link_I9fb9ed373f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2015619459&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1366&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1366"><em>Ortho-McNeil Pharm., Inc. v. Mylan Labs., Inc.</em>, 520 F.3d 1358, 1366 (Fed. Cir. 2008)</a> (“The district court was correct to reset the effective date of an ANDA directly under <a id="co_link_I9fb9ed383f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C. § 271</a> without going through <a id="co_link_I9fb9ed393f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=21USCAS355&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">21 U.S.C. § 355</a>.”).</div></div><div class="co_paragraph"><div class="co_paragraphText"> <span class="co_starPage" id="co_pp_sp_999_18"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;18&quot; }" alt="metadata" type="hidden">*18</span> Because we sustain the district court's infringement finding under <a id="co_link_I9fcc3cb03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">§ 271(e)(2)</a>, we also affirm the court's grant of injunctive relief. Although the district court erred in concluding that the remedies pursuant to <a id="co_link_I9fcc3cb13f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_22700000861f0">§ 271(e)(4)</a> were unavailable, the court granted Vanda injunctive relief consistent with those remedies. We may thus affirm the district court's grant of injunctive relief pursuant to <a id="co_link_I9fcc3cb23f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_22700000861f0">§ 271(e)(4)</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F252044320422" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF25">25</a><a id="co_anchor_B252044320422"></a>Additionally, Vanda did not need to file a cross-appeal to allow us to affirm the district court's grant of injunctive relief with respect to the FDA. Without filing a cross-appeal, “an appellee may ‘urge in support of a decree any matter appearing in the record, although his argument may involve an attack upon the reasoning of the lower court,’ but may not ‘attack the decree with a view either to enlarging his own rights thereunder or of lessening the rights of his adversary.’ ” <a id="co_link_I1c6383d241b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1999113010&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>El Paso Nat. Gas Co. v. Neztsosie</em>, 526 U.S. 473, 479, 119 S.Ct. 1430, 143 L.Ed.2d 635 (1999)</a> (quoting <a id="co_link_I1c6383d641b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1924124102&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>United States v. Am. Ry. Exp. Co.</em>, 265 U.S. 425, 435, 44 S.Ct. 560, 68 L.Ed. 1087 (1924)</a> ); <em>see also </em><a id="co_link_I9fe51be53f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1984115864&amp;pubNum=0000350&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_350_844&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_844"><em>Radio Steel &amp; Mfg. Co. v. MTD Prods., Inc.</em>, 731 F.2d 840, 844 (Fed. Cir. 1984)<input id="co_docMarker_22" type="hidden"></a> (holding that “a party will not be permitted to argue before us an issue on which it has lost and on which it has not appealed, where the result of acceptance of its argument would be a reversal or modification of the judgment rather than an affirmance”).</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F262044320422" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF26">26</a><a id="co_anchor_B262044320422"></a>The district court expressly ordered relief that Vanda argues may be affirmed on the basis of <a id="co_link_I9ff08d923f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_22700000861f0">§ 271(e)(4)</a>. <em>See</em> J.A. 33. Thus, our affirmance does not enlarge Vanda's rights under the judgment or require its amendment. Indeed, Vanda could not have filed a cross-appeal in this case because “[a] party that is not adversely affected by a judgment lacks standing to [cross-appeal].” <a id="co_link_I9ff08d913f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2004656871&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1156&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1156"><em>TypeRight Keyboard Corp. v. Microsoft Corp.</em>, 374 F.3d 1151, 1156 (Fed. Cir. 2004)</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">We have considered West-Ward's remaining arguments but find them to be unpersuasive.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I7fbdd790476f11e8a94cdbee4df18b01"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">Conclusion</span></div><div class="co_paragraph"><div class="co_paragraphText">For the foregoing reasons, we affirm the district court's decision.</div></div><div class="co_paragraph"><div class="co_paragraphText"><strong>AFFIRMED</strong></div></div></div></div></div></div></div><div class="co_contentBlock co_briefItState co_opinionBlock"><h2 id="co_dissent_opinion"></h2><div class="co_docDelivery_dottedLine"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/co_docDelivery_dottedLine.png" alt=""></div><div class="co_contentBlock x_opinionBlockBody"><div class="co_contentBlock x_opinionDissent"><div class="co_contentBlock x_dissentAuthorLineBlock"><div class="co_contentBlock x_dissentAuthorLine"><span class="co_smallCaps"><a id="co_link_I406ad6b03f4f11e8b6a4b140d77433d6" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0324402101&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Prost</a></span>, <em>Chief Judge</em>, dissenting.</div></div><div class="co_contentBlock x_opinionBody"><div class="co_contentBlock co_briefItState co_section" id="co_anchor_I7fbe73d0476f11e8a94cdbee4df18b01"><div class="co_paragraph"><div class="co_paragraphText">I would find the asserted patent claims to be directed to a law of nature. The majority finds the claims herein are not directed to a natural law at step one of the <a id="co_link_Ia004b1e83f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a> analysis, but its efforts to distinguish <a id="co_link_Ia004b1d13f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a> cannot withstand scrutiny. The majority relies on the claims' recitation of specific applications of the discovery underpinning the patent to find no natural law is claimed. But it conflates the inquiry at step one with the search for an inventive concept at step two. Once the natural law claimed in the <a id="co_link_Ia004b1db3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> is understood in a manner consistent with <a id="co_link_Ia004b1dd3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a>, what remains fails to supply the requisite inventive concept to transform the natural law into patent-eligible subject matter. Although I agree with the majority's reasoning that the district court had jurisdiction under the Hatch-Waxman Act, I would not reach the issues of written description, infringement, and injunctive relief because I would find the <a id="co_link_Ia004b1e73f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> claims ineligible subject matter. Accordingly, I respectfully dissent.</div></div><div class="co_paragraph"><div class="co_paragraphText">In order “to transform an unpatentable law of nature into a patent-eligible application of such a law, a patent must do more than simply state the law of nature while adding the words ‘apply it.’ ” <a id="co_link_I1c9653a241b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo Collaborative Servs. v. Prometheus Labs., Inc.</em>, 566 U.S. 66, 72, 132 S.Ct. 1289, 182 L.Ed.2d 321 (2012)</a>. While the claims here do not solely state a law of nature, they do no more than simply direct the relevant audience to apply it.</div></div><div class="co_paragraph"><div class="co_paragraphText"> <span class="co_starPage" id="co_pp_sp_999_19"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;19&quot; }" alt="metadata" type="hidden">*19</span> The <a id="co_link_I4083b5e03f4f11e8b6a4b140d77433d6" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> itself identifies its invention as “compris[ing] the discovery that treatment of a patient, who has lower CYP2D6 activity than a normal person, with a drug that is pre-disposed to cause QT prolongation and is metabolized by the CYP2D6 enzyme, can be accomplish[ed] more safely by administering a lower dose of the drug than would be administered to a person who has normal CYP2D6 enzyme activity.” <a id="co_link_Ia00fd5613f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> col. 2 ll. 15–21. Nevertheless, the majority concludes that the claims here are not directed to ineligible subject matter at step one of the <a id="co_link_I368fb3c0440611e8bca58a29e807ded0" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a>/<a id="co_link_I4c18daf0440611e88bc3c0b3ed894d23" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2033619398&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Alice</em></a> inquiry. Majority Op. at 28. I disagree.</div></div><div class="co_paragraph"><div class="co_paragraphText">The representative claim in <a id="co_link_Ia0110de13f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a>, i.e., Claim 1, recited:</div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText">A method of optimizing therapeutic efficacy for treatment of an immune-mediated <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Icac9cfe6475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Icac9cfe6475411db9765f9243f53508a">gastrointestinal disorder</a>, comprising:</div></div><div class="co_paragraph co_indentLeft2"><div class="co_paragraphText">(a) administering a drug providing 6-thioguanine to a subject having said immune-mediated <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Icac9cfe6475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Icac9cfe6475411db9765f9243f53508a_0">gastrointestinal disorder</a>; and</div></div><div class="co_paragraph co_indentLeft2"><div class="co_paragraphText">(b) determining the level of 6-thioguanine in said subject having said immune-mediated <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Icac9cfe6475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Icac9cfe6475411db9765f9243f53508a_1">gastrointestinal disorder</a>,</div></div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText">wherein the level of 6-thioguanine less than about 230 pmol per 8x10<sup>8</sup> red blood cells indicates a need to increase the amount of said drug subsequently administered to said subject and<input id="co_docMarker_23" type="hidden"></div></div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText">wherein the level of 6-thioguanine greater than about 400 pmol per 8x10<sup>8</sup> red blood cells indicates a need to decrease the amount of said drug subsequently administered to said subject.</div></div><div class="co_paragraphText co_flush"><a id="co_link_I1cb155b241b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em>, 566 U.S. at 74–75, 132 S.Ct. 1289</a> (quoting <a id="co_link_Ia0209e453f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2002176446&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I175c6f3071fc11d7ab54daa4035d65fa&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">U.S. Patent No. 6,355,623</a> col. 20 ll. 10–20).</div></div><div class="co_paragraph"><div class="co_paragraphText">The Court stated that the patent in <a id="co_link_Ia02c85213f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a> “set forth laws of nature—namely, relationships between concentrations of certain metabolites in the blood and the likelihood that a dosage of a thiopurine drug will prove ineffective or cause harm.” <a id="co_link_I1cccccfe41b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 77, 132 S.Ct. 1289</a>. As one example of the laws of nature set forth in the patent, the Court pointed to Claim 1's statement “that <em>if</em> the levels of 6-TG in the blood (of a patient who has taken a dose of a thiopurine drug) exceed about 400 pmol per 8x10<sup>8</sup> red blood cells, <em>then</em> the administered dose is likely to produce toxic side effects.” <a id="co_link_Ia02c852c3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id</em>.</a> Thus, the law of nature identified by the Supreme Court in <a id="co_link_Ia02c852e3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a> encompassed not only the bare fact of the relationship between thiopurine metabolite concentrations and efficacy or side effects of a thiopurine drug, but also the precise levels of concentration in question. <em>See </em><a id="co_link_I1ccccd0e41b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>id.</em> at 74, 132 S.Ct. 1289</a> (“But those in the field did not know the precise correlations between metabolite levels and likely harm or ineffectiveness. The patent claims at issue here set forth processes embodying researchers' findings that identified these correlations with some precision.”).</div></div><div class="co_paragraph"><div class="co_paragraphText">In the present case, Claim 1 of the <a id="co_link_Ia02e0bc03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> reads as follows:</div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText">A method for treating a patient with iloperidone, wherein the patient is suffering from <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Ic8ad584c475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ic8ad584c475411db9765f9243f53508a_8">schizophrenia</a>, the method comprising the steps of:</div></div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText">determining whether the patient is a CYP2D6 poor metabolizer by:</div></div><div class="co_paragraph co_indentLeft2"><div class="co_paragraphText">obtaining or having obtained a biological sample from the patient;</div></div><div class="co_paragraph co_indentLeft2"><div class="co_paragraphText">and</div></div><div class="co_paragraph co_indentLeft2"><div class="co_paragraphText">performing or having performed a <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=mproc&amp;entityId=Ib3510dc6475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ib3510dc6475411db9765f9243f53508a_6">genotyping</a> assay on the biological sample to determine if the patient has a CYP2D6 poor metabolizer genotype; and</div></div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText">if the patient has a CYP2D6 poor metabolizer genotype, then internally administering iloperidone to the patient in an amount of 12 mg/day or less, and</div></div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText">if the patient does not have a CYP2D6 poor metabolizer genotype, then internally administering iloperidone to the patient in an amount that is greater than 12 mg/day, up to 24 mg/day,</div></div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText">wherein a risk of QTc prolongation for a patient having a CYP2D6 poor metabolizer genotype is lower following the internal administration of 12 mg/day or less than it would be if the iloperidone were administered in an amount of greater than 12 mg/day, up to 24 mg/day.</div></div><div class="co_paragraphText co_flush"> <span class="co_starPage" id="co_pp_sp_999_20"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;20&quot; }" alt="metadata" type="hidden">*20</span> <a id="co_link_Ia03426403f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> col. 17 ll. 2–25.</div></div><div class="co_paragraph"><div class="co_paragraphText">This claim, which is representative of the <a id="co_link_Ia03ba0503f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a>, also sets forth a natural relationship—namely, the relationship between the CYP2D6 genotype and the likelihood that a dosage of iloperidone will cause QTc prolongation. The majority notes that the claims in <a id="co_link_Ia03ba0523f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a> were directed to the relationships that comprised the natural law, and not “to a novel method of treating a disease.” Majority Op. at 29. Here, according to the majority, while the inventors <em>recognized</em> a natural law, “that is not what they claimed.” <em>Id.</em> at 30. Rather, the claims of the <a id="co_link_Ia03ba05d3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> require a treating doctor to administer iloperidone in “specific dosages” based on the results of a genotyping assay. <em>Id.</em> But reciting specific metes and bounds in the claims did not prevent the Supreme Court from concluding those claims set forth a natural law in <a id="co_link_Ia03ba0603f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a>. We are not free to depart from the Supreme Court's holding.</div></div><div class="co_paragraph"><div class="co_paragraphText">As the majority notes, the <a id="co_link_Ia043b6a03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> claims a method of treating <input id="co_docMarker_24" type="hidden"><a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Ic8ad584c475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ic8ad584c475411db9765f9243f53508a_9">schizophrenia</a> with iloperidone “that is safer for patients because it reduces the risk of QTc prolongation.” Majority Op. at 30. This is no more than an optimization of an existing treatment of <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Ic8ad584c475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ic8ad584c475411db9765f9243f53508a_10">schizophrenia</a>, just as the claims in <a id="co_link_Ia043b6a23f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a> concerned “optimizing therapeutic efficacy” of thiopurine drugs. <a id="co_link_Ia043b6ad3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a> warned against “drafting effort[s] designed to monopolize the law of nature itself.” <a id="co_link_I1cf2cb9d41b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">566 U.S. at 77, 132 S.Ct. 1289</a>. The majority does not heed that warning.</div></div><div class="co_paragraph"><div class="co_paragraphText">The Court in <a id="co_link_Ia04cde613f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a> found that the claim limitation concerning “administering” a thiopurine drug to a patient “simply refer[red] to the relevant audience, namely doctors who treat patients with certain diseases with thiopurine drugs”—an audience that existed long before the patent disclosure. <a id="co_link_I1d02f82e41b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 78, 132 S.Ct. 1289</a>. So too here. The audience of physicians treating <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Ic8ad584c475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ic8ad584c475411db9765f9243f53508a_11">schizophrenia</a> with iloperidone long predated the <a id="co_link_Ia04cde6c3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a>. The patent simply discloses the natural law that a known side effect of the existing treatment could be reduced by administering a lower dose to CYP2D6 poor-metabolizers. It claims no more than instructions directing that audience to apply the natural law in a routine and conventional manner.</div></div><div class="co_paragraph"><div class="co_paragraphText">The majority fails to reconcile this substantive similarity between our case and <a id="co_link_Ia0531ff13f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a>. Instead, it points to the specific dosages as a distinction between the administering step here and that in <a id="co_link_Ia0531ffc3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a>. But <a id="co_link_Ia05320073f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a> examined the significance of the “administering” step in its search for an inventive concept, <em>not</em> as part of the determination whether the claims were directed to a natural law at the threshold. And the specific dosage adds nothing inventive to the claims beyond the natural law.</div></div><div class="co_paragraph"><div class="co_paragraphText"> <span class="co_starPage" id="co_pp_sp_999_21"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;21&quot; }" alt="metadata" type="hidden">*21</span> Nor does the other element of specificity identified by the majority rescue the claims. The claims here specify a means of identifying a patient's genotype (a “genetic assay”), while the claims in <a id="co_link_Ia062fe713f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a> left open the means of measuring the relevant metabolite. But the genetic assay is purely conventional pre-solution activity that cannot be used to circumvent eligibility under <a id="co_link_Ia062fe7d3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a>. <em>See </em><a id="co_link_I1d1a9edf41b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em>, 566 U.S. at 79, 132 S.Ct. 1289</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">The majority notes the claims here <em>require</em> treatment with iloperidone within the dosage range indicated, while the claims in <a id="co_link_Ia06c4d413f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a> could be infringed by treatment with thiopurine “<em>whether that treatment does, or does not, change in light of the inference</em>” indicated by the natural law. <a id="co_link_I1d2f384f41b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em>, 566 U.S. at 86, 132 S.Ct. 1289</a> (emphasis added); <em>see</em> Majority Op. at 30–31. But that inquiry in <a id="co_link_Ia06c4d4e3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a> also came as part of the search for an inventive concept, and requiring a dosage instead of indicating a dosage is not sufficient at step two. The difference is of no moment.</div></div><div class="co_paragraph"><div class="co_paragraphText">The majority points to the Supreme Court's statement in <a id="co_link_Ia07bdda13f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a> that “[u]nlike, say, a typical patent on a new drug or a new way of using an existing drug, the patent claims do not confine their reach to particular applications of those laws.” Majority Op. at 29–30 (quoting <a id="co_link_I1d4fb89f41b511e8bc86b6a21dce84ca" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em>, 566 U.S. at 87, 132 S.Ct. 1289</a>). It similarly points to our decision in <a id="co_link_Ia07bddaf3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039315377&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Rapid Litigation Management Ltd. v. CellzDirect, Inc.</em></a>, wherein we indicated that “the natural ability of the subject matter to <em>undergo</em> the process does not make the claim ‘directed to’ that natural ability,” lest we find ineligible methods of “treating <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a_0">cancer</a> with chemotherapy (as directed to <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a_1">cancer</a> cells' inability to survive chemotherapy), or treating headaches with <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3af17fb7475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3af17fb7475111db9765f9243f53508a_0">aspirin</a> (as directed to the human body's natural response to <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3af17fb7475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3af17fb7475111db9765f9243f53508a_1">aspirin</a>).” <a id="co_link_Ia07bddb13f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039315377&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1049&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1049">827 F.3d 1042, 1049 (Fed. Cir. 2016)</a>. But that is not this case.<input id="co_docMarker_25" type="hidden"></div></div><div class="co_paragraph"><div class="co_paragraphText">Whatever weight can be ascribed to the foregoing statements about methods of treatment, we remain beholden to the holding of <a id="co_link_Ia08071813f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a>, which, in my view, requires us to find the claims directed to a natural law at step one. (And I find no inventive concept in the claims once the natural law at issue is properly understood in view of <a id="co_link_Ia080718c3f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a>.)<sup id="co_footnoteReference_B00102044320422_ID0EIZDK"><a href="#co_footnote_B00102044320422" class="co_footnoteReference">1</a></sup></div></div><div class="co_paragraph"><div class="co_paragraphText">My conclusion is not at odds with <a id="co_link_Ia089e7623f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039315377&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>CellzDirect</em></a>. There, the alleged law of nature was the capability of hepatocyte cells to survive multiple freeze-thaw cycles. Because the “end result” of the claims therein was “not simply an observation or detection of the ability of hepatocytes to survive multiple freeze-thaw cycles” but rather “a new and useful method of preserving hepatocyte cells,” we held the claims were not directed to a law of nature. <a id="co_link_Ia089e7633f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039315377&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1049&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1049"><em>Id.</em> at 1049</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">Here, the end result of the claimed process is no more than the conclusion of a natural law. The fact that a reduction of iloperidone dosage in poor metabolizers to the may reduce QTc prolongation is both the means and the ends of this claim. The recitation of the specific dosages adds no more than a conventional application of that natural law. I see no distinction from <a id="co_link_Ia08d90e13f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000780&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a>, so I would hold the asserted claims directed to ineligible subject matter and lacking an inventive concept sufficient to transform it into patent-eligible subject matter. I respectfully dissent.</div></div></div></div></div></div></div><div class="co_parallelCites"><h2 id="co_allCitations" class="co_parallelCitesBlockLabel co_printHeading">All Citations</h2>--- F.3d ----, 2018 WL 1770273</div><div id="co_footnoteSection" class="co_footnoteSection co_briefItState"><h2 class="co_footnoteSectionTitle co_printHeading">Footnotes</h2><div><div class="co_footnoteNumber"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;1&quot; }" alt="metadata" type="hidden"><span id="co_footnote_B00012044320422"><a href="#co_footnoteReference_B00012044320422_ID0E22BG">1</a></span></div><div class="co_footnoteBody"><div class="co_paragraph"><div class="co_paragraphText">The parties have not appealed any determinations with respect to the <a id="co_link_I99cf2fc03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2009579817&amp;pubNum=0004073&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'198 patent</a>. The parties stipulated to the infringement of claim 3 of the <a id="co_link_I99cf2fc13f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2009579817&amp;pubNum=0004073&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'198 patent</a> and the court concluded that claim 3 would not have been obvious.</div></div></div></div><div><div class="co_footnoteNumber"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;1&quot; }" alt="metadata" type="hidden"><span id="co_footnote_B00022044320422"><a href="#co_footnoteReference_B00022044320422_ID0EE6BG">2</a></span></div><div class="co_footnoteBody"><div class="co_paragraph"><div class="co_paragraphText">The QT interval is the time between the Q and T waves of the heart rhythm. When corrected for the patient's heart rate it is abbreviated QTc.</div></div></div></div><div><div class="co_footnoteNumber"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;2&quot; }" alt="metadata" type="hidden"><span id="co_footnote_B00032044320422"><a href="#co_footnoteReference_B00032044320422_ID0EMHAI">3</a></span></div><div class="co_footnoteBody"><div class="co_paragraph"><div class="co_paragraphText">During the pendency of this appeal, ownership of ANDA 20-5480 transferred from Roxane Laboratories Inc. to West-Ward. For simplicity, we refer to the ANDA applicant throughout as West-Ward.</div></div></div></div><div><div class="co_footnoteNumber"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;3&quot; }" alt="metadata" type="hidden"><span id="co_footnote_B00042044320422"><a href="#co_footnoteReference_B00042044320422_ID0ETZAI">4</a></span></div><div class="co_footnoteBody"><div class="co_paragraph"><div class="co_paragraphText">The court specifically stated that Vanda was “not entitled to relief pursuant to <a id="co_link_I9ad26ef03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_f4aa000038542">35 U.S.C. § 271(e)(4)(A)</a> for the <a id="co_link_I9ad26ef13f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610</a> [p]atent because the <a id="co_link_I9ad26ef23f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610</a> [p]atent did not issue until after the effective date of any FDA approval of [West-Ward's] ANDA....” <a id="co_link_I9ad26ef43f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2039653953&amp;pubNum=0007903&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_7903_435&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_7903_435"><em>Opinion</em>, 203 F.Supp.3d at 435</a>. But the parties have treated the district court's reference to “the effective date of any FDA approval” as a typographical error, and the district court's rationale as being based on the <a id="co_link_I9ad26ef53f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2032082448&amp;pubNum=0004074&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=PA&amp;docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">'610 patent</a> not having issued until after the filing date of the ANDA. <em>See</em> Appellant Br. 28; Appellee Br. 60 &amp; n.6. We do the same.</div></div></div></div><div><div class="co_footnoteNumber"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;5&quot; }" alt="metadata" type="hidden"><span id="co_footnote_B00052044320422"><a href="#co_footnoteReference_B00052044320422_ID0EKVBI">5</a></span></div><div class="co_footnoteBody"><div class="co_paragraph"><div class="co_paragraphText">Because we determine that <a id="co_link_I9b6909a03f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=28USCAS1338&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_8b3b0000958a4">28 U.S.C. § 1338(a)</a> provides a proper basis for jurisdiction, we do not reach the parties' declaratory judgment jurisdiction arguments.</div></div></div></div><div><div class="co_footnoteNumber"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;6&quot; }" alt="metadata" type="hidden"><span id="co_footnote_B00062044320422"><a href="#co_footnoteReference_B00062044320422_ID0E3MCI">6</a></span></div><div class="co_footnoteBody"><div class="co_paragraph"><div class="co_paragraphText">We note that West-Ward did not argue to the district court at the pleadings stage that the complaint should be dismissed for failure to state a claim upon which relief could be granted on this basis. <em>Cf. </em><a id="co_link_I9c15c4613f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027068440&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1381&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1381"><em>AstraZeneca II</em>, 669 F.3d at 1381</a> (concluding that “the district court erred in part by concluding that [patentee's] failure to state a cognizable <a id="co_link_I9c15c4623f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">§ 271(e)(2)</a> claim defeated its jurisdiction” and affirming the dismissal for “fail[ure] to state a <a id="co_link_I9c15c4633f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS271&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=SP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_1184000067914">§ 271(e)(2)</a> claim” where applicant moved to dismiss both for lack of jurisdiction and failure to state a claim).</div></div></div></div><div><div class="co_footnoteNumber"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;7&quot; }" alt="metadata" type="hidden"><span id="co_footnote_B00072044320422"><a href="#co_footnoteReference_B00072044320422_ID0ES5CI">7</a></span></div><div class="co_footnoteBody"><div class="co_paragraph"><div class="co_paragraphText">Because we conclude that the district court did not clearly err in finding induced infringement, we need not and do not reach Vanda's arguments in the alternative on contributory infringement.</div></div></div></div><div><div class="co_footnoteNumber"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;10&quot; }" alt="metadata" type="hidden"><span id="co_footnote_B00082044320422"><a href="#co_footnoteReference_B00082044320422_ID0EMUDI">8</a></span></div><div class="co_footnoteBody"><div class="co_paragraph"><div class="co_paragraphText">Because we affirm the district court's infringement findings with respect to these independent claims, we need not reach this issue regarding the dependent claims because any error in the district court's analysis of the dependent claims is harmless. <input id="co_docMarker_26" type="hidden"><em>See </em><a id="co_link_I9d34f0013f3c11e8a52cd6d03b429fd5" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2014959885&amp;pubNum=0000506&amp;originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;refType=RP&amp;fi=co_pp_sp_506_1312&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1312"><em>TiVo, Inc. v. EchoStar Commc'ns Corp.</em>, 516 F.3d 1290, 1312 (Fed. Cir. 2008)</a> (affirming infringement finding as to some but not all claims and explaining that “[b]ecause the damages calculation at trial was not predicated on the infringement of particular claims, and because we have upheld the jury's verdict that all of the accused devices infringe the software claims, we affirm the damages award entered by the district court”).</div></div></div></div><div><div class="co_footnoteNumber"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;13&quot; }" alt="metadata" type="hidden"><span id="co_footnote_B00092044320422"><a href="#co_footnoteReference_B00092044320422_ID0ECWAK">9</a></span></div><div class="co_footnoteBody"><div class="co_paragraph"><div class="co_paragraphText">For purposes of validity, the parties did not argue the claims separately, so they rise or fall together.</div></div></div></div><div><div class="co_footnoteNumber"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S7c72dc103f3c11e88fe6cda34d31207a&quot;, &quot;pageNumber&quot;: &quot;21&quot; }" alt="metadata" type="hidden"><span id="co_footnote_B00102044320422"><a href="#co_footnoteReference_B00102044320422_ID0EIZDK">1</a></span></div><div class="co_footnoteBody"><div class="co_paragraph"><div class="co_paragraphText">Indeed, the unpredictable results of clinical testing regarding the relationship among CYP2D6, iloperidone, and QTc prolongation formed the basis of the district court's finding of non-obviousness. <em>See</em> J.A. 13–15. In particular, the district court pointed to West-Ward's evidence that “it was unpredictable whether any dosage adjustment would be needed for CYP2D6 poor metabolizers, much less the amount of adjustment needed to achieve the pharmacokinetic profile seen in normal metabolizers.” J.A. 14. That is, the district court found non-obviousness based on the revelation of the natural law underpinning the claims, not in any other aspect of the claims.</div></div></div></div></div><table id="co_endOfDocument"><tbody><tr><td>End of Document</td><td class="co_endOfDocCopyright">© 2018 Thomson Reuters. No claim to original U.S. Government Works.</td></tr></tbody></table></div><input class="co_chunkNumber" value="0" type="hidden"><input id="co_finalChunkMarker" type="hidden"></div><input id="co_document_metaInfo_I7b55ac403f3c11e8a70fc9d8a0b2aef5" value="{&quot;FirstLineCite&quot;:null,&quot;PU&quot;:null,&quot;accessControl&quot;:null,&quot;accessionNumber&quot;:&quot;&quot;,&quot;acquirerCompany&quot;:null,&quot;activeDate&quot;:null,&quot;additionalLinks&quot;:null,&quot;agreementDisplayDate&quot;:null,&quot;announcementDate&quot;:null,&quot;articleTitle&quot;:null,&quot;borrower&quot;:null,&quot;caseRequired&quot;:null,&quot;ciCompany&quot;:null,&quot;cicOfficer&quot;:null,&quot;cipOfficer&quot;:null,&quot;cite&quot;:&quot;--- F.3d ----&quot;,&quot;citeAbbreviation&quot;:null,&quot;citePrimary&quot;:null,&quot;city&quot;:null,&quot;collection&quot;:&quot;w_cs_fed1&quot;,&quot;compoundTitle&quot;:null,&quot;containerId&quot;:null,&quot;containerType&quot;:null,&quot;contentType&quot;:&quot;Cases&quot;,&quot;contentTypeId&quot;:&quot;1&quot;,&quot;correlationIds&quot;:null,&quot;country&quot;:null,&quot;countryDocumentCountry&quot;:null,&quot;countryDocumentGuid&quot;:null,&quot;court&quot;:&quot;C.A.Fed. (Del.)&quot;,&quot;courtDocumentType&quot;:null,&quot;courtNumber&quot;:&quot;4217&quot;,&quot;courtYear&quot;:&quot;C.A.Fed. (Del.), 2018&quot;,&quot;date&quot;:&quot;April 13, 2018&quot;,&quot;dateFile&quot;:&quot;April 13, 2018&quot;,&quot;dealDate&quot;:null,&quot;dealTrackPublishDate&quot;:null,&quot;dealType&quot;:null,&quot;dealValue&quot;:null,&quot;description&quot;:null,&quot;docFamilyGuid&quot;:&quot;I7c5234b03f3c11e88fe6cda34d31207a&quot;,&quot;docGuid&quot;:&quot;I7b55ac403f3c11e8a70fc9d8a0b2aef5&quot;,&quot;docLink&quot;:&quot;https://1.next.westlaw.com/Document/I7b55ac403f3c11e8a70fc9d8a0b2aef5/View/FullText.html?originationContext=document&amp;contextData=(sc.CustomDigest)&amp;needToInjectTerms=False&quot;,&quot;documentTitle&quot;:null,&quot;edgarFileNumber&quot;:null,&quot;entityId&quot;:null,&quot;expertType&quot;:null,&quot;fileName&quot;:null,&quot;fileNumber&quot;:&quot;&quot;,&quot;fileSize&quot;:0,&quot;fileType&quot;:null,&quot;filerCik&quot;:null,&quot;filerName&quot;:null,&quot;filingDate&quot;:null,&quot;filingYear&quot;:null,&quot;firmName&quot;:null,&quot;formNumber&quot;:null,&quot;formSubType&quot;:null,&quot;formType&quot;:null,&quot;formTypeDisplay&quot;:null,&quot;formVolume&quot;:null,&quot;functionalCite&quot;:&quot;2018 WL 1770273&quot;,&quot;fundFirmCompoundTitle&quot;:null,&quot;fundLocation&quot;:null,&quot;fundName&quot;:null,&quot;fundTargetSize&quot;:null,&quot;fundType&quot;:null,&quot;fundYear&quot;:null,&quot;fundraisingStatus&quot;:null,&quot;getTocData&quot;:false,&quot;hasDraftingNotes&quot;:null,&quot;hasVideoContent&quot;:null,&quot;impersonationKey&quot;:null,&quot;inlineKeyCiteFlagsIncluded&quot;:false,&quot;inlineKeyCiteFlagsResolutionStatus&quot;:null,&quot;insiderName&quot;:null,&quot;ip_assignmentsAction&quot;:null,&quot;ip_citeParallel&quot;:null,&quot;ip_derwentPublishedDate&quot;:null,&quot;ip_docket&quot;:null,&quot;ip_documentDate&quot;:&quot;April 13, 2018&quot;,&quot;ip_issuedDate&quot;:null,&quot;ip_litAlertAttorney&quot;:null,&quot;ip_patStatCode&quot;:null,&quot;ip_patentOwner&quot;:null,&quot;ip_publishedDate&quot;:null,&quot;ip_shortTitle&quot;:null,&quot;isDisplayMiniReport&quot;:false,&quot;isGatewayDocument&quot;:false,&quot;isLargeDocument&quot;:false,&quot;isPersistedContent&quot;:false,&quot;isPublicRecordsBlockedByPermissibleUse&quot;:false,&quot;isPublicRecordsBlockedBySocialSecurityAdmin&quot;:false,&quot;isPublicRecordsDocument&quot;:false,&quot;isRefsAndAnnos&quot;:false,&quot;isRegChangeDocument&quot;:false,&quot;isSearchable&quot;:null,&quot;isSecureContent&quot;:false,&quot;issueDate&quot;:null,&quot;issuerName&quot;:null,&quot;jobDescription&quot;:null,&quot;judge&quot;:&quot;Lourie, Circuit Judge.&quot;,&quot;jurisAbbrev&quot;:null,&quot;jurisdiction&quot;:&quot;DE&quot;,&quot;jurisdictionFacet&quot;:&quot;Federal|**|Cts. of Appeals|**|Federal Cir.&quot;,&quot;jurisdictionText&quot;:&quot;Delaware&quot;,&quot;knos&quot;:null,&quot;lastRoundExitComb&quot;:null,&quot;legacyId&quot;:&quot;2044320422&quot;,&quot;letterType&quot;:null,&quot;locationOfIncorporation&quot;:null,&quot;maxOfferingPrice&quot;:null,&quot;natureOfTransaction&quot;:null,&quot;newsImageHrefLarge&quot;:null,&quot;newsImageHrefSmall&quot;:null,&quot;normalizedDocType&quot;:null,&quot;normalizedFormType&quot;:null,&quot;offeringType&quot;:null,&quot;organizationName&quot;:null,&quot;originatingDoc&quot;:null,&quot;pageCount&quot;:null,&quot;persistedDocGuid&quot;:null,&quot;plcFirmStyleAvailable&quot;:false,&quot;plcResourceName&quot;:&quot;&quot;,&quot;portfolioCompanyLocation&quot;:null,&quot;portfolioCompanyName&quot;:null,&quot;prMetaInfo1&quot;:null,&quot;prMetaInfo2&quot;:null,&quot;prMetaInfo3&quot;:null,&quot;prMetaInfo4&quot;:null,&quot;prMetaInfo5&quot;:null,&quot;primaryEditorialService&quot;:null,&quot;profileType&quot;:null,&quot;pubSeries&quot;:null,&quot;publishDate&quot;:null,&quot;questionText&quot;:null,&quot;redlined&quot;:false,&quot;registrationDate&quot;:null,&quot;renditionId&quot;:null,&quot;royaltyId&quot;:&quot;0&quot;,&quot;rulebookNViews&quot;:null,&quot;serialNumber&quot;:&quot;2044320422&quot;,&quot;status&quot;:null,&quot;subContentType&quot;:&quot;Caselaw - NRS&quot;,&quot;subContentTypeId&quot;:&quot;27&quot;,&quot;subTitle&quot;:null,&quot;targetCompany&quot;:null,&quot;testimonyType&quot;:null,&quot;titleHtml&quot;:&quot;Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals International Limited&quot;,&quot;titleText&quot;:&quot;Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals International Limited&quot;,&quot;totalAmountIssuedWithCurrency&quot;:null,&quot;totalPages&quot;:&quot;&quot;,&quot;trademarkStatus&quot;:null,&quot;transactionAmountWithCurrency&quot;:null,&quot;transactionValue&quot;:null,&quot;valuationComb&quot;:null,&quot;viewExpressions&quot;:&quot;DE|FED|FDL|000&quot;,&quot;westlawDatabaseIdentifier&quot;:&quot;CQFEDS&quot;,&quot;westlawDocumentNumber&quot;:&quot;&quot;}" type="hidden"><input id="co_document_documentNavigation_Search_Search-v1-results-navigation-i0ad604ab000001630667802a2028f1f7-Nav-CUSTOMDIGEST-fragmentIdentifier-I7b55ac403f3c11e8a70fc9d8a0b2aef5-startIndex-1-contextData--28sc.CustomDigest-29-transitionType-CustomDigestItem_CUSTOMDIGEST_138" value="{&quot;AnswerSnippetId&quot;:null,&quot;CurrentDocumentGuid&quot;:&quot;I7b55ac403f3c11e8a70fc9d8a0b2aef5&quot;,&quot;CurrentPosition&quot;:138,&quot;CurrentWatsonAnswerText&quot;:null,&quot;EnableConceptCounts&quot;:false,&quot;HighlightPoints&quot;:null,&quot;HighlightTerms&quot;:null,&quot;InPlanUrl&quot;:null,&quot;IsSnapSnippet&quot;:false,&quot;ListCount&quot;:1157,&quot;Message&quot;:null,&quot;NextDocument&quot;:{&quot;SkipLinkOutDoc&quot;:false,&quot;Title&quot;:&quot;Berkheimer v. HP Inc.&quot;,&quot;Url&quot;:&quot;/Document/Ib73698c00d3011e8818da80a62699cb5/View/FullText.html?navigationPath=Search%2Fv1%2Fresults%2Fnavigation%2Fi0ad604ab000001630667802a2028f1f7%3FNav%3DCUSTOMDIGEST%26fragmentIdentifier%3DIb73698c00d3011e8818da80a62699cb5%26startIndex%3D1%26contextData%3D%2528sc.CustomDigest%2529%26transitionType%3DCustomDigestItem&amp;listSource=Search&amp;list=CUSTOMDIGEST&amp;rank=139&amp;grading=na&amp;sessionScopeId=7f37bc759ec9f9864b92cef6ac1b964c4cf54544f9347b0fcb95acf38263c8f1&amp;originationContext=Custom%20Digest&amp;transitionType=CustomDigestItem&amp;contextData=%28sc.CustomDigest%29&amp;listPageSource=edc4a850c828227f4c8d5f819b26133f#co_anchor_F92043776259&quot;},&quot;NovusQueryType&quot;:null,&quot;NovusSearchResult&quot;:null,&quot;NumberOfSnips&quot;:0,&quot;ParagraphId&quot;:null,&quot;PreviousDocument&quot;:{&quot;SkipLinkOutDoc&quot;:false,&quot;Title&quot;:&quot;Voter Verified, Inc. v. Election Systems &amp; Software LLC&quot;,&quot;Url&quot;:&quot;/Document/Ide1c6e0044b311e89d46ed79fb792237/View/FullText.html?navigationPath=Search%2Fv1%2Fresults%2Fnavigation%2Fi0ad604ab000001630667802a2028f1f7%3FNav%3DCUSTOMDIGEST%26fragmentIdentifier%3DIde1c6e0044b311e89d46ed79fb792237%26startIndex%3D1%26contextData%3D%2528sc.CustomDigest%2529%26transitionType%3DCustomDigestItem&amp;listSource=Search&amp;list=CUSTOMDIGEST&amp;rank=137&amp;grading=na&amp;sessionScopeId=7f37bc759ec9f9864b92cef6ac1b964c4cf54544f9347b0fcb95acf38263c8f1&amp;originationContext=Custom%20Digest&amp;transitionType=CustomDigestItem&amp;contextData=%28sc.CustomDigest%29&amp;listPageSource=edc4a850c828227f4c8d5f819b26133f#co_anchor_F132044364596&quot;},&quot;ReturnTo&quot;:{&quot;SkipLinkOutDoc&quot;:false,&quot;Title&quot;:&quot;list&quot;,&quot;Url&quot;:&quot;/Search/Results.html?jurisdiction=CTAF&amp;saveJuris=False&amp;contentType=CUSTOMDIGEST&amp;querySubmissionGuid=i0ad604ab000001630667802a2028f1f7&amp;startIndex=1&amp;tocGuid=I4aee2539c6f64c1812a4c2f3395c2607&amp;categoryPageUrl=Home%2FWestKeyNumberSystem&amp;searchId=i0ad604ab000001630667802a2028f1f7&amp;kmSearchIdRequested=False&amp;simpleSearch=False&amp;isAdvancedSearchTemplatePage=False&amp;skipSpellCheck=False&amp;isTrDiscoverSearch=False&amp;ancillaryChargesAccepted=False&amp;proviewEligible=False&amp;transitionType=ReturnToList&amp;contextData=%28sc.CustomDigest%29#I7b55ac403f3c11e8a70fc9d8a0b2aef5&quot;},&quot;SearchQuery&quot;:null,&quot;SearchQueryType&quot;:null,&quot;SearchWithinQuery&quot;:null,&quot;SecondaryHighlightTerms&quot;:null,&quot;ShowSkipOutOfPlanOption&quot;:false}" type="hidden"><div id="co_nrsOutline" class="co_hideState"></div><input id="co_documentContentCacheKey" value="WestlawNext|none|I7b55ac403f3c11e8a70fc9d8a0b2aef5|||||||Search|Search/v1/results/navigation/i0ad604ab000001630667802a2028f1f7?Nav=CUSTOMDIGEST&amp;fragmentIdentifier=I7b55ac403f3c11e8a70fc9d8a0b2aef5&amp;startIndex=1&amp;contextData=%28sc.CustomDigest%29&amp;transitionType=CustomDigestItem|CUSTOMDIGEST|138|False|True|{&quot;HighlightPoints&quot;:null,&quot;HighlightTerms&quot;:null,&quot;SearchWithinQuery&quot;:null,&quot;SecondaryHighlightTerms&quot;:null}|False|||False|False|||True|S|False|Core|||001|False|False|False|False|False|" type="hidden"><input id="co_documentFlagInfo" value="{&quot;docGuid&quot;:&quot;I7b55ac403f3c11e8a70fc9d8a0b2aef5&quot;,&quot;flags&quot;:[],&quot;metas&quot;:[{&quot;contentType&quot;:&quot;CASELAW&quot;,&quot;docCollection&quot;:&quot;w_cs_fed1&quot;,&quot;docFamilyGuid&quot;:&quot;I7c5234b03f3c11e88fe6cda34d31207a&quot;,&quot;legacyId&quot;:&quot;2044320422&quot;,&quot;sourcePubId&quot;:&quot;506&quot;}]}" type="hidden">




							</div>

				</div>
			</div>
		</div>
	</div>
	<!-- LEFT COLUMN -->  
	<div id="co_leftColumn">
		<div class="co_innertube">
			<div id="coid_website_folderingWidgetDiv"></div>
		</div>
	</div>
			<!-- RIGHT COLUMN -->
			<div id="co_rightColumn" class="co_addFocusCorrection">
				<div class="co_innertube">		
					<div id="coid_website_relatedInfoIPWidgetDiv" style="display: none;" aria-expanded="false">
					</div>




<div id="coid_website_documentToolWidgetDiv"></div>
		<div id="coid_website_relatedInfoWidgetDiv"> <div class="co_genericBox co_relatedinfo_topic_container" id="co_relatedinfo_formfamilies_container"></div></div>
		<div id="coid_website_recommendedDocuments" class="co_recommendedDocumentContainer"> </div>

<div id="downloadUserDocument"></div>
					<div id="downloadUserDocument"></div>
				</div>
			</div>

 <input class="hideTopTopics" id="hideTopTopics" name="hideTopTopics" type="hidden">
		<div class="co_clear"></div>
	</div>


	<!-- BEGIN FOOTER -->
	<div id="co_footerContainer"><div id="co_cookiePolicyContainer">
	<div class="co_cookiePolicyContent">
			<h3><b>Our policy towards the use of cookies</b></h3>
			<p>All Thomson Reuters websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.</p>
			<ul class="co_inlineList">
				<li>
					<a id="coid_website_cookiePolicyLinkOut" href="javascript:void(0)">Read cookie policy</a>
				</li>
				<li>
					<a id="coid_website_closeCookiePolicy" href="javascript:void(0)">Close</a>
				</li>
			<p></p>
			<button type="button" id="coid_website_cookiePolicyAcknowledged" title="Close message to acknowledge cookie policy" class="co_absolute">
				<span class="icon25 icon_close_x"></span>
			</button>
	</ul></div>
</div>


		
		<div class="co_innertube co_clearfix" id="co_footer" style="display: block;">







<div class="co_floatLeft">
	<div id="co_footerLinks">
		<ul class="co_inlineList">
					<li><a id="coid_websiteFooter_userSettings" href="javascript:void(0);"><span class="icon25 icon_gear_document"></span>Preferences</a></li>
				<li><a id="coid_websiteFooter_helplink" href="javascript:void(0);"><span class="icon25 icon_question_mark"></span>Training &amp; Support</a></li>
				
					<li><a id="coid_websiteFooter_signofflink" href="javascript:void(0);"><span class="icon25 icon_exit_door"></span>Sign Off</a></li>

		</ul>
	</div>
	<div id="co_footerCopyright">
		<ul class="co_inlineList">

			<li>Westlaw. <a href="/Copyright?transitionType=Default&amp;contextData=(sc.Default)"> © 2018</a> Thomson Reuters</li>
			<li><a id="coid_websiteFooter_privacyPolicyLink" href="javascript:void(0)">Privacy Statement</a></li>
			<li><a href="/Accessibility?transitionType=Default&amp;contextData=(sc.Default)">Accessibility</a></li>
				<li id="co_footer_supplier"><a id="coid_website_supplierTerms" href="javascript:void(0);">Supplier Terms</a></li>
				<li id="co_footerContactUs"><a href="/ContactUs?transitionType=Default&amp;contextData=(sc.Default)">Contact Us</a></li>
				<li id="co_footerCs">1-800-REF-ATTY (1-800-733-2889)</li>
				<li id="co_footer_improve"><strong><a id="coid_websiteFooter_pageSurvey" href="javascript:void(0);">Improve Westlaw</a></strong></li>
		</ul>


	</div>
</div>





<div id="co_trLogo" class="co_floatRight">

	<a id="co_trLogo_link" href="#">
		<img alt="Thomson Reuters" src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/v2/co_logo_thomsonReuters.png" width="134" height="30">
	</a>
</div>



		</div>
	</div>
			<div id="coid_Trmr" style="display:none; visibility:hidden"></div>
		</div>
	</div>
	
	<!--static content version number-->
<script type="text/javascript">





	
		window['Server/Routing'] = {
			Search: 'search.int.next.westlaw.com',
			TypeAhead: 'typeahead.int.next.westlaw.com',
			Nlu: 'nlu.int.next.westlaw.com',
			Document: 'document.int.next.westlaw.com',
			Foldering: 'foldering.int.next.westlaw.com',
			CSS: 'ca.next.westlaw.com/StaticContent_40.1.1015',
			Images: 'ia.next.westlaw.com/StaticContent_40.1.1015',
			JavaScript: 'ja.next.westlaw.com/StaticContent_40.1.1015',
			RelatedInfo: 'relatedinfo.int.next.westlaw.com',
			Events: 'events.int.next.westlaw.com',
			KM: 'NONE',
			RequestDirector: 'www.westlaw.com',
			SocialPlatform: 'https://community-sso.thomsonreuters.com',
			Sync: 'sync.westlaw.com',
			Video: 'v1.next.westlaw.com',
			FormsAssembly: 'formsassembly.int.forms.westlaw.com',
			Publishing: 'publishing.int.next.westlaw.com',
			WebContent: 'webcontent.int.next.westlaw.com',
			Alert: 'alert.int.next.westlaw.com',
			Report: 'report.int.next.westlaw.com',
			ProductMetadata: 'pmd.int.next.westlaw.com/pmd',
			Website: '1.next.westlaw.com',
			WebsiteDefault: '1.next.westlaw.com',
			HistoryListener: 'historylistener.int.next.westlaw.com',
			FormsAssemblyTest: ''
		};
	
		
			if (window.location.host !== '1.next.westlaw.com') {
				window['Server/Routing'].ProxiedWebsite = '1.next.westlaw.com';
				window['Server/Routing'].Website = window.location.host;
				window['Server/Routing'].WebsiteDefault = window.location.host;
			}
		
</script>

<script type="text/javascript"></script>

	<script type="text/javascript" src="https://1.next.westlaw.com/v2/js/UrlRouting.40.1.1013.0.js"></script>
	
	<script type="text/javascript" crossorigin="anonymous" charset="utf-8" src="https://ja.next.westlaw.com/StaticContent_40.1.1015/External/vendor/datejs@1.0/cultures/en-US.js"></script>
<script type="text/javascript" crossorigin="anonymous" charset="utf-8" src="https://ja.next.westlaw.com/StaticContent_40.1.1015/v2/Products/WestlawNext/js/LocalizationResources/Localized/Messages.js"></script>

	
<script type="text/javascript">

	







</script>





















	
	














<script type="text/javascript">
window['Server/User'] = {
  "FirmName": "SEOUL NATIONAL UNIV (LV A)",
  "_AlertsIsAdmin": false,
  "_FeatureExposure": "Released",
  "ClientId": "SEOUL NU - WL NEXT",
  "_AlertsAccessFunctionalityTurnedOn": true,
  "_AlertsAccessCategoryApplied": false,
  "_ShowErrorDetails": false,
  "OnePassUserName": "5405685",
  "OnePassUserNameEncoded": "5405685",
  "ClientMatter": {
    "ClientId": "SEOUL NU - WL NEXT",
    "CompositeClientMatter": "SEOUL NU - WL NEXT",
    "DefaultClientId": "Seoul NU - WL Next",
    "ClientIdPromptText": "",
    "IsClientNonChargeable": "False",
    "NoClientId": "False",
    "TrackableCode": "D",
    "UserTurnedTrackingOn": false
  },
  "ClientReportingAttributes": {
    "PracticeArea": "",
    "ResearchReasonCode": "",
    "ResearchDescription": ""
  },
  "BillingMethodForDisplayOnly": "TRANSACTIONAL",
  "HasFlashPlayer": false,
  "IsUltra": true,
  "CustomerStorageKey": "E41F133AB8A01ED395E1D85D67D9406C",
  "SessionCreatedDateTime": "04/27/2018 09:20:24",
  "HasLoggedAggregateNotificationCount": false
};


window['Server/ViewModelData'] = {
  "DocumentGuid": "I7b55ac403f3c11e8a70fc9d8a0b2aef5",
  "DocumentCitation": "--- F.3d ----",
  "DocumentTitle": "Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals International Limited",
  "DocumentMetaDescription": "View on Westlaw or start a FREE TRIAL today, Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals International Limited, Cases",
  "ViewType": "FullText",
  "Rank": 138,
  "Grading": "na",
  "KMEnableTermNavigation": false,
  "KMEnableDocumentNavigation": false,
  "LegacyId": "2044320422",
  "DocumentSource": {
    "Key": "094be5ec528a4ebcb516957557b7ae19",
    "NavigationPath": "Search/v1/results/navigation/i0ad604ab000001630667802a2028f1f7?Nav=CUSTOMDIGEST&fragmentIdentifier=I7b55ac403f3c11e8a70fc9d8a0b2aef5&startIndex=1&contextData=%28sc.CustomDigest%29&transitionType=CustomDigestItem",
    "ListSource": "Search",
    "List": "CUSTOMDIGEST",
    "ListPageSourceKey": "edc4a850c828227f4c8d5f819b26133f"
  },
  "HasDraftingNotes": false,
  "HasDocumentSections": false,
  "EnableBestPortion": true,
  "SubContentTypeId": "27",
  "DisableDocMetaInfoRetrievalOnWarningPage": false,
  "TermNavigationPreference": "AllTerms",
  "ShowMainToolbar": true,
  "ShowRelatedAnalysis": false,
  "ListSource": "Search",
  "IsRelatedFullTextView": false,
  "KeyCiteAlertWarning": "None",
  "DocketTrackWarning": "None",
  "DocumentSections": [],
  "RulebookMode": false,
  "RulebookModeContent": false,
  "NotesOfDecisionsCount": 0,
  "TocReportDocGuids": [],
  "TocReportViewMode": false,
  "IsMedLitStubDocument": false,
  "TrackableCode": "D",
  "NonTrackableCode": "H",
  "FullTocOnDoc": false,
  "ViewExpressions": []
};


window['Server/WidgetDomIds'] = {
  "DocToolbar": "co_docToolbar",
  "DocDisplay": "coid_website_documentWidgetDiv",
  "DocTools": "coid_website_documentToolWidgetDiv",
  "DocTopToolbar": "co_docTopToolbar",
  "DocRightToolbar": "co_newDocToolbar",
  "TopTopics": "coid_website_relatedInfoWidgetDiv",
  "DocBottomToolbar": "co_docFooterToolbar"
};


window['Server/PageData'] = {
  "DocumentTabView": {
    "IsSkipOutOfPlanChecked": false,
    "IsUserDocument": false,
    "UserDocumentData": {
      "documentGuid": "I7b55ac403f3c11e8a70fc9d8a0b2aef5"
    },
    "HasProfileSubTab": false,
    "DisplayOptions": {
      "showMainToolbar": true,
      "isNewDocumentView": false,
      "disableDocToolbar": false,
      "isAbstractView": false,
      "chunkSize": "L",
      "chunkableHeadnotes": false,
      "doCompleteSizeChecking": true,
      "ViewType": "FullText",
      "stickyHeader": true,
      "displayRelatedContentLink": true,
      "snippetRelocationInfo": {
        "contentType": "Cases",
        "subContentTypeId": "27"
      }
    },
    "ShowMainToolbar": true,
    "DocumentPersisted": false,
    "DocumentGuidNotFound": false,
    "ContentType": "Cases",
    "ExpandDocumentLevelTOC": true
  },
  "CobaltPageHeader": {
    "ShowPauseLink": false,
    "ShowCommunityContainer": false,
    "EnablePageHeaderV2": true,
    "ShowBetaFeedbackLink": false,
    "Notifications": {
      "HideNotificationToastAfterDuration": false,
      "NotificationClickGoDirectlyToAlerts": false
    }
  },
  "CompartmentStartPageId": "",
  "CobaltMasterFooterInSession": {
    "TRLogoImageLinkUrl": "http://www.thomsonreuters.com",
    "ShowWhatIsNewLink": false,
    "Unreleased": false,
    "IsAnonymousSession": false,
    "ShowMyContacts": false,
    "ShowPromotions": false,
    "ShowResetPromotions": false,
    "ShowCampusPolicy": false,
    "IsTransferContentAvailable": false,
    "ShowProductStartGuide": false,
    "HelpGuideDisplayName": "",
    "HelpGuideFileName": "",
    "HelpGuidePath": "",
    "CampusPolicyDisplayName": "",
    "CampusPolicyPath": "",
    "ShowAnalyticsLink": false,
    "AnalyticsPath": "Session/SignOn.html?transitionType=Default&contextData=(sc.Default)",
    "ShowMyAccountLink": false,
    "MyAccountPath": "WESTLAW/Common/Landing/MyAccountLanding",
    "LegalSolutionsLink": "http://legalsolutions.thomsonreuters.com/law-products/westlaw-legal-research/training-support",
    "SupplierTermsUrl": "http://legalsolutions.com/westlaw-additional-terms",
    "PrivacyPolicyPath": "https://www.thomsonreuters.com/en/privacy-statement.html"
  },
  "ActOnTracking": {
    "EnableActOnTracking": false,
    "ActOnTrackingInstanceId": ""
  },
  "CobaltPage": {
    "SetInCache": [
      {
        "Vertical": "Global",
        "Name": "ResultsPerPage",
        "Value": 20
      },
      {
        "Vertical": "Global",
        "Name": "ResultsPerPageAllowableValues",
        "Value": [
          "100",
          "20",
          "50"
        ]
      },
      {
        "Vertical": "Global",
        "Name": "Locale",
        "Value": ""
      },
      {
        "Vertical": "Global",
        "Name": "TimeZone",
        "Value": "Central Standard Time"
      },
      {
        "Vertical": "Global",
        "Name": "MultiFacetsEnabled",
        "Value": false
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_CASE",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_ANALYTICAL",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_PENDINGREG",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_PENDINGLEG",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_KNOWHOW",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "JurisdictionsContentType",
        "Value": "default"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_DOCKET",
        "Value": "CASE_TITLE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_BRIEF",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_TRIAL-TRANSCRIPTS",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_ADMINDECISION",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_FORM",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_NEWS",
        "Value": "DATE_DESCENDING"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_ORAL-ARGUMENTS",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "InstantSuggestions",
        "Value": true
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_TCO",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultNews_DuplicateIdentifier",
        "Value": false
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_REGULATION",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_EXPERTWITNESS",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "SliderDetail",
        "Value": "default"
      },
      {
        "Vertical": "Search",
        "Name": "ViewExpression",
        "Value": ""
      },
      {
        "Vertical": "Search",
        "Name": "DefaultPage",
        "Value": "ALL"
      },
      {
        "Vertical": "Search",
        "Name": "JurisdictionsGlobal",
        "Value": "CTAF"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_PMM",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_STATUTE",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_JURYVERDICT",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "SuppressRecentFiltersTooltip",
        "Value": false
      },
      {
        "Vertical": "Document",
        "Name": "HeadnotesDualColumnView",
        "Value": false
      },
      {
        "Vertical": "Document",
        "Name": "CiteAdvisorRulesSet",
        "Value": "standard"
      },
      {
        "Vertical": "Document",
        "Name": "CiteAdvisorItalicizeTitle",
        "Value": false
      },
      {
        "Vertical": "Document",
        "Name": "CiteAdvisorParallelCites",
        "Value": "CAFormat"
      },
      {
        "Vertical": "Document",
        "Name": "CiteAdvisorUseForCopyWithReference",
        "Value": true
      },
      {
        "Vertical": "Document",
        "Name": "CiteAdvisorCitationStyle",
        "Value": "LegalBriefs"
      },
      {
        "Vertical": "Document",
        "Name": "CiteAdvisorIncludeHistory",
        "Value": true
      },
      {
        "Vertical": "Document",
        "Name": "CiteAdvisorUnderlineTitle",
        "Value": true
      },
      {
        "Vertical": "Document",
        "Name": "HideHeadnotesBox",
        "Value": false
      },
      {
        "Vertical": "Foldering",
        "Name": "ShowAnnotationsPreferenceKey",
        "Value": "checked"
      },
      {
        "Vertical": "Website",
        "Name": "ShowKeyboardInstructions",
        "Value": true
      },
      {
        "Vertical": "Website",
        "Name": "DocumentFullscreenShowTerms",
        "Value": true
      },
      {
        "Vertical": "Website",
        "Name": "NewFeatureLightboxDisplayBlackList",
        "Value": ""
      },
      {
        "Vertical": "Website",
        "Name": "DocumentFullscreenTextSize",
        "Value": ""
      },
      {
        "Vertical": "Website",
        "Name": "DocumentFullscreenMargin",
        "Value": ""
      },
      {
        "Vertical": "Website",
        "Name": "DeliveryOptionSelected",
        "Value": "None"
      },
      {
        "Vertical": "Website",
        "Name": "DocumentFullscreenShowLinks",
        "Value": true
      },
      {
        "Vertical": "Website",
        "Name": "LastViewNotificationDate",
        "Value": ""
      },
      {
        "Vertical": "Website",
        "Name": "DocumentDisplayTextSize",
        "Value": ""
      },
      {
        "Vertical": "Website",
        "Name": "DisplaySearchTerms",
        "Value": true
      },
      {
        "Vertical": "Website",
        "Name": "KnowHowSpeedReadExpandAll",
        "Value": true
      },
      {
        "Vertical": "Website",
        "Name": "DocumentDisplayFont",
        "Value": ""
      },
      {
        "Vertical": "Website",
        "Name": "DocumentDisplayMargin",
        "Value": ""
      },
      {
        "Vertical": "Website",
        "Name": "DocumentFullscreenFont",
        "Value": ""
      },
      {
        "Vertical": "SAP",
        "Name": "PLAN ICONS",
        "Value": "NO"
      },
      {
        "Vertical": "SAP",
        "Name": "SKIP OUT OF PLAN",
        "Value": "NO"
      },
      {
        "Vertical": "SAP",
        "Name": "WARNING FLAG",
        "Value": "N"
      }
    ],
    "PingSync": "false",
    "ViewData": {
      "IsSponsorSession": true,
      "SearchWidgetParameters": {
        "search": {
          "renderCustomPageSearchWidget": false,
          "categoryPageTitle": "291 PATENTS",
          "isCategoryPageTopical": false,
          "topicKeyText": "291 PATENTS",
          "filters": {
            "jurisdiction": "CTAF",
            "sequence": 0,
            "content": "CUSTOMDIGEST",
            "index": false,
            "customDigest": true,
            "collectionSets": [
              "w_cs_cd_toc"
            ],
            "tocNode": "I4aee2539c6f64c1812a4c2f3395c2607",
            "keyNumber": "291",
            "displayJurisdictionSelector": true,
            "displayAdvancedSearchLink": false,
            "categoryPageUrl": "Home/WestKeyNumberSystem",
            "categoryPageContentType": "CUSTOMDIGEST",
            "categoryPageCheckboxLimit": 0,
            "resultsLimit": 0,
            "categoryPageAlertClippable": false,
            "isAdvancedSearchTemplatePage": false
          },
          "CustomPageSetForZone": false,
          "supportedFeatures": [],
          "skipSpellCheck": false,
          "browseHierarchyPathFromRoot": []
        },
        "SearchCompartmentName": "WestlawNext",
        "SearchDropDownItems": [],
        "grading": "na",
        "searchWidgetPosition": "Default",
        "hideSearchWidget": false,
        "makeSearchWidget": true,
        "prefersForceTnc": false,
        "prefersForceTncSingleQuote": true,
        "forceTncCounter": 0,
        "forceTncCounterThreshold": 5,
        "enableFavoriteSearch": false,
        "dynamicPage": false,
        "isAdvancedSearchTemplatePage": false
      },
      "ShowClientIdWidget": true,
      "OpenFindDropDown": false,
      "TimeoutInMinutes": 90,
      "FeatureConfigurations": {
        "FOLDERS": false,
        "HISTORY": true,
        "FOLDER_SHARING": false,
        "HIGHLIGHTS": false,
        "NOTES": false,
        "ANNOTATIONS": false,
        "BLOCK NOTES SHARING": false,
        "CONTACTS": false,
        "FAVORITES": false,
        "USER PROFILE": false,
        "KM": false,
        "FolderCachingDisabled": true,
        "KM IPAD": false,
        "SAO_INVITING": true,
        "SAO_SAMEEMAILDOMAIN": false,
        "CASENOTEBOOKEXPORT": false,
        "DOWNLOADDELIVERY": true,
        "DROPBOXDELIVERY": false,
        "EMAILDELIVERY": true,
        "EMAILWITHREFERENCEDELIVERY": false,
        "KINDLEDELIVERY": false,
        "PRINTDELIVERY": true,
        "KEYCITEALERTS": false,
        "LEGACYALERTACCESS": false,
        "BLOCKPERSISTENTINFO": true,
        "BLOCK100KANCILLARY": false,
        "DISPLAYMASHUPCHARGEWARNING": false,
        "SHOWCHARGEONWARNINGSCREEN": false,
        "SHOWCHARGELINKONWARNINGSCREEN": false,
        "USERISTRANSACTIONAL": true,
        "USER FORM UPLOAD": false,
        "MATTERUPLOADUSERDOC": false,
        "FOLDERUPLOADUSERDOC": false,
        "DISPLAY SESSION PAUSE LINK": false,
        "PASSTHRUPDFS": false,
        "processRIHistoryAsynchronously": true,
        "processDocumentHistoryAsynchronously": true,
        "PRINTBLANKFORMS": false,
        "WFBTRIALBLOCKSHARE": false,
        "ATTORNEY PORTAL": false,
        "SMALLLAWWORKBENCHMATTERTREE": false,
        "JUDICIALCHAMBERS": false,
        "CITATIONUS": false,
        "CITATIONCAN": false,
        "MYPLANSTATICDOC": true,
        "ALLOWFOLDERSHAREACROSSORGS": true,
        "BLOCKFOLDERSHAREFROMORGS": true,
        "ALLOWOFFLINEACCESS": false,
        "WEBHOSTEDCLIENTID": false,
        "WEBHOSTEDCLIENTIDIPAD": false,
        "WEBHOSTEDCLIENTIDSELECTION": false,
        "PRERELCONTENTFEAT": false,
        "ALERTS": false,
        "ALERTS ENHANCED": false,
        "ISEMULATEUSER": false,
        "WCLP": false,
        "NEWSLETTER": false,
        "KCALERT": false,
        "COINV ALERTS": false,
        "CITRANSITION": false,
        "BLCALERT": false,
        "DKTALERT": false,
        "DKTTRACK": true,
        "PUBALERT": false,
        "CWALERT": false,
        "POB ALERT": false,
        "POB WATCH": false,
        "CWALERTPremium": false,
        "CAPITOLWATCH": false,
        "ALERT SUMMARY REPORT": false,
        "WCLP CONTINUOUS": false,
        "KCALERT CONTINUOUS": false,
        "CWALERT CONTINUOUS": false,
        "POBA CONTINUOUS": false,
        "POBW CONTINUOUS": false,
        "NEWSLETTER DLY": false,
        "NEWSLETTER WKDY": false,
        "KCALERT DLY SINGLE": false,
        "KCALERT WKDY SINGLE": false,
        "BIALERT DLY SINGLE": false,
        "BLCALERT DAILY": false,
        "BLCALERT MULTI DAILY": false,
        "CWALERT DAILY": false,
        "BIALERT WKDY SINGLE": false,
        "BLCALERT BIWEEKLY": false,
        "BLCALERT CONTINUOUS": false,
        "WCLP WEEKLY": false,
        "NEWSLETTER WEEKLY": false,
        "KCALERT WEEKLY": false,
        "BIALERT WEEKLY": false,
        "BLCALERT WEEKLY": false,
        "DKTALERT WEEKLY": false,
        "DKTTRACK WEEKLY": true,
        "POBA WEEKLY": false,
        "POBW WEEKLY": false,
        "WCLP BIWEEKLY": false,
        "KCALERT BIWEEKLY": false,
        "BIALERT BIWEEKLY": false,
        "DKTALERT BIWEEKLY": false,
        "DKTTRACK BIWEEKLY": true,
        "NEWSLETTER BIWEEKLY": false,
        "POBA BIWEEKLY": false,
        "POBW BIWEEKLY": false,
        "WCLP MONTHLY": false,
        "NEWSLETTER MONTHLY": false,
        "KCALERT MONTHLY": false,
        "BIALERT MONTHLY": false,
        "BLCALERT MONTHLY": false,
        "DKTALERT MONTHLY": false,
        "DKTTRACK MONTHLY": true,
        "POBA MONTHLY": false,
        "POBW MONTHLY": false,
        "WCLP DLY SINGLE": false,
        "WCLP DLY MULT": false,
        "WCLP WKDY SINGLE": false,
        "WCLP WKDY MULT": false,
        "PUBALERT DLY SINGLE": false,
        "PUBALERT WKDY SINGLE": false,
        "DKTALERT WKDY SINGLE": false,
        "DKTALERT DLY SINGLE": false,
        "DKTTRACK WKDY SINGLE": true,
        "DKTTRACK DLY SINGLE": true,
        "CAPITOLWATCHTRACK DLY SINGLE": false,
        "CAPITOLWATCHTRACK DLY MULT": false,
        "CAPITOLWATCHTRACK WKDY SINGLE": false,
        "CAPITOLWATCHTRACK WKDY MULT": false,
        "CAPITOLWATCHTRACK WEEKLY": false,
        "CAPITOLWATCHTRACK BIWEEKLY": false,
        "CAPITOLWATCHTRACK MONTHLY": false,
        "POBA DLY SINGLE": false,
        "POBA DLY MULT": false,
        "POBA WKDY SINGLE": false,
        "POBA WKDY MULT": false,
        "POBW DLY SINGLE": false,
        "POBW DLY MULT": false,
        "POBW WKDY SINGLE": false,
        "POBW WKDY MULT": false,
        "showMatterTree": false,
        "WELCOME TO WLN BOX": false,
        "dataRoomReadSource": "Original",
        "dataRoomWriteDestination": "Single",
        "dataRoomFoldersWriteDestination": "SingleDataRoom",
        "showNapaContent": true,
        "PublicRecordsAccess": false,
        "PublicRecordsEnhancedSecurity": false,
        "PublicRecordsBlockRoaming": false,
        "PublicRecordsBlockHomeTrust": false,
        "PublicRecordsAllowRoamTrust": false,
        "PublicRecordsBypassCountry": false,
        "PublicRecordsBlockIPUndefined": false,
        "PublicRecordsBlockUndefinedTrust": false,
        "PublicRecordsDowngradeEmailIPRoaming": false,
        "PublicRecordsDowngradeEmailIPUndefined": false,
        "PublicRecordsUnmaskRoam": false,
        "DISABLE PR ANC MASK": false,
        "PublicRecordsSsnOnlyOK": false,
        "ReversePhoneGateway": false,
        "QSentReport": false,
        "CreditHeaderContentDatabaseGroup": false,
        "PolkGateway": false,
        "PolkReport": false,
        "DriversLicenseRecordsContentDatabaseGroup": false,
        "UCC COLUMN RESULTS": false,
        "matterTreeType": "None",
        "ISCAMPUSUSER": false,
        "ISCAMPUSNEWSUSER": false,
        "ISCAMPUSBUSINESSUSER": false,
        "isUnreleasedFeatureExposure": false,
        "WLANALYTICS ACCESS": false,
        "NEWSALERTAUTHOR": false,
        "NEWSALERTEDITOR": false,
        "UNRELEASED CAT PAGES": false,
        "INTERNAL ADMIN LIMITS": false,
        "DATAROOMALERTS": false,
        "DLVRY SESSION LIMIT": false,
        "DLVRY DAILY LIMIT": false,
        "DLVRY SESSION LIMIT PRAC LAW": false,
        "DLVRY DAILY LIMIT PRAC LAW": false,
        "DLVRY SESSN LIMIT PRAC LAW TRL": false,
        "DLVRY DAILY LIMIT PRAC LAW TRL": false,
        "CONTENT DLVRY RSTRCT": true,
        "BLOCKAUWLN": false,
        "BLOCKCANWLN": false,
        "BLOCKHKWLN": false,
        "BLOCKUKWLN": false,
        "ALERTS ADDRESS BOOK": true,
        "ALERTS BATCH PROCESSING": false,
        "ALERTS CALENDARING": true,
        "ALERTS FUNCTIONALITY": true,
        "ECHACCESS": false,
        "PMD VERSION": "5207",
        "USER ACADEMIC": true,
        "USER CORPORATE": false,
        "USER DEVELOPER": false,
        "USER GOVERNMENT": false,
        "USER INTERNAL": false,
        "USER LARGE LAW": false,
        "USER MEDIUM LAW": false,
        "USER SMALL LAW": false,
        "SIGNOFF SURVEY": false,
        "INLINE KC CASES BRIEF": false,
        "BYPASS WARN INLINE KC": false,
        "BLOCK PL ITEMS": false,
        "PRACTICAL LAW": false,
        "PRDCT PLCUK": false,
        "PRDCT PLCAU": false,
        "DISABLE PL REL CONTENT CACHE": false,
        "HISTORY UI": true,
        "EDSECTIONALLOW": false,
        "TAPSELECTED": false,
        "REDLINING": false,
        "WLNBYPASSBLOCK": false,
        "BLOCK NATIVE SIGNIN": false,
        "BLC ZONE": false,
        "CUSTOM PAGES": false,
        "CUSTOM PAGES READ": false,
        "CUSTOM PAGE ADMIN": false,
        "ELIBRARIES CP ZONE": false,
        "TYPE AHEAD": false,
        "PATRONHELP": false,
        "HISTORY RETENTION 1": false,
        "HISTORY RETENTION 180": false,
        "BLC POWERSEARCH": false,
        "PRDCT CORRECTIONAL": false,
        "EASY EDIT": false,
        "ENHANCED RB": false,
        "ENHANCED RB STICKY": false,
        "WMGRAPHICAL": false,
        "PRPTSUBSCRIBER": false,
        "BLOCK PRPT BLC": false,
        "PLCT DISPLAY LEGAL ANALYTICS": false,
        "PRPT SMALL": false,
        "PRPT CORPCOUNSEL": false,
        "PRPT LARGE": false,
        "BLOCK PRPT LARGE PAGES": false,
        "PRPT GOVT": false,
        "PRPT NONTRACKABLE": false,
        "PRPT KM LITIGATION": false,
        "PRPT KM TRANSACTIONAL": false,
        "WAYWO": false,
        "AnonymousSession": false,
        "AnonymousSessionBlock": false,
        "SOCIAL PLATFORM": false,
        "BLOCK TNP PLUS": false,
        "TNP TEPC CALC": false,
        "TNP CORTC CALC": false,
        "APFF ACCESS": false,
        "TDRC": false,
        "FPC": false,
        "FPP": false,
        "TAXHYPERION NLTR": false,
        "WCO ACCESS": false,
        "BLOCKMYSTARTPAGELINK": false,
        "TNP CEC CALC": false,
        "TNPNATLANG": false,
        "TAXNEWSCATEGORIES": false,
        "TNPDIGMCMECHAN": false,
        "TNPDIGBROWN": false,
        "TNPDIGNIKOLAKAKIS": false,
        "TNPDIGHAYHOETAXATION": false,
        "TNPDIGKERZNER": false,
        "TNPDIGSCHWARTZ": false,
        "TNPDIGINNES": false,
        "TNPDIGARON": false,
        "TNPDIGCARR": false,
        "TNPDIGGAMBLE": false,
        "TNPDIGTAXATIONOFREALESTATE": false,
        "TNPDIGBROOKS": false,
        "TNPDIGMUNRO": false,
        "TNPDIGTHAW": false,
        "TNPDIGVINER": false,
        "TNPDIGFRIEDLANDER": false,
        "TNPDIGBUTCHER": false,
        "TNPDIGALEXANDER": false,
        "TNPDIGHAYHOECASELAW": false,
        "TNPDIGHAYHOEFEDPROVLEGIS": false,
        "TNPDIGHAYHOEGOVPUBLICATIONS": false,
        "TNPDIGJOLIN": false,
        "TNPDIGSTILLABOWER": false,
        "TNPDIGCASESINDEXCITATOR": false,
        "TNPDIGSEGUIN": false,
        "TNPDIGWISE": false,
        "TNPDIGBOWEN": false,
        "TNPDIGBISCOTT": false,
        "TNPDIGEDMUNDS": false,
        "TNPDIGMANNGUIDETOREVIEW": false,
        "TNPDIGCOMPILATIONENGAGEMENTS": false,
        "TNPDIGGUIDETOESTATEANDTRUSTS": false,
        "TNPDIGITIZATION": false,
        "TNPLITIGATOR": false,
        "TNPCROSSREFFILTER": false,
        "RESULTLISTEASYEDIT": false,
        "RESULTLISTQDRAFT": false,
        "DISPLAY TEST PREF TAB": false,
        "BlindLog": false,
        "EncryptLog": false,
        "MASS EMAILER": false,
        "ADCVERREDLININGTOGGLE": false,
        "ENVHEALTHSAFETYPRACPG": false,
        "INSURCOMPLIANCEPRACPG": false,
        "BLOCK WLN PATRON": false,
        "DSP INT HEADNOTE INFO": false,
        "PRDCT WLNLINKS": false,
        "GAO LH PDFS OPEN IN LINKS": false,
        "WLNLINKS UK": false,
        "BLOCK WLNLINKS EMBEDDED LINKS": false,
        "BLOCK LICENSE AGREEMENT": false,
        "FIRMSTYLE": false,
        "SMART BREADCRUMB DISPLAY": false,
        "IRS WLN PAGE": false,
        "FORMSAUTOSHAREOFF": false,
        "WLNPLTRACK": false,
        "WLNPL GOVTHOMEPAGE": false,
        "WLNPL CORPHOMEPAGE": false,
        "WLNPL DEFAULTHOMEPAGE": true,
        "ENABLE-LEGI-GOV-LINKS": false,
        "ENABLE BAILII LINKS": false,
        "BLOCK SHARE NOTE LINK": false,
        "BLCCAN ZONE": false,
        "BLCCAN SUBSCRIBER": false,
        "BLOCKBLCCAN": true,
        "BLOCKBLC": false,
        "WM SEARCH RESULTS": false,
        "WMHK SEARCH RESULTS": false,
        "WMAU SEARCH RESULTS": false,
        "TAX PWC USER": false,
        "TAX KPMG USER": false,
        "COPY USER DATA": false,
        "ASSIGNCLIENTFILE": false,
        "RESEARCH REPORT": false,
        "FOLDER ANALYSIS": false,
        "FOLDER ANALYSIS ADDL CONTENT": false,
        "TIME ZONE AUSTRALIA": false,
        "TIME ZONE NEW ZEALAND": false,
        "EY WLN PAGE": false,
        "FOLDER DESCRIPTION": false,
        "ENABLE CONTRACT EXPRESS": false,
        "CONTRACT EXPRESS PL AU": false,
        "CONTRACT EXPRESS PL US": false,
        "ASK-EDITOR": false,
        "BLOCK OPEN WEB": false,
        "PLUK SUBSCRIBER": false,
        "WLUK SUBSCRIBER": false,
        "LIBRARY SUBSCRIBER": false,
        "CHECKPOINTDIRECTLINK": false,
        "BLOCKCHECKPOINTLINKS": false,
        "LINK BUILDER": false,
        "BCICALCULATOR": false,
        "PLUK-ENAB-ALLCONTACTS": false,
        "ALLOW ICLR": true,
        "BLOCK PROVIEW FEDERATED SEARCH": false,
        "DOC ANALYSIS": false,
        "DT DocAnalysis": false,
        "GENERATE WLUK TRANSTOKEN": false,
        "WFB USEMOCKFORMS": false,
        "BLOCKSESSIONPAUSEDISPLAY": false,
        "PWC WLN PAGE": false,
        "KPMG WLN PAGE": false,
        "CROSSBORDER DASHBOARD": false,
        "TR DISCOVER SEARCH": false,
        "VIRTUAL ASSISTANT": false,
        "BLCDEALTRACKALERT": false,
        "BLCDEALTRACKALERT BIWEEKLY": false,
        "BLCDEALTRACKALERT CONTINUOUS": false,
        "BLCDEALTRACKALERT DAILY": false,
        "BLCDEALTRACKALERT MONTHLY": false,
        "BLCDEALTRACKALERT MULTIDAY": false,
        "BLCDEALTRACKALERT WEEKLY": false,
        "EY MIGRATION POP UP": false,
        "KPMG MIGRATION POP UP": false,
        "PWC MIGRATION POP UP": false,
        "IRS MIGRATION POP UP": false,
        "TAX MIGRATE": false,
        "SEARCH TABS": false,
        "JOURNAL PURCHASE FORM": false,
        "WLUK EDITORS PICKS TAB": false,
        "LEGAL LIT ANALYTICS": false,
        "UKMATTERMAPS": false,
        "USMATTERMAPS": false,
        "DISPLAY PL MESSAGE 1": false,
        "DISPLAY PL MESSAGE 2": false,
        "GRADING TOOL": false,
        "MODERN DOC DISPLAY": false,
        "INDIGO SEARCH": false,
        "INDIGO DISPLAY": false,
        "PSEUDO BLOCK INDIGO DISPLAY": true,
        "INDIGO DISPLAY PREF": false,
        "INDIGO HOT DOCS": false,
        "INDIGO RESEARCH REPORT": false,
        "COMPARE BLACKLINING": false,
        "NOTIFICATION CENTER": false,
        "PRIOR USER INTERACTIONS": false,
        "COLD START": false,
        "TOC FOR CASES": false,
        "MATERIAL KEY FACT FILTER": false,
        "PROCEDURAL POSTURE FILTER": false,
        "FAVORITE SEARCHES": false,
        "FOLDER KEYCITE CHANGE": false,
        "FOLDER RECOMMEND CHANGE": false,
        "FOLDER RECOMMEND ALERT": false,
        "RECENT FILTERS": false,
        "SEARCH RESULT CITING REFS": false,
        "SEARCH RESULT NEG HISTORY": false,
        "QUESTIONANSWERING": false,
        "ITDEPENDS": false,
        "ITDEPENDSQUESTIONANSWER": false,
        "WLUK DOC ALERTS": false,
        "WLUK JCL ALERTS": false,
        "PA REGULATIONS STATUS FILTER": false,
        "ALWAYS CLIENT ID PROMPT": false,
        "PL US BANNER": false,
        "ANSWERS FEEDBACK": false,
        "KC IMPLIED OVERRULINGS": false,
        "ENHANCED THEME": false,
        "DOC ANALYZER TOUR": false,
        "LIT ANALYTICS TOUR": false,
        "HOME PAGE TOUR": false,
        "BUSINESS DEVELOPMENT PL US": false,
        "WLNPL SLF HOMEPAGE": false
      },
      "IsUserMigrated": false,
      "SupportedFeatures": [
        "PRACTICALLAW",
        "ALERTS",
        "BROWSE",
        "BROWSEPREVIEW",
        "CASEEVALUATORWLN",
        "CDN",
        "CLIENTID",
        "CONTACTS",
        "CONTENTTYPEDELIVERYLIMIT",
        "COREUI",
        "CUSTOMPAGES",
        "DELIVERY",
        "DOCKETS",
        "DOCUMENTORDERING",
        "DOCUMENTS",
        "DROPBOX",
        "ERRORS",
        "FAVORITESORGANIZER",
        "FINDANDPRINT",
        "FOLDERS",
        "FOLDERSEXTERNALSHARING",
        "GLOSSARY",
        "WAYWO",
        "IOS",
        "IPAD",
        "FACTORANALYSIS",
        "KEYNUMBERSEARCH",
        "KM",
        "LINKIN",
        "LINKOUT",
        "LIVECHAT",
        "MOBILE",
        "MYPLAN",
        "NYOFFICALDIGEST",
        "PRICINGGUIDE",
        "PROMOTIONS",
        "PUBLICATIONFAVORITES",
        "RELATEDINFORMATION",
        "RELATEDTOPICS",
        "REPORTSHARED",
        "REVERSEPROXY",
        "SEARCH",
        "SHAREPOINTSEARCH",
        "SHAREPOINTWIDGETS",
        "SOCIALPLATFORM",
        "SURVEY",
        "USERAGREEMENT",
        "USERDOCUMENTS",
        "USEREMULATION",
        "USERSETTINGS",
        "BANKRUPTCYEXPLORER",
        "BUSINESSINVESTIGATOR",
        "BUSINESSLAWCENTER",
        "CASENOTEBOOK",
        "DUNANDBRADSTREETBUSINESS",
        "EXPERIANBUSINESSCREDIT",
        "EXPERTDUEDILIGENCE",
        "EXPERTEVALUATOR",
        "MATTERBENCHMARKING",
        "RECENTHISTORY",
        "WEB2MASHUP",
        "AUTHORITYCOMPILER",
        "SEARCHTEMPLATEPREVIEW",
        "PEOPLEMAP",
        "PUBLICRECORDS",
        "DOCKETGATEWAY",
        "WEBCONTENT",
        "PROFESSIONAL",
        "SUGGESTEDDOCUMENTS",
        "EMBEDDEDTEXT",
        "PRODUCTVIEW",
        "PRIVATEFILES",
        "STATEQACOMPARE",
        "SOURCELINK",
        "PMDPROTECTEDCONTENT",
        "ROADRUNNER",
        "REDLINE",
        "SUPERBROWSE",
        "TOCREPORTVIEW",
        "DATACOMPARISONREPORT",
        "GRAPHICALFACETS",
        "COPYUSERDATA",
        "SHAREDNOTES",
        "RESEARCHACCELERATOR",
        "WEBINARS",
        "READINGMODE",
        "ANALYTICS",
        "HIDESEARCHTERMHIGHLIGHTINGPREFERENCE",
        "MONETIZATION",
        "SHOWDOCUMENTANALYZEROVERVIEWPREFERENCE",
        "SHOWLITANALYTICSOVERVIEWPREFERENCE",
        "SHOWHOMEPAGEOVERVIEWPREFERENCE",
        "FOUNDATION"
      ],
      "ActiveBrowserPingInitialWaitInMinutes": 3,
      "ActiveBrowserPingFrequencyInMinutes": 3,
      "ShowClientIdToast": false,
      "DataRoomFeatures": [],
      "SocialPlatformProductId": "140",
      "MaxFileUploadSize": 157286400,
      "SnapEngageScriptUrl": "",
      "DeliveryQueueQueried": false,
      "DeliveryQueueTotal": 0,
      "DeliveryQueueInProgress": 0,
      "DeliveryQueueDocketsInProgress": 0,
      "DeliveryQueueInError": 0,
      "DeliveryQueueNotification": 0
    },
    "WidgetDomIds": {
      "FooterDivId": "co_footer",
      "ErrorSummaryWidget": "coid_website_errorsSummaryPlaceHolder",
      "DockWidget": "co_dockContainer",
      "RecentFoldersWidget": "co_recentFoldersContainer",
      "RecentHistoryWidget": "co_recentHistoryContainer",
      "FrequentFavoritesWidget": "co_frequentFavoritesContainer",
      "AlertsCenter": "co_alertsCenterContainer",
      "ClientIdWidget": "co_clientIdContainer",
      "SignOff": "co_signOffContainer",
      "WhatIsNext": "co_whatIsNextContainer",
      "SearchWidget": "coid_website_searchWidget"
    },
    "RedirectError": {
      "Show": false
    },
    "DomStorageHasBeenCleared": false,
    "LiveChat": {
      "Show": false,
      "Options": {
        "QueueNumber": 0
      }
    },
    "WelcomeLightbox": {
      "Show": false
    },
    "SyncInitiated": false,
    "SyncCapable": false,
    "SubscriptionRenewalBanner": {
      "Show": false
    },
    "IsBusinessLawCenter": false
  },
  "TabScripts": {
    "DocSource": "094be5ec528a4ebcb516957557b7ae19",
    "DocGuid": "I7b55ac403f3c11e8a70fc9d8a0b2aef5",
    "NavigationPath": "Search/v1/results/navigation/i0ad604ab000001630667802a2028f1f7?Nav=CUSTOMDIGEST&fragmentIdentifier=I7b55ac403f3c11e8a70fc9d8a0b2aef5&startIndex=1&contextData=%28sc.CustomDigest%29&transitionType=CustomDigestItem",
    "ListSource": "Search",
    "List": "CUSTOMDIGEST",
    "Rank": 138,
    "DocumentVersionNumber": 0
  }
};


window['Server/KM'] = {
  "SessionId": "",
  "FirmName": "",
  "FirmLogoUri": "",
  "FirmWelcomeUri": "",
  "Protocol": "http"
};


window['Server/Configuration'] = {
  "CompartmentName": "WestlawNext",
  "CookieDomain": "next.westlaw.com",
  "EnableIpad": false,
  "EnableIphone": false,
  "IsIPadAppRenderingMode": false,
  "IsIPhoneAppRenderingMode": false,
  "IOSNativeVersion": "0.0.0",
  "EnableSync": false,
  "EnableDeliveryQueue": true,
  "EnableDeliveryWidget": true,
  "ProductName": "WestlawNext",
  "ProductDisplayName": "Westlaw",
  "ProductDisplayDelimiter": "|",
  "ProductViewName": "none",
  "DailyDeliveryLimit": -1,
  "DailyDeliveryCount": -1,
  "SessionDeliveryLimit": 20,
  "SupportedAlertTypes": [
    "WestClip",
    "KeyCite",
    "DocketAlert",
    "DocketTrack",
    "DealTrack",
    "PublicationAlert",
    "Newsletter",
    "BusinessInvestigator",
    "CourtWire",
    "BusinessLawCenterAlert",
    "PeopleMap",
    "CapitolWatchTrack"
  ],
  "EnableDataRoomAlerts": true,
  "GlobalizationKeyMode": "Default",
  "IsAnonymousSession": false,
  "EnableAccessibleLightbox": true,
  "EnableContactsPaging": true,
  "IsCrawlerSession": false,
  "IsGlobalizationI18NLocaleEnabled": false,
  "IsGlobalizationI18NLibraryLookupEnabled": true,
  "IsProcessCategoryPagesWithDifferentLocalesOn": false,
  "OverrideResultsPerPage": 0,
  "UseExpandableToc": true,
  "Locale": "en-US",
  "IsSmartFoldersEnabled": true,
  "IsFeatureOverlayEnabled": true,
  "IsTRDiscoverEnabled": true,
  "IsVideoTourEnabled": true,
  "IsBestPortionNavigationEnabled": true,
  "UsePageHeaderV2": true,
  "UseTypeAhead": true,
  "UseSnapshots": true,
  "IsBriefAnalyzerEnabled": true,
  "IsChargeableByDefaultForSession": true,
  "IsIssueFinderEnabled": true,
  "IsWestlawAnswersEnabled": true,
  "IsSharedHighlightsEnabled": true,
  "IsRealTimeNotificationEnabled": true,
  "EnableA11YLightboxKeyboardScroll": true,
  "IsA11YRedesignedHeaderEnabled": true,
  "IsA11YPreferencesLightboxEnabled": true,
  "SpeechToTextCustomizationIdOverride": "default",
  "InfrastructureAccessControls": [
    "iac-a11y-asbuilder-tmpl",
    "iac-a11y-header-redesign",
    "iac-accessible-clientid-widget",
    "iac-add-timezone",
    "iac-alert-admin-settings",
    "iac-alert-ny-sct-hourly",
    "iac-alerts-cal",
    "iac-alerts-customerinfo-olc",
    "iac-alerts-cw",
    "iac-alerts-docket-guid",
    "iac-alerts-productaware-history",
    "iac-alerts-standart-email-format",
    "iac-all-citations",
    "iac-allow-robots-indexing-sitemap-wln",
    "iac-analyticsclientidfeaturesenabled",
    "iac-analytics-related-filings",
    "iac-annotation-filtering",
    "iac-anonymous-cdn",
    "iac-appcommand",
    "iac-asm-policy",
    "iac-au-compartments",
    "iac-au-seo",
    "iac-autosuggest-au",
    "iac-batch-getsynopsis",
    "iac-bestlaw-tracking",
    "iac-blc-filersearch",
    "iac-blc-fs-next",
    "iac-blc-redlining",
    "iac-blc-ri-agreementsenh",
    "iac-blc-ri-newpathway",
    "iac-blc-ri-privateequity",
    "iac-blind-encrypted",
    "iac-blind-encrypted-header-enabled",
    "iac-block-uk-westlaw",
    "iac-blt-alertfulltext",
    "iac-blt-alert-type-mna-trans",
    "iac-blt-alert-type-sec-insider",
    "iac-blt-alert-type-sec-noninsider",
    "iac-blt-feature18",
    "iac-blt-feature3",
    "iac-blt-hoovers",
    "iac-blt-incorporationdata",
    "iac-blt-news",
    "iac-blt-oct2014-release",
    "iac-blt-officerlinks",
    "iac-blt-report-advisors",
    "iac-blt-securities",
    "iac-blt-securities-alerts",
    "iac-blt-subsidiaries",
    "iac-blt-table-sections",
    "iac-blt-tagged-sections",
    "iac-blt-tickercik",
    "iac-blt-webkitpdf",
    "iac-blt-xmlmindrtf",
    "iac-businesslawcenter-tdr",
    "iac-canadian-content",
    "iac-casetracking",
    "iac-change-uk-ntz-clientid",
    "iac-cig-addfoldereditem",
    "iac-cig-facet-orphan",
    "iac-cig-group-orphan",
    "iac-cig-orphan",
    "iac-cig-orphan-ind",
    "iac-cig-report-orphan",
    "iac-ci-resultlist",
    "iac-citation-reordering",
    "iac-client-chargeable-by-default",
    "iac-clientid-new-validation",
    "iac-concourselibrary-wln",
    "iac-content-finder",
    "iac-correct-dock-user-property-value",
    "iac-courtexpress",
    "iac-cpet-browseparts-novus",
    "iac-cr-effective-date-display",
    "iac-crossborder-dashboard",
    "iac-crossborder-itg",
    "iac-display-applied-filter-names-on-ssp",
    "iac-display-recent-items",
    "iac-docanalyzer-caselc-atlaslc",
    "iac-docanalyzer-cited-statutes",
    "iac-docanalyzer-filter",
    "iac-docanalyzer-footnotes",
    "iac-docanalyzer-rdintegration",
    "iac-docanalyzer-relevantportion",
    "iac-docanalyzer-secondarysources",
    "iac-docanalyzer-statutes",
    "iac-docanalyzer-ui-march-release",
    "iac-doc-medical-entities-link-out",
    "iac-docversioning-wln",
    "iac-dpa-browse-juris-landing-pg",
    "iac-dpa-curated",
    "iac-dpa-delivery-watson-answer",
    "iac-dpa-enforcementmap",
    "iac-dpa-featured-content",
    "iac-dpa-keyword-newjurs",
    "iac-dpa-keyword-novus",
    "iac-dpa-knowledgegraph",
    "iac-dpa-related-concepts",
    "iac-dpa-usabilla",
    "iac-dpa-watson-v11",
    "iac-dpa-watson-v12",
    "iac-dr-client-missed",
    "iac-dtp-bankruptcy-claims",
    "iac-dtp-dktptynmtbl",
    "iac-dtp-experts",
    "iac-dtp-openweb",
    "iac-dyn-stem-exceptions",
    "iac-enable-news-summary-alerts-delivery",
    "iac-enacted-legislation-link",
    "iac-enhanced-search-term-tooltip",
    "iac-factoranalysis-history",
    "iac-fa-searchbilling",
    "iac-fastdom-standarddocument",
    "iac-feature-overlay",
    "iac-findandprint",
    "iac-firmlibrary-wln",
    "iac-foldering-get-descendants-new",
    "iac-folderingshareacrossorgs",
    "iac-forcesignon-orphansession",
    "iac-gateway-do",
    "iac-get-renewalandtrialdata",
    "iac-grantonlyfacsinsessionbindings",
    "iac-guid-chasing-disable",
    "iac-hide-docket-monthly-frequency",
    "iac-hide-territorial-options",
    "iac-historical-datacorrections",
    "iac-image-module",
    "iac-improved-navigation",
    "iac-indigo-coldstart",
    "iac-indigo-cpet-browseparts",
    "iac-indigo-display-pref",
    "iac-indigo-fav-searches",
    "iac-indigo-folder-kc-change",
    "iac-indigo-folder-recommend-change",
    "iac-indigo-hot-docs",
    "iac-indigo-notification-center",
    "iac-indigo-paymenttype",
    "iac-indigo-pui",
    "iac-indigo-recent-filters",
    "iac-indigo-research-report",
    "iac-indigo-statutes-compare",
    "iac-indigo-typeahead",
    "iac-inlinehtmldelivery-dockettrackalert",
    "iac-internationalfind",
    "iac-ios-newadvancedsearch",
    "iac-ip2-markman",
    "iac-ip-trademark-viennacode-facet",
    "iac-itdepends",
    "iac-itg-tab",
    "iac-kc-alerts-patents",
    "iac-kc-citing-references",
    "iac-kc-citing-refs-enhanced-sw",
    "iac-kc-flags",
    "iac-kc-flags-green-c-by-boolean",
    "iac-kc-judicial-history",
    "iac-kc-negative-treatment",
    "iac-kc-rules-affected-by",
    "iac-kc-statutes-affected-by",
    "iac-kc-table-of-authorities",
    "iac-kc-validity",
    "iac-kc-wave-the-white-flag",
    "iac-keycite-nod-redesign-old-rels",
    "iac-keycite-sort-by-court-level",
    "iac-keynumber-facets",
    "iac-km-aliveserverconnection",
    "iac-km-fiacctprefs",
    "iac-la-case-outcomes",
    "iac-la-case-types",
    "iac-la-courts",
    "iac-la-delivery",
    "iac-la-law-firms",
    "iac-linkbuilder-docandcatpages",
    "iac-linkbuilder-searchresultspages",
    "iac-linkbuilder-topic-search",
    "iac-linkouturl-pubandserial",
    "iac-log-prdct-wlus-deny",
    "iac-lt-dpa-watson-integration",
    "iac-master-page",
    "iac-mattermaps-deliver-image",
    "iac-mattermaps-editmap",
    "iac-matters-by-number-wln",
    "iac-medlit",
    "iac-modal-footnotes",
    "iac-modernization-wln-ios-doc",
    "iac-most-cited-sort",
    "iac-move-menus-down",
    "iac-multipart-pdf",
    "iac-new-newsletter-template",
    "iac-newsroom-images",
    "iac-non-unique-cites",
    "iac-novustimezone",
    "iac-nyofficial-digestlink",
    "iac-oversized-and-error-email-delivery",
    "iac-pa-regulations-status-facets",
    "iac-partytype-checkbox",
    "iac-patron-category-page",
    "iac-pdf-multipart-check",
    "iac-planz-application-enabled",
    "iac-plconnect-tasks-and-synonyms",
    "iac-plconnect-tasks-ux-redesign",
    "iac-plc-rss-feeds",
    "iac-plct-crossclientid",
    "iac-plct-crossproductclientid",
    "iac-plct-globalsearch",
    "iac-plct-linkbuilder",
    "iac-plct-smalllawfirmmgmt",
    "iac-plct-ssrulebooks",
    "iac-plct-startupssmallbus",
    "iac-plct-viewalltasks",
    "iac-plc-viewonlydraftingnotes",
    "iac-plc-waywo",
    "iac-plplus-application-enabled",
    "iac-plplus-calendar",
    "iac-pl-scrollissues",
    "iac-pluk-asset-page-enable-wln-links",
    "iac-pluk-cdn-available-for-ip",
    "iac-plus-clientidinsession",
    "iac-plus-clientidpromptpltowl",
    "iac-plus-documentononepage",
    "iac-plus-feedback",
    "iac-plus-homebanner",
    "iac-plus-knowhowbooleanquery",
    "iac-plus-linkbuilder",
    "iac-plus-notesformating",
    "iac-plus-searchcontext",
    "iac-plus-truncatejurinsearch",
    "iac-plus-unhideannotations",
    "iac-plus-viewmorelessdetails",
    "iac-portalmanager-combined",
    "iac-portalmanager-contentlinks",
    "iac-portalmanager-findbypartyname",
    "iac-portalmanager-search",
    "iac-practical-law-display-changes",
    "iac-practicallaw-itg-dropdown",
    "iac-practical-law-subheadings",
    "iac-practiceareas-asterisknote",
    "iac-practicepoint-smartsearch-onesynonym",
    "iac-practicepoint-smartsearch-synonyms",
    "iac-practicepoint-smartsearch-treatises",
    "iac-practitioner-insights-alerts-no-logo",
    "iac-pr-add-bing",
    "iac-pr-addfoldereditem",
    "iac-pr-entity-extraction",
    "iac-pr-fein-plus3",
    "iac-price-guide-link",
    "iac-pricing-guide-redirect",
    "iac-privacy-policy",
    "iac-pr-polkrpt",
    "iac-pr-qsentrpt",
    "iac-pr-section-delivery",
    "iac-pr-ssn-only-search",
    "iac-pr-use-pipl-v5",
    "iac-public-record-prod-gateway",
    "iac-public-records",
    "iac-public-records-alerts",
    "iac-public-records-firstamerican",
    "iac-public-records-report-excel-delivery",
    "iac-public-records-report-filtering",
    "iac-pubrec-real-time-monitor",
    "iac-qanda",
    "iac-qanda-pinpoint",
    "iac-qanda-typeahead",
    "iac-raise-document-limit",
    "iac-ra-no-rank1docs-cache",
    "iac-remove-nyor-hard-coded-collections",
    "iac-remove-securedatatoken",
    "iac-research-accel",
    "iac-research-accel-synopsis",
    "iac-ri-bill-activity",
    "iac-ri-bill-tracking",
    "iac-ri-capitol-watch",
    "iac-ri-category-delivery",
    "iac-ri-citestyles-endpoint-v2-enable",
    "iac-ri-context-analysis",
    "iac-ri-editorial-materials",
    "iac-ri-filings",
    "iac-ri-fnd-newpathway",
    "iac-ri-form-families",
    "iac-ri-legislative-timeline",
    "iac-ri-no-single-rn-uds-post",
    "iac-ri-notes-of-decisions",
    "iac-ri-opinions",
    "iac-ri-professional-references",
    "iac-ri-reduce-uds-rn-data",
    "iac-ri-topics",
    "iac-ri-versions",
    "iac-sb-list-items-delivery",
    "iac-search-como-group1",
    "iac-search-como-group2",
    "iac-search-como-group3",
    "iac-search-como-group4",
    "iac-search-como-group6",
    "iac-search-como-group7",
    "iac-search-como-group8",
    "iac-search-como-public-records",
    "iac-search-como-recodocs",
    "iac-search-como-reghist",
    "iac-search-custom-nyor-reranking",
    "iac-search-delivery-group1",
    "iac-search-delivery-group2",
    "iac-search-delivery-group3",
    "iac-search-delivery-group4",
    "iac-search-delivery-group5",
    "iac-search-firmcentral",
    "iac-search-knowhowrankoption",
    "iac-search-matterroom",
    "iac-search-nl-thresholding-option",
    "iac-search-pmd-result-types",
    "iac-search-result-duplicate-identifier",
    "iac-search-suggestions",
    "iac-search-within-favourites-plcuk",
    "iac-searchwithin-ios",
    "iac-shared-highlights",
    "iac-share-folders-with-cobalt-contacts",
    "iac-sharing-with-the-same-domain",
    "iac-show50statesurvey-inlineflags",
    "iac-small-law-survey-redirect",
    "iac-smartbreadcrumb-add-navid",
    "iac-smartbreadcrumbs-au",
    "iac-smartfolders-ss",
    "iac-snapshots-state",
    "iac-snowdonia-beta",
    "iac-sortoption-courtlevel-pref",
    "iac-starpages-plcuk",
    "iac-staticqa",
    "iac-staticqa-history",
    "iac-staticqa-searchbilling",
    "iac-statutes-new-ast-pdfs",
    "iac-superbrowse-mult-gradeheads",
    "iac-superbrowse-paging",
    "iac-taxpage-eylogo",
    "iac-term-frequency-sorting",
    "iac-transfer-content",
    "iac-trd-alternate-search",
    "iac-trd-juris-facet",
    "iac-trd-legalanalytics",
    "iac-trd-lpafacet-subsearch",
    "iac-trillium-crsw-doc-enhance",
    "iac-trillium-link",
    "iac-uk-a11y-clientid-lightbox",
    "iac-uk-clientid",
    "iac-uk-compartments",
    "iac-uk-fd-and-fs",
    "iac-uk-keywordfinder",
    "iac-uk-linkbuilder",
    "iac-uk-linkbuilder-copy",
    "iac-uk-nonpltracking",
    "iac-uk-performance-new-static-content-or",
    "iac-unlink-unmigrated",
    "iac-use-new-training-user",
    "iac-userdoclink-wln",
    "iac-us-knowhow-algorithm",
    "iac-v3inapplibrary",
    "iac-validity-highlighting",
    "iac-verify-eaddress-against-existance",
    "iac-webinars",
    "iac-website-throttle",
    "iac-westsearch-cases-keynumberfacet",
    "iac-westsearch-cases-partyfacet",
    "iac-westsearch-cases-synopsis",
    "iac-westsearch-cases-topicfacet",
    "iac-westsearch-enhancements",
    "iac-without-flash-dependencies",
    "iac-wln-cig-linkedreport",
    "iac-wlndoc-sharednotes",
    "iac-wln-global-search-judicial-chambers",
    "iac-wln-historicalheader",
    "iac-wln-ios-display-toa",
    "iac-wln-newfiletype",
    "iac-wlnopenweb-serverbrowsepage",
    "iac-wln-ri-tabs",
    "iac-wln-save-snippet",
    "iac-wln-strong-downgrade-email",
    "iac-wlntax-blue-flag",
    "iac-wln-toc-keyciteflag",
    "iac-wl-startpage",
    "iac-wl-striphash",
    "iac-wordsphrases-snippet-support"
  ],
  "IsTypeAheadNewUiEnabled": true,
  "ContactsPageSize": 300,
  "ShowPrivacyPolicy": true,
  "ShowCookiePolicy": true,
  "ResearchReportDocumentLimit": 1000,
  "IsSaveSnippetEnabled": true,
  "IsHideAnnotationsSharedByInactiveUsersEnabled": true,
  "AllowPauseOnLinkOut": true,
  "IsMaintainDocumentPositionRIEnabled": true,
  "IsFormsEngine2Enabled": false,
  "IsFormsEngine2DownloadEnabled": false,
  "IsIndigoDisplayEnabled": false
};


window['Server/Mobile'] = {
  "IsNativeIPad": false,
  "IsNativeIPhone": false
};


window['Server/Messages'] = {
  "ProductName": "Westlaw",
  "ProductSupportNumber": "1-800-WESTLAW (1-800-937-8529)"
};


window['Server/Net'] = {
  "PageContextData": "(sc.CustomDigest)",
  "CacheScopeList": [
    "^/RelatedInfo/v[3456]/keycite/content/",
    "^/RelatedInfo/v3/content/json/",
    "^/RelatedInfo/v1/wlncCaselawHistory\\\\?",
    "^/RelatedInfo/v1/wlncCitingReferences\\\\?",
    "^/RelatedInfo/v1/wlncCourtDocs\\\\?",
    "^/RelatedInfo/v1/wlncLegalMemos\\\\?",
    "^/RelatedInfo/v1/kcJudicialHistory\\\\?",
    "^/RelatedInfo/v1/kcCitingReferences\\\\?",
    "^/RelatedInfo/v1/riFilings\\\\?",
    "^/RelatedInfo/v1/kcNegativeTreatment\\\\?",
    "^/RelatedInfo/v1/kcTableOfAuthorities\\\\?",
    "^/RelatedInfo/v1/kcBillDrafts\\\\?",
    "^/RelatedInfo/v1/kcLegislativeMaterials\\\\?",
    "^/RelatedInfo/v1/kcRegulatoryHistory\\\\?",
    "^/RelatedInfo/v1/kcValidity\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnAgreements\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnAgreementsTwoStep\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnSecCommentLetters\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnSecCommentLettersTwoStep\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFilingsAndDisclosures\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFilingsAndDisclosuresTwoStepViaMA\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFilingsAndDisclosuresExhibits\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFilingsAndDisclosuresExhibitsTwoStep\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFilingsAndDisclosuresExhibitsTwoStepViaMAAndFD\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnMergersAndAcquisitions\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnMergersAndAcquisitionsEnhanced\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnMergersAndAcquisitionsEnhancedTwoStep\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnMergersAndAcquisitionsRelated\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnRandPTransactionFullTextCategory\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnRandPTransactionFullTextCategoryTwoStep\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFilingFullTextCategory\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFundsInvestments\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFundsInvestmentsV2\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFundsInvestmentsTwoStepViaMA\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFundsInvestmentsTwoStepViaFDAndMA\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnPefundsFundsFirms\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnAgreementsEnh\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnAgreementsEnhTwoStep\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnAgreementsEnhTwoStepViaMA\\\\?",
    "^/RelatedInfo/v1/tnpCases\\\\?",
    "^/RelatedInfo/v1/tnpCommentary\\\\?",
    "^/RelatedInfo/v1/tnpCompliance\\\\?",
    "^/RelatedInfo/v1/tnpGovernmentDocuments\\\\?",
    "^/RelatedInfo/v1/tnpHistory\\\\?",
    "^/RelatedInfo/v1/tnpHistoryAndTreatments\\\\?",
    "^/RelatedInfo/v1/tnpLegislation\\\\?",
    "^/Search/v1/search/external/results",
    "^/Search/v3/search/results",
    "^/Search/v1/results",
    "^/Document/v1/fulltext/",
    "^/Document/v1/list/fulltext/",
    "^/Document/v1/Mobile/FullText/",
    "^/Document/v1/fixedheader/",
    "^/Document/v1/list/fixedheader/",
    "^/Document/v1/list/Mobile/Fulltext/",
    "^/Document/v[12]/MetaInfo/"
  ],
  "SessionScope": "7f37bc759ec9f9864b92cef6ac1b964c4cf54544f9347b0fcb95acf38263c8f1",
  "UserScope": "5405685",
  "CacheScope": "c75990ffa2ebcade90cc638443682cd1"
};


window['Server/Events'] = {
  "PageEventIdentifier": "f96b8b4ef56f4283bf5cd3e3aa9e65b3",
  "PageName": "Cobalt.Website.ServerPage.Document",
  "ResourceToken": "v1|7539b81e83d4e275acffa2d4240aa1f42b9ccbe37fe7f18c9102cabbce64f129"
};

</script>


	
	

<!-- View Path: ~/Document/Views/DocumentTabView.cshtml -->
<script type="text/javascript">
window.__viewName = '~/Document/Views/DocumentTabView.cshtml';
</script>
<script type="text/javascript" crossorigin="anonymous" charset="utf-8" src="https://ja.next.westlaw.com/StaticContent_40.1.1015/webpack/Products/WestlawNext/webpack-loader.js"></script>

	

<div id="co_searchDisableDiv" class="co_screenOverlay co_hideState"></div><div id="co_dragDrop_parent_0"></div></body></html>